<?xml version="1.0" encoding="UTF-8"?>
 <forms>  
  <collectionName>XML-5590324</collectionName>
  <collectionDescription>Load XML</collectionDescription>   
 <form>
  <context>Theradex</context>
  <createdBy>DEETJENM</createdBy>
  <dateCreated>2016-12-06T13:01:37</dateCreated>
  <dateModified>2017-01-30T14:33:01</dateModified>
  <modifiedBy>DEETJENM</modifiedBy>
  <longName>EC10014</longName>
  <preferredDefinition>Eligibility Checklist for 10014</preferredDefinition>
  <cadsrRAI>2.16.840.1.113883.3.26.2</cadsrRAI>
  <publicID>5590324</publicID>
  <version>1</version>
  <workflowStatusName>RELEASED</workflowStatusName>
  <categoryName>Eligibility</categoryName>
  <type>CRF</type>
  <headerInstruction/>
     <module>
    <displayOrder>0</displayOrder>
    <maximumModuleRepeat>0</maximumModuleRepeat>
    <longName>Pre-requisites</longName>
        <preferredDefinition>Pre-requisites</preferredDefinition>
    <publicID>5590591</publicID>
    <version>1</version>
    <usageCategory>
     <usageType>None</usageType>
    </usageCategory>
         <question>
      <publicID>5590592</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>0</displayOrder>
      <dateCreated>2016-12-06T13:01:38</dateCreated>
      <dateModified>2016-12-06T13:01:38</dateModified>
      <questionText>Please select the cohort</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Treatment Cohort Study Code</longName>
       <shortName>TX_COHORT_ST_CD</shortName>
       <publicID>4386401</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The code that represents the information pertaining to studies in which subsets of a defined population are identified.</preferredDefinition>
              <valueDomain>
        <longName>Cohort Code</longName>
        <shortName>COHORT_CD</shortName>
        <publicID>4386399</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>Theradex</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>25</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>0</value>
          <valueMeaning>
           <publicID>4386400</publicID>
           <version>1</version>
           <longName>Current Active Cohort</longName>
                                 <preferredDefinition>Occurring in or belonging to the present time.: Exerting influence or producing an effect; taking part in an activity.: A group of individuals, identified by a common characteristic.</preferredDefinition>
          </valueMeaning>
          <beginDate>2014-07-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>1</value>
          <valueMeaning>
           <publicID>4386711</publicID>
           <version>1</version>
           <longName>Future Active Cohort</longName>
                                 <preferredDefinition>A time that is yet to come.: Exerting influence or producing an effect; taking part in an activity.: A group of individuals, identified by a common characteristic.</preferredDefinition>
          </valueMeaning>
          <beginDate>2014-07-18T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Please select the cohort</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Please select the cohort</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4386401&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>0</value>
        <meaningText>Current Active Cohort</meaningText>
        <description>Occurring in or belonging to the present time.: Exerting influence or producing an effect; taking part in an activity.: A group of individuals, identified by a common characteristic.</description>
                <valueMeaning>
         <publicID>4386400</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>1</value>
        <meaningText>Future Active Cohort</meaningText>
        <description>A time that is yet to come.: Exerting influence or producing an effect; taking part in an activity.: A group of individuals, identified by a common characteristic.</description>
                <valueMeaning>
         <publicID>4386711</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
       </module>
   <module>
    <displayOrder>1</displayOrder>
    <maximumModuleRepeat>0</maximumModuleRepeat>
    <longName>Extra Enrollment fields for CTMS</longName>
        <preferredDefinition>Enrollment</preferredDefinition>
    <publicID>5590325</publicID>
    <version>1</version>
    <usageCategory>
     <usageType>None</usageType>
    </usageCategory>
         <question>
      <publicID>5590327</publicID>
      <version>1</version>
      <isDerived>true</isDerived>
      <displayOrder>0</displayOrder>
      <dateCreated>2016-12-06T13:01:37</dateCreated>
      <dateModified>2016-12-06T13:01:37</dateModified>
      <questionText>Weight</questionText>
      <instruction>
       <text>In kilograms</text>
      </instruction>
      <isEditable>No</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Weight Value</longName>
       <shortName>PRSN_WT_VAL</shortName>
       <publicID>2179689</publicID>
       <version>4</version>
       <context>DCP</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The number that describes the vertical force exerted by the mass of an individual as a result of gravity.</preferredDefinition>
              <valueDomain>
        <longName>Weight Value</longName>
        <shortName>WT_VAL</shortName>
        <publicID>2179445</publicID>
        <version>2</version>
        <type>NonEnumerated</type>
        <context>DCP</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>NUMBER</datatypeName>
        <decimalPlace>3</decimalPlace>
        <maximumLengthNumber>7</maximumLengthNumber>
                               </valueDomain>
       <dataElementDerivation>
        <componentDataElement>
         <usageCategory>
          <usageType>Mandatory</usageType>
         </usageCategory>
         <displayOrder>0</displayOrder>
         <dataElement>
          <publicID>0</publicID>
          <version>0</version>
          <valueDomain>
           <shortName>PRSN_WT_VAL</shortName>
           <type>NonEnumerated</type>
           <workflowStatusName>RELEASED</workflowStatusName>
           <valueDomainConcept>
            <nciTermBrowserLink>http://blankNode</nciTermBrowserLink>
           </valueDomainConcept>
          </valueDomain>
         </dataElement>
        </componentDataElement>
       </dataElementDerivation>
               <referenceDocument>
         <name>CRF TEXT</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>Weight Measure</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF TEXT1</name>
         <type>Alternate Question Text</type>
         <context>DCP</context>
         <doctext>Weight at Time of Event</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Weight</name>
         <type>Preferred Question Text</type>
         <context>DCP</context>
         <doctext>Weight</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Patient weight</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NINDS CDE Project</name>
         <type>REFERENCE</type>
         <context>NINDS</context>
         <doctext>NINDS CDE Project</doctext>
         <languageName>ENGLISH</languageName>
         <URL>http://www.commondataelements.ninds.nih.gov/</URL>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text2</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Weight (kg)</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>What is your current weight?</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>What is your current weight?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text3</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Patient&apos;s weight (in kilograms)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NIDA CTN PhenX Body Mass Index for SAATier1</name>
         <type>Alternate Question Text</type>
         <context>NIDA</context>
         <doctext>Record current weight in pounds or kilograms</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NRG_CRF Text</name>
         <type>Alternate Question Text</type>
         <context>NRG</context>
         <doctext>What is your weight now?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Body Mass (kg)</name>
         <type>Alternate Question Text</type>
         <context>DCI</context>
         <doctext>Body Mass (kg)</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>How much do you normally weigh?</name>
         <type>Alternate Question Text</type>
         <context>CCR</context>
         <doctext>How much do you normally weigh?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 1</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Weight in kg:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NRDS Alternate Text</name>
         <type>Alternate Question Text</type>
         <context>NRDS</context>
         <doctext>Weight</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text4</name>
         <type>Alternate Question Text</type>
         <context>Alliance</context>
         <doctext>Weight  1</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text5</name>
         <type>Alternate Question Text</type>
         <context>Alliance</context>
         <doctext>Weight 2</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text6</name>
         <type>Alternate Question Text</type>
         <context>Alliance</context>
         <doctext>Average Weight</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>DCP Text- 2</name>
         <type>Alternate Question Text</type>
         <context>DCP</context>
         <doctext>Weight in kg</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=2179689&amp;version=4</cdeBrowserLink>
      </dataElement>
           </question>
     <question>
      <publicID>5590338</publicID>
      <version>1</version>
      <isDerived>true</isDerived>
      <displayOrder>1</displayOrder>
      <dateCreated>2016-12-06T13:01:37</dateCreated>
      <dateModified>2016-12-06T13:01:37</dateModified>
      <questionText>Height</questionText>
      <instruction>
       <text>In centimeters</text>
      </instruction>
      <isEditable>No</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Height Value</longName>
       <shortName>PRSN_HT_VAL</shortName>
       <publicID>2179643</publicID>
       <version>4</version>
       <context>DCP</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The number that describes the vertical distance of an individual.</preferredDefinition>
              <valueDomain>
        <longName>Height Value</longName>
        <shortName>HT_VAL</shortName>
        <publicID>2179483</publicID>
        <version>2</version>
        <type>NonEnumerated</type>
        <context>DCP</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>NUMBER</datatypeName>
        <decimalPlace>3</decimalPlace>
        <maximumLengthNumber>7</maximumLengthNumber>
                               </valueDomain>
       <dataElementDerivation>
        <componentDataElement>
         <usageCategory>
          <usageType>Mandatory</usageType>
         </usageCategory>
         <displayOrder>0</displayOrder>
         <dataElement>
          <publicID>0</publicID>
          <version>0</version>
          <valueDomain>
           <shortName>PRSN_WT_VAL</shortName>
           <type>NonEnumerated</type>
           <workflowStatusName>RELEASED</workflowStatusName>
           <valueDomainConcept>
            <nciTermBrowserLink>http://blankNode</nciTermBrowserLink>
           </valueDomainConcept>
          </valueDomain>
         </dataElement>
        </componentDataElement>
       </dataElementDerivation>
               <referenceDocument>
         <name>Height</name>
         <type>Preferred Question Text</type>
         <context>DCP</context>
         <doctext>Height</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF TEXT</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>Height Measure</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>6671-TA</name>
         <type>Alternate Question Text</type>
         <context>DCP</context>
         <doctext>Patient height</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NIDA CTN PhenX Body Mass Index for SAATier1</name>
         <type>Alternate Question Text</type>
         <context>NIDA</context>
         <doctext>Record standing height in meters (or centimeters) or inches</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>What is your current height?</name>
         <type>Alternate Question Text</type>
         <context>iCaRe2</context>
         <doctext>What is your current height?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 1</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Height in cm:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NRDS Alternate Text</name>
         <type>Alternate Question Text</type>
         <context>NRDS</context>
         <doctext>Height</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>DCP Text -3</name>
         <type>Alternate Question Text</type>
         <context>DCP</context>
         <doctext>Height in cm</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=2179643&amp;version=4</cdeBrowserLink>
      </dataElement>
           </question>
     <question>
      <publicID>5590340</publicID>
      <version>1</version>
      <isDerived>true</isDerived>
      <displayOrder>2</displayOrder>
      <dateCreated>2016-12-06T13:01:37</dateCreated>
      <dateModified>2016-12-06T13:01:37</dateModified>
      <questionText>BSA</questionText>
            <isEditable>No</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Body Surface Area Value</longName>
       <shortName>PERS_BSA_VAL</shortName>
       <publicID>653</publicID>
       <version>6</version>
       <context>CTEP</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>the calculated numerical quantity that represents the 2-dimensional extent of the body surface relating height to weight.</preferredDefinition>
              <valueDomain>
        <longName>Body Surface Area Value</longName>
        <shortName>BSA_VAL</shortName>
        <publicID>2015823</publicID>
        <version>6</version>
        <type>NonEnumerated</type>
        <context>CTEP</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>NUMBER</datatypeName>
        <decimalPlace>3</decimalPlace>
        <maximumLengthNumber>5</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
        <UOMName>m2</UOMName>
                               </valueDomain>
       <dataElementDerivation>
        <componentDataElement>
         <usageCategory>
          <usageType>Mandatory</usageType>
         </usageCategory>
         <displayOrder>0</displayOrder>
         <dataElement>
          <publicID>0</publicID>
          <version>0</version>
          <valueDomain>
           <shortName>PRSN_WT_VAL</shortName>
           <type>NonEnumerated</type>
           <workflowStatusName>RELEASED</workflowStatusName>
           <valueDomainConcept>
            <nciTermBrowserLink>http://blankNode</nciTermBrowserLink>
           </valueDomainConcept>
          </valueDomain>
         </dataElement>
        </componentDataElement>
       </dataElementDerivation>
               <referenceDocument>
         <name>1-COMMENT</name>
         <type>COMMENT</type>
         <context>CTEP</context>
         <doctext>Instruction adding unit of measure to template form: (m^2)</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COMMENT_199</name>
         <type>COMMENT</type>
         <context>CTEP</context>
         <doctext>BSA may be calculated when the height and weight of the patient are known. Formula for this calculation must be specified by the protocol.</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Body Surface Area</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>BSA</name>
         <type>Preferred Question Text</type>
         <context>CTEP</context>
         <doctext>BSA</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Source</name>
         <type>DATA_ELEMENT_SOURCE</type>
         <context>CTEP</context>
         <doctext>Data element and all values comply with Clinical Data Update System (CDUS) v3.0 Release 2</doctext>
         <languageName>ENGLISH</languageName>
         <URL>http://ctep.cancer.gov/reporting/cdus.html</URL>
                 </referenceDocument>
        <referenceDocument>
         <name>BSA</name>
         <type>Alternate Question Text</type>
         <context>SWOG</context>
         <doctext>BSA (first day this cycle)</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>ECOG CRF 1</name>
         <type>Alternate Question Text</type>
         <context>ECOG-ACRIN</context>
         <doctext>Patient Body Surface Area Measurement</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NCI Vital Signs CRF</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>Body Surface Area (BSA)</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 1</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>BSA:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>% BSA in Body Region</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=653&amp;version=6</cdeBrowserLink>
      </dataElement>
           </question>
     <question>
      <publicID>5590341</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>3</displayOrder>
      <dateCreated>2016-12-06T13:01:37</dateCreated>
      <dateModified>2016-12-06T13:01:37</dateModified>
      <questionText>Patient Secondary Identifier</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Other Identifier Number</longName>
       <shortName>PT_OTHER_ID_NUM</shortName>
       <publicID>2006895</publicID>
       <version>2</version>
       <context>CTEP</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>the unique patient identifier assigned by an institution or lab (not assigned by a cooperative group).</preferredDefinition>
              <valueDomain>
        <longName>Patient Identifier Number</longName>
        <shortName>PT_ID_NUM</shortName>
        <publicID>2018384</publicID>
        <version>1</version>
        <type>NonEnumerated</type>
        <context>CTEP</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>20</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                               </valueDomain>
                      <referenceDocument>
         <name>Patient Secondary Identifier</name>
         <type>Preferred Question Text</type>
         <context>CTEP</context>
         <doctext>Patient Secondary Identifier</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Please enter Patient ID number</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=2006895&amp;version=2</cdeBrowserLink>
      </dataElement>
           </question>
     <question>
      <publicID>5613573</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>4</displayOrder>
      <dateCreated>2017-01-05T13:28:02</dateCreated>
      <dateModified>2017-01-05T13:28:02</dateModified>
      <questionText>Subgroup</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Treatment Cohort Study 10014 Code</longName>
       <shortName>TX_COHRT_SDY_10014_CD</shortName>
       <publicID>5604191</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The code that represents the information pertaining to protocol 10014 in which subsets of a defined population are identified.</preferredDefinition>
              <valueDomain>
        <longName>10014 Cohort Code</longName>
        <shortName>5604186v1.0</shortName>
        <publicID>5604186</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>Theradex</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>250</maximumLengthNumber>
                         <permissibleValue>
          <value>SG4</value>
          <valueMeaning>
           <publicID>5604187</publicID>
           <version>1</version>
           <longName>SG4 = Cohort D: Previous ACT with CAR</longName>
                                 <preferredDefinition>SG4 = Cohort D: Previous ACT with CAR</preferredDefinition>
          </valueMeaning>
          <beginDate>2016-12-14T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>SG3</value>
          <valueMeaning>
           <publicID>5604188</publicID>
           <version>1</version>
           <longName>SG3 = Cohort C: Previous ACT with HLA class II TCR</longName>
                                 <preferredDefinition>SG3 = Cohort C: Previous ACT with HLA class II TCR</preferredDefinition>
          </valueMeaning>
          <beginDate>2016-12-14T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>SG2</value>
          <valueMeaning>
           <publicID>5604189</publicID>
           <version>1</version>
           <longName>SG2 = Cohort B: Previous ACT with HLA class I TCR</longName>
                                 <preferredDefinition>SG2 = Cohort B: Previous ACT with HLA class I TCR</preferredDefinition>
          </valueMeaning>
          <beginDate>2016-12-14T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>SG1</value>
          <valueMeaning>
           <publicID>5604190</publicID>
           <version>1</version>
           <longName>SG1 = Cohort A: Previous ACT with expanded TIL</longName>
                                 <preferredDefinition>SG1 = Cohort A: Previous ACT with expanded TIL</preferredDefinition>
          </valueMeaning>
          <beginDate>2016-12-14T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Subgroup</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Subgroup</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5604191&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>SG1</value>
        <meaningText>SG1 = Cohort A: Previous ACT with expanded TIL</meaningText>
        <description>SG1 = Cohort A: Previous ACT with expanded TIL</description>
                <valueMeaning>
         <publicID>5604190</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>SG2</value>
        <meaningText>SG2 = Cohort B: Previous ACT with HLA class I TCR</meaningText>
        <description>SG2 = Cohort B: Previous ACT with HLA class I TCR</description>
                <valueMeaning>
         <publicID>5604189</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>SG3</value>
        <meaningText>SG3 = Cohort C: Previous ACT with HLA class II TCR</meaningText>
        <description>SG3 = Cohort C: Previous ACT with HLA class II TCR</description>
                <valueMeaning>
         <publicID>5604188</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>3</displayOrder>
        <value>SG4</value>
        <meaningText>SG4 = Cohort D: Previous ACT with CAR</meaningText>
        <description>SG4 = Cohort D: Previous ACT with CAR</description>
                <valueMeaning>
         <publicID>5604187</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5590342</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>5</displayOrder>
      <dateCreated>2016-12-06T13:01:37</dateCreated>
      <dateModified>2017-01-05T13:28:02</dateModified>
      <questionText>Primary Site of Disease</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Primary Site of Disease Name</longName>
       <shortName>PRIM_SITE_DZ_NM</shortName>
       <publicID>2188441</publicID>
       <version>1</version>
       <context>CCR</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>Name of the primary anatomic site of disease using a set of values in compliance with the Adverse Event Expedited Reporting System (AdEERS).</preferredDefinition>
               <designation>
         <createdBy>REEVESD</createdBy>
         <dateCreated>2004-09-06T00:00:00</dateCreated>
         <dateModified>2005-01-18T15:17:20</dateModified>
         <modifiedBy>REEVESD</modifiedBy>
         <languageName>ENGLISH</languageName>
         <name>ENGLISH</name>
         <type>CONTEXT NAME</type>
         <context>CCR</context>
                 </designation>
              <valueDomain>
        <longName>Primary Site of Disease Text Name</longName>
        <shortName>PRIM_SITE_DZ_TXT_NM</shortName>
        <publicID>2188216</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>20</maximumLengthNumber>
                         <permissibleValue>
          <value>Esophagus</value>
          <valueMeaning>
           <publicID>2567240</publicID>
           <version>1</version>
           <longName>Esophagus</longName>
                                 <preferredDefinition>The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.</preferredDefinition>
          </valueMeaning>
         </permissibleValue>
         <permissibleValue>
          <value>Bone</value>
          <valueMeaning>
           <publicID>2816296</publicID>
           <version>1</version>
           <longName>Bone</longName>
                                 <preferredDefinition>Bone; a rigid connective tissue that makes up the skeleton of vertebrates.</preferredDefinition>
          </valueMeaning>
          <beginDate>2008-12-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Soft Tissue</value>
          <valueMeaning>
           <publicID>2990372</publicID>
           <version>1</version>
           <longName>Soft Tissue</longName>
                       <designation>
             <createdBy>WONGW</createdBy>
             <dateCreated>2015-08-20T16:49:09</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Soft tissue</name>
             <type>VM Alt Name</type>
             <context>COG</context>
                         </designation>
                                 <preferredDefinition>Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.</preferredDefinition>
          </valueMeaning>
          <beginDate>2010-02-03T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Appendix</value>
          <valueMeaning>
           <publicID>2558237</publicID>
           <version>1</version>
           <longName>Appendix</longName>
                       <designation>
             <createdBy>DAVISJ</createdBy>
             <dateCreated>2015-08-20T15:04:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Appendiceal</name>
             <type>VM Alt Name</type>
             <context>COG</context>
                         </designation>
                                 <preferredDefinition>Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:42</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Brain</value>
          <valueMeaning>
           <publicID>2558329</publicID>
           <version>1</version>
           <longName>Brain</longName>
                       <designation>
             <createdBy>COLBERTM</createdBy>
             <dateCreated>2014-08-22T00:00:00</dateCreated>
             <dateModified>2014-08-22T00:00:00</dateModified>
             <modifiedBy>COLBERTM</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Test2AltnNameOnlyOne</name>
             <type>Biomarker Synonym</type>
             <context>NCIP</context>
                         </designation>
                                 <preferredDefinition>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:42</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Mediastinum</value>
          <valueMeaning>
           <publicID>2559163</publicID>
           <version>1</version>
           <longName>Mediastinum</longName>
                                  <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2010-03-30T10:39:39</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>A group of organs surrounded by loose connective tissue, separating the two pleural sacs, between the sternum anteriorly and the vertebral column posteriorly as well as from the thoracic inlet superiorly to the diaphragm inferiorly. The mediastinum contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.
</text>
             <type>NCI</type>
                           <classification>
               <name>Common Biorepository Model</name>
               <publicID>3204728</publicID>
               <version>1</version>
               <preferredDefinition>A common model to contain summary-level details of biorepository / biobank holdings which can be advertised through the OBBR Specimen Resource Locator</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>A group of organs surrounded by loose connective tissue, separating the two pleural sacs, between the sternum anteriorly and the vertebral column posteriorly as well as from the thoracic inlet superiorly to the diaphragm inferiorly. The mediastinum contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:45</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Pericardium</value>
          <valueMeaning>
           <publicID>2559784</publicID>
           <version>1</version>
           <longName>Pericardium</longName>
                                 <preferredDefinition>A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:47</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Peritoneum</value>
          <valueMeaning>
           <publicID>2559796</publicID>
           <version>1</version>
           <longName>Peritoneum</longName>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-05-14T13:46:55</dateCreated>
             <dateModified>2011-03-25T13:44:59</dateModified>
             <modifiedBy>UMLLDR</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>Peritoneum</text>
             <type>Manually-curated</type>
                           <classification>
               <name>Common Biorepository Model</name>
               <publicID>3204728</publicID>
               <version>1</version>
               <preferredDefinition>A common model to contain summary-level details of biorepository / biobank holdings which can be advertised through the OBBR Specimen Resource Locator</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>(PAIR-ih-toe-NEE-um) The tissue that lines the abdominal wall and covers most of the organs in the abdomen.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:47</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Pleura</value>
          <valueMeaning>
           <publicID>2559813</publicID>
           <version>1</version>
           <longName>Pleura</longName>
                       <designation>
             <createdBy>GOODINM</createdBy>
             <dateCreated>2017-03-29T10:28:06</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Pleura/Pleural effusion</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-05-14T13:47:46</dateCreated>
             <text>Pleura</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>(PLOOR-a) A thin layer of tissue covering the lungs and the wall of the chest cavity to protect and cushion the lungs. A small amount of fluid that acts as a lubricant allows the lungs to move smoothly in the chest cavity during breathing.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:47</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Prostate</value>
          <valueMeaning>
           <publicID>2567246</publicID>
           <version>1</version>
           <longName>Prostate</longName>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2011-06-08T17:57:47</dateCreated>
             <dateModified>2016-10-20T13:13:39</dateModified>
             <modifiedBy>UMLLDR</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>Prostate</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>A gland in the male reproductive system just below the bladder. It surrounds part of the urethra, the canal that empties the bladder. It produces a fluid that forms part of semen. (NCI-GLOSS)</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:48</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Rectum</value>
          <valueMeaning>
           <publicID>2567247</publicID>
           <version>1</version>
           <longName>Rectum</longName>
                                 <preferredDefinition>The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:48</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Breast</value>
          <valueMeaning>
           <publicID>2561089</publicID>
           <version>1</version>
           <longName>Breast</longName>
                                 <preferredDefinition>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-04-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Kidney</value>
          <valueMeaning>
           <publicID>2561100</publicID>
           <version>1</version>
           <longName>Kidney</longName>
                                 <preferredDefinition>One of the two organs that excrete the urine. The kidneys are bean-shaped organs (about 11 cm long, 5 cm wide, and 3 cm thick) lying on either side of the vertebral column, posterior to the peritoneum, about opposite the twelfth thoracic and first three lumbar vertebrae. SYN ren, nephros.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-04-17T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Chest</value>
          <valueMeaning>
           <publicID>2562261</publicID>
           <version>1</version>
           <longName>Chest</longName>
                                  <definition>
             <createdBy>CHILLIJ</createdBy>
             <dateCreated>2008-05-06T14:58:03</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>includes lungs, mediastinum, chest wall, thoracic spine</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The anterior side of the thorax from the neck to the abdomen. The shape of the chest is often regarded as potential insight into a disease process, as in the case of barrel chest and respiratory dysfunction. </preferredDefinition>
          </valueMeaning>
          <beginDate>2002-08-06T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Cerebellum</value>
          <valueMeaning>
           <publicID>2566001</publicID>
           <version>1</version>
           <longName>Cerebellum</longName>
                                 <preferredDefinition>The portion of the brain located at the base of the skull that is responsible for balance, equilibrium and movement.</preferredDefinition>
          </valueMeaning>
          <beginDate>2003-05-28T13:41:21</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Brainstem</value>
          <valueMeaning>
           <publicID>2566002</publicID>
           <version>1</version>
           <longName>Brainstem</longName>
                                 <preferredDefinition>Brainstem</preferredDefinition>
          </valueMeaning>
          <beginDate>2003-05-28T13:42:47</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Spleen</value>
          <valueMeaning>
           <publicID>2567549</publicID>
           <version>1</version>
           <longName>Spleen</longName>
                                 <preferredDefinition>An organ that produces lymphocytes, filters the blood, stores blood cells, and destroys those that are aging. It is located on the left side of the abdomen near the stomach. (OCC)</preferredDefinition>
          </valueMeaning>
          <beginDate>2003-12-19T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Thyroid</value>
          <valueMeaning>
           <publicID>2567249</publicID>
           <version>1</version>
           <longName>Thyroid</longName>
                                 <preferredDefinition>Thyroid</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-02-09T15:03:26</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Ovary</value>
          <valueMeaning>
           <publicID>2574083</publicID>
           <version>1</version>
           <longName>Ovary</longName>
                                 <preferredDefinition>One of the paired female reproductive glands containing the ova or germ cells; the ovary&apos;s stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova; surrounding this stroma is a more condensed layer of stroma called the tunica albuginea.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-02-09T15:03:26</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Stomach</value>
          <valueMeaning>
           <publicID>2567248</publicID>
           <version>1</version>
           <longName>Stomach</longName>
                                 <preferredDefinition>The organ located between the esophagus and the small intestine where digestion of food occurs before passing to the small intestine.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-02-09T15:03:26</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Mouth</value>
          <valueMeaning>
           <publicID>2568124</publicID>
           <version>1</version>
           <longName>Mouth</longName>
                                 <preferredDefinition>The cavity lying at the upper end of the alimentary canal, bounded on the outside by the lips and inside by the oropharynx and containing in humans the tongue, gums, and teeth.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-02-11T09:22:35</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Skull</value>
          <valueMeaning>
           <publicID>2568921</publicID>
           <version>1</version>
           <longName>Skull</longName>
                                 <preferredDefinition>The skeleton of the head including the bones of the face and the bones enclosing the brain.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:35:45</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Mandible</value>
          <valueMeaning>
           <publicID>2568922</publicID>
           <version>1</version>
           <longName>Mandible</longName>
                                 <preferredDefinition>The largest and strongest bone of the FACE constituting the lower jaw. It supports the lower teeth.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:35:45</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Sternum</value>
          <valueMeaning>
           <publicID>2568924</publicID>
           <version>1</version>
           <longName>Sternum</longName>
                                 <preferredDefinition>No value exists.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:35:45</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Ribs</value>
          <valueMeaning>
           <publicID>2568925</publicID>
           <version>1</version>
           <longName>Ribs</longName>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2011-07-13T16:51:12</dateCreated>
             <text>Ribs</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>Any one of the paired bones, 12 on either side, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk. The long curved bones which form the rib cage. Generally, ribs 1 to 7 are connected to the sternum&apos; by their costal cartilages and are called true ribs, whereas ribs 8 to 12 are termed false ribs.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:37:47</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Humerus</value>
          <valueMeaning>
           <publicID>2568928</publicID>
           <version>1</version>
           <longName>Humerus</longName>
                                 <preferredDefinition>No value exists.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:37:48</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Radius</value>
          <valueMeaning>
           <publicID>2568929</publicID>
           <version>1</version>
           <longName>Radius</longName>
                       <designation>
             <createdBy>UMLLOADER_AIM</createdBy>
             <dateCreated>2008-12-02T09:47:02</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Radius</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>AIM</name>
               <publicID>2614824</publicID>
               <version>1</version>
               <preferredDefinition>Annotations and Imaging Markup (AIM) is an information model used to capture information about how images are perceived by human or machine observers that is directly tied to medical images.</preferredDefinition>
               <classificationSchemeItem>
                <name>ValueDomain</name>
                <publicID>2812708</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>UMLLOADER_AIM</createdBy>
             <dateCreated>2008-12-02T09:47:03</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Radius</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>AIM</name>
               <publicID>2614824</publicID>
               <version>1</version>
               <preferredDefinition>Annotations and Imaging Markup (AIM) is an information model used to capture information about how images are perceived by human or machine observers that is directly tied to medical images.</preferredDefinition>
               <classificationSchemeItem>
                <name>ValueDomain</name>
                <publicID>2812708</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>A straight line from the center to the perimeter of a circle or from the center to the surface of a sphere.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:37:48</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Ulna</value>
          <valueMeaning>
           <publicID>2568930</publicID>
           <version>1</version>
           <longName>Ulna</longName>
                                 <preferredDefinition>Ulna</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:40:01</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Femur</value>
          <valueMeaning>
           <publicID>2568931</publicID>
           <version>1</version>
           <longName>Femur</longName>
                                 <preferredDefinition>The longest and largest bone of the skeleton, it is situated between the hip and the knee.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:40:01</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Tibia</value>
          <valueMeaning>
           <publicID>2568932</publicID>
           <version>1</version>
           <longName>Tibia</longName>
                                 <preferredDefinition>The second longest bone of the skeleton. It is located on the medial side of the lower leg, articulating with the FIBULA laterally, the TALUS distally, and the FEMUR proximally.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:40:01</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Fibula</value>
          <valueMeaning>
           <publicID>2568933</publicID>
           <version>1</version>
           <longName>Fibula</longName>
                                 <preferredDefinition>The bone of the lower leg lateral to and smaller than the tibia. In proportion to its length, it is the most slender of the long bones.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T08:40:01</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung</value>
          <valueMeaning>
           <publicID>2567244</publicID>
           <version>1</version>
           <longName>Lung</longName>
                                 <preferredDefinition>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has but two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T11:05:18</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Liver</value>
          <valueMeaning>
           <publicID>2567243</publicID>
           <version>1</version>
           <longName>Liver</longName>
                                 <preferredDefinition>A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T11:06:36</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Skin</value>
          <valueMeaning>
           <publicID>2567252</publicID>
           <version>1</version>
           <longName>Skin</longName>
                                 <preferredDefinition>An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-03-31T11:07:55</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Sigmoid Colon</value>
          <valueMeaning>
           <publicID>2581640</publicID>
           <version>1</version>
           <longName>Sigmoid Colon</longName>
                                 <preferredDefinition>The portion of the colon that connects to the descending colon above and the rectum below.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T15:18:49</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Anus</value>
          <valueMeaning>
           <publicID>2569544</publicID>
           <version>1</version>
           <longName>Anus</longName>
                                 <preferredDefinition>(AY-nus) The opening of the rectum to the outside of the body.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-12T11:26:45</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Jejunum</value>
          <valueMeaning>
           <publicID>2569556</publicID>
           <version>1</version>
           <longName>Jejunum</longName>
                                 <preferredDefinition>No value exists.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-12T11:34:54</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Ileum</value>
          <valueMeaning>
           <publicID>2569557</publicID>
           <version>1</version>
           <longName>Ileum</longName>
                                 <preferredDefinition>Ileum</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-12T11:34:54</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Pelvis</value>
          <valueMeaning>
           <publicID>2562158</publicID>
           <version>1</version>
           <longName>Pelvis</longName>
                                 <preferredDefinition>The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-12T11:13:32</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Vagina</value>
          <valueMeaning>
           <publicID>2574082</publicID>
           <version>1</version>
           <longName>Vagina</longName>
                                 <preferredDefinition>The female genital canal, extending from the uterus to the vulva.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-12T11:13:32</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Pancreas</value>
          <valueMeaning>
           <publicID>2567245</publicID>
           <version>1</version>
           <longName>Pancreas</longName>
                       <designation>
             <createdBy>ROUILLAS</createdBy>
             <dateCreated>2013-10-30T14:22:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Pancreas adenocarcinoma/other</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                 <preferredDefinition>A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon).</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-12T11:45:09</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Cervix</value>
          <valueMeaning>
           <publicID>2567212</publicID>
           <version>1</version>
           <longName>Cervix</longName>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2011-06-08T17:55:36</dateCreated>
             <dateModified>2016-10-20T13:13:39</dateModified>
             <modifiedBy>UMLLDR</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>Cervix</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>(SER-viks) The lower, narrow end of the uterus that forms a canal between the uterus and vagina.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-13T13:17:09</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Colon</value>
          <valueMeaning>
           <publicID>2567239</publicID>
           <version>1</version>
           <longName>Colon</longName>
                                 <preferredDefinition>The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-13T13:17:09</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Uterus</value>
          <valueMeaning>
           <publicID>2567250</publicID>
           <version>1</version>
           <longName>Uterus</longName>
                                 <preferredDefinition>A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-05-13T13:19:08</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Bone Marrow</value>
          <valueMeaning>
           <publicID>2581613</publicID>
           <version>1</version>
           <longName>Bone Marrow</longName>
                       <designation>
             <createdBy>WONGW</createdBy>
             <dateCreated>2014-07-28T15:38:57</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Bone marrow</name>
             <type>VM Alt Name</type>
             <context>COG</context>
                         </designation>
                                 <preferredDefinition>The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. </preferredDefinition>
          </valueMeaning>
          <beginDate>2004-06-02T16:05:56</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Back</value>
          <valueMeaning>
           <publicID>2569779</publicID>
           <version>1</version>
           <longName>Back</longName>
                                 <preferredDefinition>The dorsal area between the base of the neck and the sacrum. </preferredDefinition>
          </valueMeaning>
          <beginDate>2004-06-04T11:34:49</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Testicle</value>
          <valueMeaning>
           <publicID>2569938</publicID>
           <version>1</version>
           <longName>Testicle</longName>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2011-07-13T16:55:04</dateCreated>
             <dateModified>2016-10-20T13:13:39</dateModified>
             <modifiedBy>UMLLDR</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>TESTICLE</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>Either of the paired male reproductive glands that produce the male germ cells and the male hormones.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-06-04T18:01:16</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Duodenum</value>
          <valueMeaning>
           <publicID>2569848</publicID>
           <version>1</version>
           <longName>Duodenum</longName>
                                 <preferredDefinition>(doo-ah-DEE-num) The first part of the small intestine.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-06-04T15:50:07</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Penis</value>
          <valueMeaning>
           <publicID>2569903</publicID>
           <version>1</version>
           <longName>Penis</longName>
                                 <preferredDefinition>An external male reproductive organ. It contains a tube called the urethra, which carries semen and urine to the outside of the body.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-06-04T17:29:23</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Pharynx</value>
          <valueMeaning>
           <publicID>2569909</publicID>
           <version>1</version>
           <longName>Pharynx</longName>
                                 <preferredDefinition>(FAIR-inks) The hollow tube about 5 inches long that starts behind the nose and ends at the top of the trachea (windpipe) and esophagus (the tube that goes to the stomach).</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-06-04T17:30:54</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Nasopharynx</value>
          <valueMeaning>
           <publicID>2571143</publicID>
           <version>1</version>
           <longName>Nasopharynx</longName>
                                 <preferredDefinition>The nasal part of the pharynx, lying above the level of the soft palate.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-07-20T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Ureter</value>
          <valueMeaning>
           <publicID>2567218</publicID>
           <version>1</version>
           <longName>Ureter</longName>
                                 <preferredDefinition>The thick-walled tube that carries urine from each kidney to the bladder.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-08-27T16:04:25</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Peripheral Blood</value>
          <valueMeaning>
           <publicID>2559785</publicID>
           <version>1</version>
           <longName>PERIPHERAL BLOOD</longName>
                       <designation>
             <createdBy>WONGW</createdBy>
             <dateCreated>2013-05-15T14:55:43</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Peripheral blood</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                         </designation>
            <designation>
             <createdBy>WONGW</createdBy>
             <dateCreated>2015-02-24T17:16:02</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Blood</name>
             <type>VM Alt Name</type>
             <context>COG</context>
                         </designation>
                                 <preferredDefinition>PERIPHERAL BLOOD</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-06T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>CSF</value>
          <valueMeaning>
           <publicID>2567374</publicID>
           <version>1</version>
           <longName>Cerebrospinal fluid</longName>
                                 <preferredDefinition>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-06T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Cerebrum</value>
          <valueMeaning>
           <publicID>2571793</publicID>
           <version>1</version>
           <longName>Cerebrum</longName>
                                 <preferredDefinition>Cerebrum</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-06T13:54:59</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Bile Duct</value>
          <valueMeaning>
           <publicID>2571102</publicID>
           <version>1</version>
           <longName>Bile Duct</longName>
                                 <preferredDefinition>A tube through which bile passes in and out of the liver.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Fallopian Tube</value>
          <valueMeaning>
           <publicID>2567224</publicID>
           <version>1</version>
           <longName>Fallopian tube</longName>
                                 <preferredDefinition>One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Ear, External</value>
          <valueMeaning>
           <publicID>2571867</publicID>
           <version>1</version>
           <longName>Ear, External</longName>
                                 <preferredDefinition>Ear, External</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Ear, Inner</value>
          <valueMeaning>
           <publicID>2571868</publicID>
           <version>1</version>
           <longName>Ear, Inner</longName>
                                 <preferredDefinition>Ear, Inner</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Ear, Mid</value>
          <valueMeaning>
           <publicID>2571869</publicID>
           <version>1</version>
           <longName>Ear, Mid</longName>
                                 <preferredDefinition>Ear, Mid</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Eye, Globe</value>
          <valueMeaning>
           <publicID>2571870</publicID>
           <version>1</version>
           <longName>Eye, Globe</longName>
                                 <preferredDefinition>Eye, Globe</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Eye, Orbit</value>
          <valueMeaning>
           <publicID>2571871</publicID>
           <version>1</version>
           <longName>Eye, Orbit</longName>
                                 <preferredDefinition>Eye, Orbit</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Nose</value>
          <valueMeaning>
           <publicID>2571872</publicID>
           <version>1</version>
           <longName>Nose</longName>
                                 <preferredDefinition>Nose</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Sinuses</value>
          <valueMeaning>
           <publicID>2571873</publicID>
           <version>1</version>
           <longName>Sinuses</longName>
                                 <preferredDefinition>Sinuses</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Throat</value>
          <valueMeaning>
           <publicID>2571874</publicID>
           <version>1</version>
           <longName>Throat</longName>
                                 <preferredDefinition>Throat</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Axilla</value>
          <valueMeaning>
           <publicID>2571875</publicID>
           <version>1</version>
           <longName>Lymph Node, Axilla</longName>
                                 <preferredDefinition>Lymph Node(s), Axilla</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Brachial</value>
          <valueMeaning>
           <publicID>2571876</publicID>
           <version>1</version>
           <longName>Lymph Node, Brachial</longName>
                                 <preferredDefinition>Lymph Node(s), Brachial</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Cervical</value>
          <valueMeaning>
           <publicID>2571877</publicID>
           <version>1</version>
           <longName>Lymph Node, Cervical</longName>
                                 <preferredDefinition>Lymph Node(s), Cervical</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Epitrochlear</value>
          <valueMeaning>
           <publicID>2571878</publicID>
           <version>1</version>
           <longName>Lymph Node, Epitrochlear</longName>
                                 <preferredDefinition>Lymph Node(s), Epitrochlear</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Femoral</value>
          <valueMeaning>
           <publicID>2571879</publicID>
           <version>1</version>
           <longName>Lymph Node, Femoral</longName>
                                 <preferredDefinition>Lymph Node(s), Femoral</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Hilar</value>
          <valueMeaning>
           <publicID>2571880</publicID>
           <version>1</version>
           <longName>Lymph Node, Hilar</longName>
                                 <preferredDefinition>Lymph Node(s), Hilar</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Iliac</value>
          <valueMeaning>
           <publicID>2571881</publicID>
           <version>1</version>
           <longName>Lymph Node, Iliac</longName>
                                 <preferredDefinition>Lymph Node(s), Iliac</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Inguinal</value>
          <valueMeaning>
           <publicID>2571882</publicID>
           <version>1</version>
           <longName>Lymph Node, Inguinal</longName>
                                 <preferredDefinition>Lymph Node(s), Inguinal</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Internal Mammary</value>
          <valueMeaning>
           <publicID>2571883</publicID>
           <version>1</version>
           <longName>Lymph Node, Internal Mammary</longName>
                                 <preferredDefinition>Lymph Node(s), Internal Mammary</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN</value>
          <valueMeaning>
           <publicID>2567213</publicID>
           <version>1</version>
           <longName>Lymph node</longName>
                                 <preferredDefinition>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Mediastinal</value>
          <valueMeaning>
           <publicID>2571884</publicID>
           <version>1</version>
           <longName>Lymph Node, Mediastinal</longName>
                                 <preferredDefinition>Lymph Node(s), Mediastinal</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Mesenteric</value>
          <valueMeaning>
           <publicID>2571885</publicID>
           <version>1</version>
           <longName>Lymph Node, Mesenteric</longName>
                                 <preferredDefinition>Lymph Node(s), Mesenteric</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Mid Pelvis</value>
          <valueMeaning>
           <publicID>2571890</publicID>
           <version>1</version>
           <longName>Lymph Node, Mid-Pelvis</longName>
                                 <preferredDefinition>Lymph Node(s), Mid-Pelvis</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Neck</value>
          <valueMeaning>
           <publicID>2571891</publicID>
           <version>1</version>
           <longName>Lymph Node, Neck</longName>
                                 <preferredDefinition>Lymph Node(s), Neck</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Occipital</value>
          <valueMeaning>
           <publicID>2571892</publicID>
           <version>1</version>
           <longName>Lymph Node, Occipital</longName>
                                 <preferredDefinition>Lymph Node(s), Occipital</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Paraaortic</value>
          <valueMeaning>
           <publicID>2571893</publicID>
           <version>1</version>
           <longName>Lymph Node, Paraaortic</longName>
                                 <preferredDefinition>Lymph Node(s), Paraaortic</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Pelvis</value>
          <valueMeaning>
           <publicID>2571894</publicID>
           <version>1</version>
           <longName>Lymph Node, Pelvis</longName>
                                 <preferredDefinition>Lymph Node(s), Pelvis</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Periauricular</value>
          <valueMeaning>
           <publicID>2571895</publicID>
           <version>1</version>
           <longName>Lymph Node, Periauricular</longName>
                                 <preferredDefinition>Lymph Node(s), Periauricular</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Popliteal</value>
          <valueMeaning>
           <publicID>2571896</publicID>
           <version>1</version>
           <longName>Lymph Node, Popliteal</longName>
                                 <preferredDefinition>Lymph Node(s), Popliteal</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Retroperitoneal</value>
          <valueMeaning>
           <publicID>2571897</publicID>
           <version>1</version>
           <longName>Lymph Node, Retroperitoneal</longName>
                                 <preferredDefinition>Lymph Node(s), Retroperitoneal</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Subclavian</value>
          <valueMeaning>
           <publicID>2571898</publicID>
           <version>1</version>
           <longName>Lymph Node(s), Subclavian</longName>
                                 <preferredDefinition>Lymph Node, Subclavian</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Submental</value>
          <valueMeaning>
           <publicID>2571899</publicID>
           <version>1</version>
           <longName>Lymph Node, Submental</longName>
                                 <preferredDefinition>Lymph Node(s), Submental</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>LN, Supraclavicular</value>
          <valueMeaning>
           <publicID>2571900</publicID>
           <version>1</version>
           <longName>Lymph Node, Supraclavicular</longName>
                                 <preferredDefinition>Lymph Node(s), Supraclavicular</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Feet</value>
          <valueMeaning>
           <publicID>2571901</publicID>
           <version>1</version>
           <longName>Feet</longName>
                                 <preferredDefinition>Feet</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Hands</value>
          <valueMeaning>
           <publicID>2571902</publicID>
           <version>1</version>
           <longName>Hands</longName>
                                 <preferredDefinition>Hands</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Iliac</value>
          <valueMeaning>
           <publicID>2571903</publicID>
           <version>1</version>
           <longName>Iliac Bone</longName>
                                 <preferredDefinition>Iliac Bone</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Muscle, UE Distal</value>
          <valueMeaning>
           <publicID>2571906</publicID>
           <version>1</version>
           <longName>Muscle, Upper Extremity Distal</longName>
                                 <preferredDefinition>Muscle, Upper Extremity Distal</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Muscle, UE Proximal</value>
          <valueMeaning>
           <publicID>2571907</publicID>
           <version>1</version>
           <longName>Muscle, Upper Extremity Proximal</longName>
                                 <preferredDefinition>Muscle, Upper Extremity Proximal</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Muscle, LE DIstal</value>
          <valueMeaning>
           <publicID>2571908</publicID>
           <version>1</version>
           <longName>Muscle, Lower Extremity Distal</longName>
                                 <preferredDefinition>Muscle, Lower Extremity Distal</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Muscle, LE Proximal</value>
          <valueMeaning>
           <publicID>2571909</publicID>
           <version>1</version>
           <longName>Muscle, Lower Extremity Proximal</longName>
                                 <preferredDefinition>Muscle, Lower Extremity Proximal</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Spine-C</value>
          <valueMeaning>
           <publicID>2571910</publicID>
           <version>1</version>
           <longName>Spine, Cervical</longName>
                                 <preferredDefinition>Spine, Cervical</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Spine-L</value>
          <valueMeaning>
           <publicID>2571911</publicID>
           <version>1</version>
           <longName>Spine, Lumbar</longName>
                                 <preferredDefinition>Spine, Lumbar</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Spine-S</value>
          <valueMeaning>
           <publicID>2571912</publicID>
           <version>1</version>
           <longName>Spine, Sacral</longName>
                                 <preferredDefinition>Spine, Sacral</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Spine-T</value>
          <valueMeaning>
           <publicID>2571913</publicID>
           <version>1</version>
           <longName>Spine, Thoracic</longName>
                                 <preferredDefinition>Spine, Thoracic</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Adrenal Gland</value>
          <valueMeaning>
           <publicID>2569663</publicID>
           <version>1</version>
           <longName>Adrenal Gland</longName>
                       <designation>
             <createdBy>ROUILLAS</createdBy>
             <dateCreated>2014-06-26T11:14:20</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Adrenal(s)</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
            <designation>
             <createdBy>WONGW</createdBy>
             <dateCreated>2015-08-06T16:58:36</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Adrenal gland</name>
             <type>VM Alt Name</type>
             <context>COG</context>
                         </designation>
            <designation>
             <createdBy>GOODINM</createdBy>
             <dateCreated>2017-03-29T10:28:06</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Adrenal</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
                                 <preferredDefinition>Paired glands situated in the retroperitoneal tissues at the superior pole of each kidney.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Other Site</value>
          <valueMeaning>
           <publicID>2571914</publicID>
           <version>1</version>
           <longName>Other Site</longName>
                                 <preferredDefinition>Other Site</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-15T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Hilum</value>
          <valueMeaning>
           <publicID>2571940</publicID>
           <version>1</version>
           <longName>Hilum, Thoracic</longName>
                                 <preferredDefinition>Hilum, Thoracic or Pulmonary</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Ant-LLL</value>
          <valueMeaning>
           <publicID>2571941</publicID>
           <version>1</version>
           <longName>Lung, Anterior Left Lower Lobe</longName>
                                 <preferredDefinition>Left Lower Lobe of the Anterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Ant-LUL</value>
          <valueMeaning>
           <publicID>2571942</publicID>
           <version>1</version>
           <longName>Lung, Anterior Left Upper Lobe</longName>
                                 <preferredDefinition>Left Upper Lobe of the Anterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Ant-RLL</value>
          <valueMeaning>
           <publicID>2571943</publicID>
           <version>1</version>
           <longName>Lung, Anterior Right Lower Lobe</longName>
                                 <preferredDefinition>Right Lower Lobe of the Anterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Ant-RML</value>
          <valueMeaning>
           <publicID>2571944</publicID>
           <version>1</version>
           <longName>Lung, Anterior RIght Middle Lobe</longName>
                                 <preferredDefinition>Right Middle Lobe of the Anterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Ant-RUL</value>
          <valueMeaning>
           <publicID>2571945</publicID>
           <version>1</version>
           <longName>Lung, Anterior Right Upper Lobe</longName>
                                 <preferredDefinition>Right Upper Lobe of the Anterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Post-LLL</value>
          <valueMeaning>
           <publicID>2571946</publicID>
           <version>1</version>
           <longName>Lung, Posterior Left Lower Lobe</longName>
                                 <preferredDefinition>Left Lower Lobe of the Posterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Post-LUL</value>
          <valueMeaning>
           <publicID>2571947</publicID>
           <version>1</version>
           <longName>Lung, Posterior Left Upper Lobe</longName>
                                 <preferredDefinition>Left Upper Lobe of the Posterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Post-RLL</value>
          <valueMeaning>
           <publicID>2571948</publicID>
           <version>1</version>
           <longName>Lung, Posterior Right Lower Lobe</longName>
                                 <preferredDefinition>Right Lower Lobe of the Posterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Post-RML</value>
          <valueMeaning>
           <publicID>2571949</publicID>
           <version>1</version>
           <longName>Lung, Posterior Right Middle Lobe</longName>
                                 <preferredDefinition>Right Middle Lobe of the Posterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Lung, Post-RUL</value>
          <valueMeaning>
           <publicID>2571950</publicID>
           <version>1</version>
           <longName>Lung, Posterior Right Upper Lobe</longName>
                                 <preferredDefinition>Right Upper Lobe of the Posterior Lung</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-09-16T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>Bladder</value>
          <valueMeaning>
           <publicID>2567211</publicID>
           <version>1</version>
           <longName>Bladder</longName>
                                 <preferredDefinition>The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.</preferredDefinition>
          </valueMeaning>
          <beginDate>2004-12-17T16:23:42</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Primary Site of Disease</name>
         <type>Preferred Question Text</type>
         <context>CCR</context>
         <doctext>Primary Site of Disease</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF TEXT1</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>Primary Site of Disease Name</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF TEXT 1</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Where is the location of the primary tumor?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 2</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Is the primary tumor a bone or soft tissue tumor?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text2</name>
         <type>Alternate Question Text</type>
         <context>Alliance</context>
         <doctext>Primary tumor site</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=2188441&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Adrenal Gland</value>
        <meaningText>Adrenal Gland</meaningText>
        <description>Paired glands situated in the retroperitoneal tissues at the superior pole of each kidney.</description>
                <valueMeaning>
         <publicID>2569663</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>Anus</value>
        <meaningText>Anus</meaningText>
        <description>(AY-nus) The opening of the rectum to the outside of the body.</description>
                <valueMeaning>
         <publicID>2569544</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>10</displayOrder>
        <value>Breast</value>
        <meaningText>Breast</meaningText>
        <description>One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.</description>
                <valueMeaning>
         <publicID>2561089</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>100</displayOrder>
        <value>Spine-T</value>
        <meaningText>Spine, Thoracic</meaningText>
        <description>Spine, Thoracic</description>
                <valueMeaning>
         <publicID>2571913</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>101</displayOrder>
        <value>Spleen</value>
        <meaningText>Spleen</meaningText>
        <description>An organ that produces lymphocytes, filters the blood, stores blood cells, and destroys those that are aging. It is located on the left side of the abdomen near the stomach. (OCC)</description>
                <valueMeaning>
         <publicID>2567549</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>102</displayOrder>
        <value>Sternum</value>
        <meaningText>Sternum</meaningText>
        <description>No value exists.</description>
                <valueMeaning>
         <publicID>2568924</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>103</displayOrder>
        <value>Stomach</value>
        <meaningText>Stomach</meaningText>
        <description>The organ located between the esophagus and the small intestine where digestion of food occurs before passing to the small intestine.</description>
                <valueMeaning>
         <publicID>2567248</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>104</displayOrder>
        <value>Testicle</value>
        <meaningText>Testicle</meaningText>
        <description>Either of the paired male reproductive glands that produce the male germ cells and the male hormones.</description>
                <valueMeaning>
         <publicID>2569938</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>105</displayOrder>
        <value>Throat</value>
        <meaningText>Throat</meaningText>
        <description>Throat</description>
                <valueMeaning>
         <publicID>2571874</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>106</displayOrder>
        <value>Thyroid</value>
        <meaningText>Thyroid</meaningText>
        <description>Thyroid</description>
                <valueMeaning>
         <publicID>2567249</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>107</displayOrder>
        <value>Tibia</value>
        <meaningText>Tibia</meaningText>
        <description>The second longest bone of the skeleton. It is located on the medial side of the lower leg, articulating with the FIBULA laterally, the TALUS distally, and the FEMUR proximally.</description>
                <valueMeaning>
         <publicID>2568932</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>108</displayOrder>
        <value>Ulna</value>
        <meaningText>Ulna</meaningText>
        <description>Ulna</description>
                <valueMeaning>
         <publicID>2568930</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>109</displayOrder>
        <value>Ureter</value>
        <meaningText>Ureter</meaningText>
        <description>The thick-walled tube that carries urine from each kidney to the bladder.</description>
                <valueMeaning>
         <publicID>2567218</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>11</displayOrder>
        <value>Cerebellum</value>
        <meaningText>Cerebellum</meaningText>
        <description>The portion of the brain located at the base of the skull that is responsible for balance, equilibrium and movement.</description>
                <valueMeaning>
         <publicID>2566001</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>110</displayOrder>
        <value>Uterus</value>
        <meaningText>Uterus</meaningText>
        <description>A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.</description>
                <valueMeaning>
         <publicID>2567250</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>111</displayOrder>
        <value>Vagina</value>
        <meaningText>Vagina</meaningText>
        <description>The female genital canal, extending from the uterus to the vulva.</description>
                <valueMeaning>
         <publicID>2574082</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>12</displayOrder>
        <value>Cerebrum</value>
        <meaningText>Cerebrum</meaningText>
        <description>Cerebrum</description>
                <valueMeaning>
         <publicID>2571793</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>13</displayOrder>
        <value>Cervix</value>
        <meaningText>Cervix</meaningText>
        <description>(SER-viks) The lower, narrow end of the uterus that forms a canal between the uterus and vagina.</description>
                <valueMeaning>
         <publicID>2567212</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>14</displayOrder>
        <value>Chest</value>
        <meaningText>Chest</meaningText>
        <description>The part of the human body between the neck and the diaphragm or the corresponding part in other vertebrates.</description>
                <valueMeaning>
         <publicID>2562261</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>15</displayOrder>
        <value>Colon</value>
        <meaningText>Colon</meaningText>
        <description>The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.</description>
                <valueMeaning>
         <publicID>2567239</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>16</displayOrder>
        <value>CSF</value>
        <meaningText>Cerebrospinal fluid</meaningText>
        <description>The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.</description>
                <valueMeaning>
         <publicID>2567374</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>17</displayOrder>
        <value>Duodenum</value>
        <meaningText>Duodenum</meaningText>
        <description>(doo-ah-DEE-num) The first part of the small intestine.</description>
                <valueMeaning>
         <publicID>2569848</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>18</displayOrder>
        <value>Ear, External</value>
        <meaningText>Ear, External</meaningText>
        <description>Ear, External</description>
                <valueMeaning>
         <publicID>2571867</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>19</displayOrder>
        <value>Ear, Inner</value>
        <meaningText>Ear, Inner</meaningText>
        <description>Ear, Inner</description>
                <valueMeaning>
         <publicID>2571868</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>Appendix</value>
        <meaningText>Appendix</meaningText>
        <description>Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ.</description>
                <valueMeaning>
         <publicID>2558237</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>20</displayOrder>
        <value>Ear, Mid</value>
        <meaningText>Ear, Mid</meaningText>
        <description>Ear, Mid</description>
                <valueMeaning>
         <publicID>2571869</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>21</displayOrder>
        <value>Esophagus</value>
        <meaningText>Esophagus</meaningText>
        <description>The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.</description>
                <valueMeaning>
         <publicID>2567240</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>22</displayOrder>
        <value>Eye, Globe</value>
        <meaningText>Eye, Globe</meaningText>
        <description>Eye, Globe</description>
                <valueMeaning>
         <publicID>2571870</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>23</displayOrder>
        <value>Eye, Orbit</value>
        <meaningText>Eye, Orbit</meaningText>
        <description>Eye, Orbit</description>
                <valueMeaning>
         <publicID>2571871</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>24</displayOrder>
        <value>Fallopian Tube</value>
        <meaningText>Fallopian tube</meaningText>
        <description>One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.</description>
                <valueMeaning>
         <publicID>2567224</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>25</displayOrder>
        <value>Feet</value>
        <meaningText>Feet</meaningText>
        <description>Feet</description>
                <valueMeaning>
         <publicID>2571901</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>26</displayOrder>
        <value>Femur</value>
        <meaningText>Femur</meaningText>
        <description>The longest and largest bone of the skeleton, it is situated between the hip and the knee.</description>
                <valueMeaning>
         <publicID>2568931</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>27</displayOrder>
        <value>Fibula</value>
        <meaningText>Fibula</meaningText>
        <description>The bone of the lower leg lateral to and smaller than the tibia. In proportion to its length, it is the most slender of the long bones.</description>
                <valueMeaning>
         <publicID>2568933</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>28</displayOrder>
        <value>Hands</value>
        <meaningText>Hands</meaningText>
        <description>Hands</description>
                <valueMeaning>
         <publicID>2571902</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>29</displayOrder>
        <value>Hilum</value>
        <meaningText>Hilum, Thoracic</meaningText>
        <description>Hilum, Thoracic or Pulmonary</description>
                <valueMeaning>
         <publicID>2571940</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>3</displayOrder>
        <value>Back</value>
        <meaningText>Back</meaningText>
        <description>The dorsal area between the base of the neck and the sacrum.</description>
                <valueMeaning>
         <publicID>2569779</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>30</displayOrder>
        <value>Humerus</value>
        <meaningText>Humerus</meaningText>
        <description>No value exists.</description>
                <valueMeaning>
         <publicID>2568928</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>31</displayOrder>
        <value>Ileum</value>
        <meaningText>Ileum</meaningText>
        <description>Ileum</description>
                <valueMeaning>
         <publicID>2569557</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>32</displayOrder>
        <value>Iliac</value>
        <meaningText>Iliac Bone</meaningText>
        <description>Iliac Bone</description>
                <valueMeaning>
         <publicID>2571903</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>33</displayOrder>
        <value>Jejunum</value>
        <meaningText>Jejunum</meaningText>
        <description>No value exists.</description>
                <valueMeaning>
         <publicID>2569556</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>34</displayOrder>
        <value>Kidney</value>
        <meaningText>Kidney</meaningText>
        <description>One of the two organs that excrete the urine. The kidneys are bean-shaped organs (about 11 cm long, 5 cm wide, and 3 cm thick) lying on either side of the vertebral column, posterior to the peritoneum, about opposite the twelfth thoracic and first three lumbar vertebrae. SYN ren, nephros.</description>
                <valueMeaning>
         <publicID>2561100</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>35</displayOrder>
        <value>Liver</value>
        <meaningText>Liver</meaningText>
        <description>A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.</description>
                <valueMeaning>
         <publicID>2567243</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>36</displayOrder>
        <value>LN</value>
        <meaningText>Lymph node</meaningText>
        <description>A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.</description>
                <valueMeaning>
         <publicID>2567213</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>37</displayOrder>
        <value>LN, Axilla</value>
        <meaningText>Lymph Node, Axilla</meaningText>
        <description>Lymph Node(s), Axilla</description>
                <valueMeaning>
         <publicID>2571875</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>38</displayOrder>
        <value>LN, Brachial</value>
        <meaningText>Lymph Node, Brachial</meaningText>
        <description>Lymph Node(s), Brachial</description>
                <valueMeaning>
         <publicID>2571876</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>39</displayOrder>
        <value>LN, Cervical</value>
        <meaningText>Lymph Node, Cervical</meaningText>
        <description>Lymph Node(s), Cervical</description>
                <valueMeaning>
         <publicID>2571877</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>4</displayOrder>
        <value>Bile Duct</value>
        <meaningText>Bile Duct</meaningText>
        <description>A tube through which bile passes in and out of the liver.</description>
                <valueMeaning>
         <publicID>2571102</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>40</displayOrder>
        <value>LN, Epitrochlear</value>
        <meaningText>Lymph Node, Epitrochlear</meaningText>
        <description>Lymph Node(s), Epitrochlear</description>
                <valueMeaning>
         <publicID>2571878</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>41</displayOrder>
        <value>LN, Femoral</value>
        <meaningText>Lymph Node, Femoral</meaningText>
        <description>Lymph Node(s), Femoral</description>
                <valueMeaning>
         <publicID>2571879</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>42</displayOrder>
        <value>LN, Hilar</value>
        <meaningText>Lymph Node, Hilar</meaningText>
        <description>Lymph Node(s), Hilar</description>
                <valueMeaning>
         <publicID>2571880</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>43</displayOrder>
        <value>LN, Iliac</value>
        <meaningText>Lymph Node, Iliac</meaningText>
        <description>Lymph Node(s), Iliac</description>
                <valueMeaning>
         <publicID>2571881</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>44</displayOrder>
        <value>LN, Inguinal</value>
        <meaningText>Lymph Node, Inguinal</meaningText>
        <description>Lymph Node(s), Inguinal</description>
                <valueMeaning>
         <publicID>2571882</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>45</displayOrder>
        <value>LN, Internal Mammary</value>
        <meaningText>Lymph Node, Internal Mammary</meaningText>
        <description>Lymph Node(s), Internal Mammary</description>
                <valueMeaning>
         <publicID>2571883</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>46</displayOrder>
        <value>LN, Mediastinal</value>
        <meaningText>Lymph Node, Mediastinal</meaningText>
        <description>Lymph Node(s), Mediastinal</description>
                <valueMeaning>
         <publicID>2571884</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>47</displayOrder>
        <value>LN, Mesenteric</value>
        <meaningText>Lymph Node, Mesenteric</meaningText>
        <description>Lymph Node(s), Mesenteric</description>
                <valueMeaning>
         <publicID>2571885</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>48</displayOrder>
        <value>LN, Mid Pelvis</value>
        <meaningText>Lymph Node, Mid-Pelvis</meaningText>
        <description>Lymph Node(s), Mid-Pelvis</description>
                <valueMeaning>
         <publicID>2571890</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>49</displayOrder>
        <value>LN, Neck</value>
        <meaningText>Lymph Node, Neck</meaningText>
        <description>Lymph Node(s), Neck</description>
                <valueMeaning>
         <publicID>2571891</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>5</displayOrder>
        <value>Bladder</value>
        <meaningText>Bladder</meaningText>
        <description>The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.</description>
                <valueMeaning>
         <publicID>2567211</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>50</displayOrder>
        <value>LN, Occipital</value>
        <meaningText>Lymph Node, Occipital</meaningText>
        <description>Lymph Node(s), Occipital</description>
                <valueMeaning>
         <publicID>2571892</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>51</displayOrder>
        <value>LN, Paraaortic</value>
        <meaningText>Lymph Node, Paraaortic</meaningText>
        <description>Lymph Node(s), Paraaortic</description>
                <valueMeaning>
         <publicID>2571893</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>52</displayOrder>
        <value>LN, Pelvis</value>
        <meaningText>Lymph Node, Pelvis</meaningText>
        <description>Lymph Node(s), Pelvis</description>
                <valueMeaning>
         <publicID>2571894</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>53</displayOrder>
        <value>LN, Periauricular</value>
        <meaningText>Lymph Node, Periauricular</meaningText>
        <description>Lymph Node(s), Periauricular</description>
                <valueMeaning>
         <publicID>2571895</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>54</displayOrder>
        <value>LN, Popliteal</value>
        <meaningText>Lymph Node, Popliteal</meaningText>
        <description>Lymph Node(s), Popliteal</description>
                <valueMeaning>
         <publicID>2571896</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>55</displayOrder>
        <value>LN, Retroperitoneal</value>
        <meaningText>Lymph Node, Retroperitoneal</meaningText>
        <description>Lymph Node(s), Retroperitoneal</description>
                <valueMeaning>
         <publicID>2571897</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>56</displayOrder>
        <value>LN, Subclavian</value>
        <meaningText>Lymph Node(s), Subclavian</meaningText>
        <description>Lymph Node, Subclavian</description>
                <valueMeaning>
         <publicID>2571898</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>57</displayOrder>
        <value>LN, Submental</value>
        <meaningText>Lymph Node, Submental</meaningText>
        <description>Lymph Node(s), Submental</description>
                <valueMeaning>
         <publicID>2571899</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>58</displayOrder>
        <value>LN, Supraclavicular</value>
        <meaningText>Lymph Node, Supraclavicular</meaningText>
        <description>Lymph Node(s), Supraclavicular</description>
                <valueMeaning>
         <publicID>2571900</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>59</displayOrder>
        <value>Lung</value>
        <meaningText>Lung</meaningText>
        <description>One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has but two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.</description>
                <valueMeaning>
         <publicID>2567244</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>6</displayOrder>
        <value>Bone</value>
        <meaningText>Bone</meaningText>
        <description>Bone; a rigid connective tissue that makes up the skeleton of vertebrates.</description>
                <valueMeaning>
         <publicID>2816296</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>60</displayOrder>
        <value>Lung, Ant-LLL</value>
        <meaningText>Lung, Anterior Left Lower Lobe</meaningText>
        <description>Left Lower Lobe of the Anterior Lung</description>
                <valueMeaning>
         <publicID>2571941</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>61</displayOrder>
        <value>Lung, Ant-LUL</value>
        <meaningText>Lung, Anterior Left Upper Lobe</meaningText>
        <description>Left Upper Lobe of the Anterior Lung</description>
                <valueMeaning>
         <publicID>2571942</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>62</displayOrder>
        <value>Lung, Ant-RLL</value>
        <meaningText>Lung, Anterior Right Lower Lobe</meaningText>
        <description>Right Lower Lobe of the Anterior Lung</description>
                <valueMeaning>
         <publicID>2571943</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>63</displayOrder>
        <value>Lung, Ant-RML</value>
        <meaningText>Lung, Anterior RIght Middle Lobe</meaningText>
        <description>Right Middle Lobe of the Anterior Lung</description>
                <valueMeaning>
         <publicID>2571944</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>64</displayOrder>
        <value>Lung, Ant-RUL</value>
        <meaningText>Lung, Anterior Right Upper Lobe</meaningText>
        <description>Right Upper Lobe of the Anterior Lung</description>
                <valueMeaning>
         <publicID>2571945</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>65</displayOrder>
        <value>Lung, Post-LLL</value>
        <meaningText>Lung, Posterior Left Lower Lobe</meaningText>
        <description>Left Lower Lobe of the Posterior Lung</description>
                <valueMeaning>
         <publicID>2571946</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>66</displayOrder>
        <value>Lung, Post-LUL</value>
        <meaningText>Lung, Posterior Left Upper Lobe</meaningText>
        <description>Left Upper Lobe of the Posterior Lung</description>
                <valueMeaning>
         <publicID>2571947</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>67</displayOrder>
        <value>Lung, Post-RLL</value>
        <meaningText>Lung, Posterior Right Lower Lobe</meaningText>
        <description>Right Lower Lobe of the Posterior Lung</description>
                <valueMeaning>
         <publicID>2571948</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>68</displayOrder>
        <value>Lung, Post-RML</value>
        <meaningText>Lung, Posterior Right Middle Lobe</meaningText>
        <description>Right Middle Lobe of the Posterior Lung</description>
                <valueMeaning>
         <publicID>2571949</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>69</displayOrder>
        <value>Lung, Post-RUL</value>
        <meaningText>Lung, Posterior Right Upper Lobe</meaningText>
        <description>Right Upper Lobe of the Posterior Lung</description>
                <valueMeaning>
         <publicID>2571950</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>7</displayOrder>
        <value>Bone Marrow</value>
        <meaningText>Bone marrow</meaningText>
        <description>The soft, sponge-like tissue in the center of bones that produces white blood cells, red blood cells, and platelets.</description>
                <valueMeaning>
         <publicID>2581613</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>70</displayOrder>
        <value>Mandible</value>
        <meaningText>Mandible</meaningText>
        <description>The largest and strongest bone of the FACE constituting the lower jaw. It supports the lower teeth.</description>
                <valueMeaning>
         <publicID>2568922</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>71</displayOrder>
        <value>Mediastinum</value>
        <meaningText>Mediastinum</meaningText>
        <description>A group of organs surrounded by loose connective tissue, separating the two pleural sacs, between the sternum anteriorly and the vertebral column posteriorly as well as from the thoracic inlet superiorly to the diaphragm inferiorly. The mediastinum contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.</description>
                <valueMeaning>
         <publicID>2559163</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>72</displayOrder>
        <value>Mouth</value>
        <meaningText>mouth</meaningText>
        <description>mouth</description>
                <valueMeaning>
         <publicID>2568124</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>73</displayOrder>
        <value>Muscle, LE DIstal</value>
        <meaningText>Muscle, Lower Extremity Distal</meaningText>
        <description>Muscle, Lower Extremity Distal</description>
                <valueMeaning>
         <publicID>2571908</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>74</displayOrder>
        <value>Muscle, LE Proximal</value>
        <meaningText>Muscle, Lower Extremity Proximal</meaningText>
        <description>Muscle, Lower Extremity Proximal</description>
                <valueMeaning>
         <publicID>2571909</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>75</displayOrder>
        <value>Muscle, UE Distal</value>
        <meaningText>Muscle, Upper Extremity Distal</meaningText>
        <description>Muscle, Upper Extremity Distal</description>
                <valueMeaning>
         <publicID>2571906</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>76</displayOrder>
        <value>Muscle, UE Proximal</value>
        <meaningText>Muscle, Upper Extremity Proximal</meaningText>
        <description>Muscle, Upper Extremity Proximal</description>
                <valueMeaning>
         <publicID>2571907</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>77</displayOrder>
        <value>Nasopharynx</value>
        <meaningText>Nasopharynx</meaningText>
        <description>The nasal part of the pharynx, lying above the level of the soft palate.</description>
                <valueMeaning>
         <publicID>2571143</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>78</displayOrder>
        <value>Nose</value>
        <meaningText>Nose</meaningText>
        <description>Nose</description>
                <valueMeaning>
         <publicID>2571872</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>79</displayOrder>
        <value>Other Site</value>
        <meaningText>Other Site</meaningText>
        <description>Other Site</description>
                <valueMeaning>
         <publicID>2571914</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>8</displayOrder>
        <value>Brain</value>
        <meaningText>Brain</meaningText>
        <description>An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.</description>
                <valueMeaning>
         <publicID>2558329</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>80</displayOrder>
        <value>Ovary</value>
        <meaningText>Ovary</meaningText>
        <description>One of the paired female reproductive glands containing the ova or germ cells; the ovary&apos;s stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova; surrounding this stroma is a more condensed layer of stroma called the tunica albuginea.</description>
                <valueMeaning>
         <publicID>2574083</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>81</displayOrder>
        <value>Pancreas</value>
        <meaningText>Pancreas</meaningText>
        <description>A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon).</description>
                <valueMeaning>
         <publicID>2567245</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>82</displayOrder>
        <value>Pelvis</value>
        <meaningText>Pelvis</meaningText>
        <description>The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.</description>
                <valueMeaning>
         <publicID>2562158</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>83</displayOrder>
        <value>Penis</value>
        <meaningText>Penis</meaningText>
        <description>An external male reproductive organ. It contains a tube called the urethra, which carries semen and urine to the outside of the body.</description>
                <valueMeaning>
         <publicID>2569903</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>84</displayOrder>
        <value>Pericardium</value>
        <meaningText>Pericardium</meaningText>
        <description>A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained.</description>
                <valueMeaning>
         <publicID>2559784</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>85</displayOrder>
        <value>Peripheral Blood</value>
        <meaningText>PERIPHERAL BLOOD</meaningText>
        <description>PERIPHERAL BLOOD</description>
                <valueMeaning>
         <publicID>2559785</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>86</displayOrder>
        <value>Peritoneum</value>
        <meaningText>Peritoneum</meaningText>
        <description>(PAIR-ih-toe-NEE-um) The tissue that lines the abdominal wall and covers most of the organs in the abdomen.</description>
                <valueMeaning>
         <publicID>2559796</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>87</displayOrder>
        <value>Pharynx</value>
        <meaningText>Pharynx</meaningText>
        <description>(FAIR-inks) The hollow tube about 5 inches long that starts behind the nose and ends at the top of the trachea (windpipe) and esophagus (the tube that goes to the stomach).</description>
                <valueMeaning>
         <publicID>2569909</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>88</displayOrder>
        <value>Pleura</value>
        <meaningText>Pleura</meaningText>
        <description>(PLOOR-a) A thin layer of tissue covering the lungs and the wall of the chest cavity to protect and cushion the lungs. A small amount of fluid that acts as a lubricant allows the lungs to move smoothly in the chest cavity during breathing.</description>
                <valueMeaning>
         <publicID>2559813</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>89</displayOrder>
        <value>Prostate</value>
        <meaningText>Prostate</meaningText>
        <description>A gland in the male reproductive system just below the bladder. It surrounds part of the urethra, the canal that empties the bladder. It produces a fluid that forms part of semen. (NCI-GLOSS)</description>
                <valueMeaning>
         <publicID>2567246</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>9</displayOrder>
        <value>Brainstem</value>
        <meaningText>Brainstem</meaningText>
        <description>Brainstem</description>
                <valueMeaning>
         <publicID>2566002</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>90</displayOrder>
        <value>Radius</value>
        <meaningText>Radius</meaningText>
        <description>A straight line from the center to the perimeter of a circle or from the center to the surface of a sphere.</description>
                <valueMeaning>
         <publicID>2568929</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>91</displayOrder>
        <value>Rectum</value>
        <meaningText>Rectum</meaningText>
        <description>The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.</description>
                <valueMeaning>
         <publicID>2567247</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>92</displayOrder>
        <value>Ribs</value>
        <meaningText>Ribs</meaningText>
        <description>Any one of the paired bones, 12 on either side, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk. The long curved bones which form the rib cage. Generally, ribs 1 to 7 are connected to the sternum&apos; by their costal cartilages and are called true ribs, whereas ribs 8 to 12 are termed false ribs.</description>
                <valueMeaning>
         <publicID>2568925</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>93</displayOrder>
        <value>Sigmoid Colon</value>
        <meaningText>Sigmoid Colon</meaningText>
        <description>The portion of the colon that connects to the descending colon above and the rectum below.</description>
                <valueMeaning>
         <publicID>2581640</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>94</displayOrder>
        <value>Sinuses</value>
        <meaningText>Sinuses</meaningText>
        <description>Sinuses</description>
                <valueMeaning>
         <publicID>2571873</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>95</displayOrder>
        <value>Skin</value>
        <meaningText>Skin</meaningText>
        <description>An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.</description>
                <valueMeaning>
         <publicID>2567252</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>96</displayOrder>
        <value>Skull</value>
        <meaningText>Skull</meaningText>
        <description>The skeleton of the head including the bones of the face and the bones enclosing the brain.</description>
                <valueMeaning>
         <publicID>2568921</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>97</displayOrder>
        <value>Spine-C</value>
        <meaningText>Spine, Cervical</meaningText>
        <description>Spine, Cervical</description>
                <valueMeaning>
         <publicID>2571910</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>98</displayOrder>
        <value>Spine-L</value>
        <meaningText>Spine, Lumbar</meaningText>
        <description>Spine, Lumbar</description>
                <valueMeaning>
         <publicID>2571911</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>99</displayOrder>
        <value>Spine-S</value>
        <meaningText>Spine, Sacral</meaningText>
        <description>Spine, Sacral</description>
                <valueMeaning>
         <publicID>2571912</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5637333</publicID>
      <version>1</version>
      <isDerived>true</isDerived>
      <displayOrder>6</displayOrder>
      <dateCreated>2017-01-30T11:53:12</dateCreated>
      <dateModified>2017-01-30T11:53:12</dateModified>
      <questionText>Performance Status</questionText>
            <isEditable>No</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Eastern Cooperative Oncology Group And Karnofsky Performance Status Score</longName>
       <shortName>ECOG_K_PERF_STAT_SC</shortName>
       <publicID>3349536</publicID>
       <version>1</version>
       <context>NCIP</context>
       <workflowStatusName>RETIRED ARCHIVED</workflowStatusName>
       <preferredDefinition>The number or value that determines the value, significance, or extent of how well a patient is able to perform ordinary tasks and to carry out daily activities based on the Eastern Cooperative Oncology Group (ECOG) and the Karnofsky Performance Statuses.</preferredDefinition>
              <valueDomain>
        <longName>Eastern Cooperative Oncology Group And Karnofsky Performance Status Score</longName>
        <shortName>ECOG_K_PERF_STAT_SC</shortName>
        <publicID>3349519</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>NCIP</context>
        <workflowStatusName>RETIRED ARCHIVED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>3</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>0</value>
          <valueMeaning>
           <publicID>3350728</publicID>
           <version>1</version>
           <longName>0=Dead (Karnofsky)</longName>
                                  <definition>
             <createdBy>MAESKEB</createdBy>
             <dateCreated>2013-12-10T14:53:29</dateCreated>
             <text>Dead</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>Dead.</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>0</value>
          <valueMeaning>
           <publicID>3350729</publicID>
           <version>1</version>
           <longName>0=Asymptomatic and fully active (ECOG)</longName>
                                  <definition>
             <createdBy>MAESKEB</createdBy>
             <dateCreated>2013-12-10T14:47:45</dateCreated>
             <text>Fully active, able to carry on all pre-disease performance without restriction.</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>Fully active, able to carry on all pre-disease performance without restriction.</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>10</value>
          <valueMeaning>
           <publicID>3350730</publicID>
           <version>1</version>
           <longName>10=Moribund, fatal processes progressing rapidly</longName>
                                 <preferredDefinition>Moribund, fatal processes progressing rapidly</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>100</value>
          <valueMeaning>
           <publicID>3350731</publicID>
           <version>1</version>
           <longName>100=Normal, no complaints, no evidence of disease</longName>
                                 <preferredDefinition>Normal, no complaints, no evidence of disease</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>1</value>
          <valueMeaning>
           <publicID>3349534</publicID>
           <version>1</version>
           <longName>1=Symptomatic; fully ambulatory; restricted in physically strenuous activity</longName>
                                  <definition>
             <createdBy>MAESKEB</createdBy>
             <dateCreated>2013-12-10T14:49:10</dateCreated>
             <text>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>20</value>
          <valueMeaning>
           <publicID>3350732</publicID>
           <version>1</version>
           <longName>20=Very sick, hospitalization indicated. Death not imminent</longName>
                                 <preferredDefinition>Very sick, hospitalization indicated. Death not imminent</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>2</value>
          <valueMeaning>
           <publicID>3349533</publicID>
           <version>1</version>
           <longName>2=Symptomatic; ambulatory; capable of self-care; greater than 50% waking hours out of bed</longName>
                                  <definition>
             <createdBy>MAESKEB</createdBy>
             <dateCreated>2013-12-10T14:49:40</dateCreated>
             <text>Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>30</value>
          <valueMeaning>
           <publicID>3350733</publicID>
           <version>1</version>
           <longName>30=Severely disabled, hospitalization indicated. Death not imminent</longName>
                                 <preferredDefinition>Severely disabled, hospitalization indicated. Death not imminent</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>3</value>
          <valueMeaning>
           <publicID>3349532</publicID>
           <version>1</version>
           <longName>3=Symptomatic; limited self-care; greater than 50% waking hours in bed</longName>
                                  <definition>
             <createdBy>MAESKEB</createdBy>
             <dateCreated>2013-12-10T14:50:02</dateCreated>
             <text>Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>40</value>
          <valueMeaning>
           <publicID>3350734</publicID>
           <version>1</version>
           <longName>40=Disabled, requires special care and assistance</longName>
                                 <preferredDefinition>Disabled, requires special care and assistance</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>4</value>
          <valueMeaning>
           <publicID>3349531</publicID>
           <version>1</version>
           <longName>4=Completely disabled; no self-care; bedridden</longName>
                                  <definition>
             <createdBy>MAESKEB</createdBy>
             <dateCreated>2013-12-10T14:50:22</dateCreated>
             <text>Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.</text>
             <type>Manually-curated</type>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>50</value>
          <valueMeaning>
           <publicID>3350735</publicID>
           <version>1</version>
           <longName>50=Requires considerable assistance and frequent medical care</longName>
                                 <preferredDefinition>Requires considerable assistance and frequent medical care</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>60</value>
          <valueMeaning>
           <publicID>3350736</publicID>
           <version>1</version>
           <longName>60=Requires occasional assistance, but is able to care for most of his/her needs</longName>
                                 <preferredDefinition>Requires occasional assistance, but is able to care for most of his/her needs</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>70</value>
          <valueMeaning>
           <publicID>3350737</publicID>
           <version>1</version>
           <longName>70=Cares for self, unable to carry on normal activity or to do active work</longName>
                                 <preferredDefinition>Cares for self, unable to carry on normal activity or to do active work</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>80</value>
          <valueMeaning>
           <publicID>3350738</publicID>
           <version>1</version>
           <longName>80=Normal activity with effort; some signs or symptoms of disease</longName>
                                 <preferredDefinition>Normal activity with effort; some signs or symptoms of disease</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>90</value>
          <valueMeaning>
           <publicID>3350739</publicID>
           <version>1</version>
           <longName>90=Able to carry on normal activity; minor signs or symptoms of disease</longName>
                                 <preferredDefinition>Able to carry on normal activity; minor signs or symptoms of disease</preferredDefinition>
          </valueMeaning>
          <beginDate>2012-01-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
       <dataElementDerivation>
        <componentDataElement>
         <usageCategory>
          <usageType>Mandatory</usageType>
         </usageCategory>
         <displayOrder>0</displayOrder>
         <dataElement>
          <publicID>0</publicID>
          <version>0</version>
          <valueDomain>
           <shortName>PRSN_WT_VAL</shortName>
           <type>NonEnumerated</type>
           <workflowStatusName>RELEASED</workflowStatusName>
           <valueDomainConcept>
            <nciTermBrowserLink>http://blankNode</nciTermBrowserLink>
           </valueDomainConcept>
          </valueDomain>
         </dataElement>
        </componentDataElement>
       </dataElementDerivation>
               <referenceDocument>
         <name>Performance Status</name>
         <type>Preferred Question Text</type>
         <context>NCIP</context>
         <doctext>Performance Status</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>On-Study KPS</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=3349536&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>0</value>
        <meaningText>0=Asymptomatic and fully active (ECOG)</meaningText>
        <description>Fully active, able to carry on all pre-disease performance without restriction.</description>
                <valueMeaning>
         <publicID>3350729</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>1</value>
        <meaningText>1=Symptomatic; fully ambulatory; restricted in physically strenuous activity</meaningText>
        <description>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.</description>
                <valueMeaning>
         <publicID>3349534</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>2</value>
        <meaningText>2=Symptomatic; ambulatory; capable of self-care; &gt;50% waking hours out of bed</meaningText>
        <description>Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.</description>
                <valueMeaning>
         <publicID>3349533</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5590336</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>7</displayOrder>
      <dateCreated>2016-12-06T13:01:37</dateCreated>
      <dateModified>2017-01-05T13:28:02</dateModified>
      <questionText>Date Informed Consent Signed</questionText>
      <instruction>
       <text>Enter the date the patient signed the informed consent form.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Informed Consent Form Signed Date</longName>
       <shortName>ICF_SIG_DT</shortName>
       <publicID>656</publicID>
       <version>4</version>
       <context>CTEP</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The date on which the patient/participant/legal representative agreed to participation in a protocol, treatment, or other activity by signing an informed consent document.</preferredDefinition>
               <designation>
         <createdBy>WOODC</createdBy>
         <dateCreated>2015-11-30T13:23:47</dateCreated>
         <languageName>ENGLISH</languageName>
         <name>Biological parent date of birth</name>
         <type>VM Alt Name</type>
         <context>COG</context>
                 </designation>
              <valueDomain>
        <longName>Date</longName>
        <shortName>DT</shortName>
        <publicID>2018550</publicID>
        <version>1</version>
        <type>NonEnumerated</type>
        <context>NCI Standards</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>DATE</datatypeName>
        <formatName>MM/DD/YYYY</formatName>
        <maximumLengthNumber>8</maximumLengthNumber>
                               </valueDomain>
                      <referenceDocument>
         <name>Source</name>
         <type>DATA_ELEMENT_SOURCE</type>
         <context>CTEP</context>
         <doctext>Data element and all values comply with Clinical Data Update System (CDUS) v3.0 Release 2</doctext>
         <languageName>ENGLISH</languageName>
         <URL>http://ctep.cancer.gov/reporting/cdus.html</URL>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Informed Consent Date Signed</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Date Informed Consent Signed</name>
         <type>Preferred Question Text</type>
         <context>CTEP</context>
         <doctext>Date Informed Consent Signed</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Date of signed</name>
         <type>Alternate Question Text</type>
         <context>NIDCR</context>
         <doctext>Date of signed, witnessed, and dated informed consent/assent</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CCR Immunotherapy Migration</name>
         <type>Alternate Question Text</type>
         <context>CCR</context>
         <doctext>On-Study Date (Consent Signed)</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NINDS CDE Project</name>
         <type>REFERENCE</type>
         <context>NINDS</context>
         <doctext>NINDS CDE Project</doctext>
         <languageName>ENGLISH</languageName>
         <URL>http://www.commondataelements.ninds.nih.gov/</URL>
                 </referenceDocument>
        <referenceDocument>
         <name>Consent NCI Standard Template Preferred Question</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>Date Consent Signed</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text1</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date informed consent signed</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Informed Consent Obtained Date</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>Informed Consent Obtained Date</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>AP Consent Date</name>
         <type>Alternate Question Text</type>
         <context>NCIP</context>
         <doctext>Analysis Project (AP) Consent Date</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text 2</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date main study informed consent signed</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 1</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Date Block 1 informed consent signed</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 2</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date of consent:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 3</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date of optional blood study consent</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 4</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date of optional tissue study consent</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 5</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date of optional leftover specimens banking consent</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF TEXT 6</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Consent Signed date</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 8</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date Informed Consent Signed:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 9</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date Consent signed:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 7</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date informed consent signed:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 10</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date consent signed:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>BPV - Date of Candidate&apos;s Consent</name>
         <type>Alternate Question Text</type>
         <context>BBRB</context>
         <doctext>Date of Candidate&apos;s Consent</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 11</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Date informed consent signed for APEC14B1:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>GTEx - Date of consent or Date of approach</name>
         <type>Alternate Question Text</type>
         <context>BBRB</context>
         <doctext>Date of consent or Date of approach</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>MCL-Lung</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Consent Sign Date (MM/DD/YYYY)</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 12</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Consent signed date:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 13</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Date second informed consent signed:</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text 4</name>
         <type>Alternate Question Text</type>
         <context>CTEP</context>
         <doctext>Date of informed consent</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>EAQ162CD Text</name>
         <type>Alternate Question Text</type>
         <context>ECOG-ACRIN</context>
         <doctext>Date informed consent obtained</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>MA39</name>
         <type>Alternate Question Text</type>
         <context>CCTG</context>
         <doctext>Date main consent was signed by the patient</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=656&amp;version=4</cdeBrowserLink>
      </dataElement>
           </question>
     <question>
      <publicID>5590326</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>8</displayOrder>
      <dateCreated>2016-12-06T13:01:37</dateCreated>
      <dateModified>2017-01-05T13:28:02</dateModified>
      <questionText>Informed Consent Version</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>No</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Informed Consent Version Template Version Text</longName>
       <shortName>INF_CONS_VS_TXT</shortName>
       <publicID>5334618</publicID>
       <version>2</version>
       <context>BBRB</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The version of the consent form in which the patient acknowledged participation on the protocol by signing the document.</preferredDefinition>
               <designation>
         <createdBy>MAESKEB</createdBy>
         <dateCreated>2016-08-12T11:44:10</dateCreated>
         <languageName>ENGLISH</languageName>
         <name>ENGLISH</name>
         <type>CONTEXT NAME</type>
         <context>DCP</context>
                 </designation>
              <valueDomain>
        <longName>Template Version Text</longName>
        <shortName>TEMPLATE_VER_TXT</shortName>
        <publicID>2188514</publicID>
        <version>1.1</version>
        <type>NonEnumerated</type>
        <context>DCP</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>ALPHANUMERIC</datatypeName>
        <maximumLengthNumber>50</maximumLengthNumber>
                               </valueDomain>
                      <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Informed Consent Version</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Version of Consent Form Signe</name>
         <type>Preferred Question Text</type>
         <context>BBRB</context>
         <doctext>Version of Consent Form Signed by Candidate</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>GTEx - Institutional version number of ICD</name>
         <type>Alternate Question Text</type>
         <context>BBRB</context>
         <doctext>Institutional version number of ICD</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5334618&amp;version=2</cdeBrowserLink>
      </dataElement>
           </question>
       </module>
   <module>
    <displayOrder>2</displayOrder>
    <maximumModuleRepeat>0</maximumModuleRepeat>
    <longName>Inclusion criteria</longName>
        <preferredDefinition>Inclusion criteria</preferredDefinition>
    <publicID>5590455</publicID>
    <version>1</version>
    <usageCategory>
     <usageType>None</usageType>
    </usageCategory>
         <question>
      <publicID>5590785</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>0</displayOrder>
      <dateCreated>2016-12-06T13:09:32</dateCreated>
      <dateModified>2016-12-06T13:09:32</dateModified>
      <questionText>Does patient have histologically or pathologically confirmed malignancy (hematologic or solid tumor) that is metastatic or unresectable and for which standard of care therapy does not exist or is no longer effective?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>PT_DZ_DO_CTEC_CD_IND</shortName>
       <publicID>4449891</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable response regarding whether the patient meets the criteria to participate in a specific clinical trial based on any abnormal condition of the body or mind that causes discomfort, dysfunction or distress to the person affected or those in contact with the person as an element of the personal medical history.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma of the bladder that is not amenable to curative surgical treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or cytologically confirmed (at original diagnosis or subsequent recurrence or progression) lymphoma, chronic lymphocytic lymphoma (CLL) or solid tumor?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Does the patient have histolo</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does the patient have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative treatments do not exist or are no longer effective?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Patients with known BRAFv600x mutation: Does patient have known BRAF-V600X mutated, histologically confirmed cancer that is metastatic or unresectable and for which curative or standard therapies do not exist or are no longer effective?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically documented solid tumors whose disease has progressed following at least one line of standard therapy and/or no standard of treatment exists that has been shown to prolong survival?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a histologically confirmed diagnosis of cancer and is being evaluated and/or treated for cancer at participating sites?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does the patient have histologically confirmed solid malignancy (excluding lymphoma) that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed locally advanced or metastatic urothelial carcinoma of the bladder that is not amenable to curative surgical treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have stage IV or recurrent/metastatic histologically or cytologically confirmed non-squamous NSCLC?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or cytologically confirmed solid tumor malignancy that is metastatic or unresectable and for whom either standard curative or palliative measures do not exist or are no longer effective, or for whom anti-PD-L1/CTLA-4 is appropriate?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed non-squamous NSCLC, with incurable advanced or metastatic disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or cytologically proven metastatic or locally advanced tumors for which no standard therapy exists, or where standard therapy has failed, or in patients otherwise ineligible for standard therapy, or for an indication that anti-PD-1 therapy has been shown to be effective in studies in HIV-uninfected participants?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have Stage IV or recurrent/metastatic histologically confirmed non-squamous NSCLC?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or pathologically confirmed diagnosis of peripheral T-cell lymphoma (PTCL) follicular variant or angioimmunoblastic T-cell lymphoma (AITL) as per World Health Organization (WHO) 2008 criteria?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed, locally advanced or metastatic predominantly urothelial carcinoma of the bladder, ureter, or urethra that is not amenable to curative surgical treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have pathologically confirmed diagnosis of a solid tumor cancer for which there is no known standard therapy capable of extending life expectancy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed relapsed/refractory ALK+ ALCL (with ALK positivity defined by immunohistochemistry and/or FISH/cytogenetics), MCL, or BCL6+ DLBCL (with BCL6 positivity defined by immunohistochemistry)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has primary oropharynx HNSCC, is disease HPV (-) according to local institutional definition using either p16 immunohistochemistry or HPV testing?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed, relapsed/refractory ALK+ ALCL (with ALK positivity defined by immunohistochemistry and/or FISH/cytogenetics), MCL, or BCL6+ DLBCL (with BCL6 positivity defined by immunohistochemistry from any prior biopsy)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a histologically or cytologically confirmed diagnosis of cancer and is being evaluated and/or treated for cancer at participating sites?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or cytologically confirmed Alveolar Soft Part Sarcoma (ASPS) that is not curable by surgery?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed locally advanced or metastatic Transitional Cell Carcinoma (TCC) which has progressed after standard therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed progressive, metastatic castration resistant prostate adenocarcinoma?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or pathologically confirmed malignancy (hematologic or solid tumor) that is metastatic or unresectable and for which standard of care therapy does not exist or is no longer effective?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have Stage IV or recurrent/metastatic histologically confirmed non-small cell lung cancer (NSCLC)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 29</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have invasive cancer in the contralateral breast?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 32</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has renal cell cancer associated with HLRCC, is disease metastatic and/or unresectable?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 31</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have myelodysplastic syndrome/acute myeloid leukemia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 30</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have EHE that contains TAZ-CAMTA1 gene fusion as detected by fusion fluorescent in-situ hybridization (FISH) performed in a central reference laboratory at Cleveland Clinic?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 35</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does pateint have any of the following tumor types: melanoma, bone sarcomas, Soft tissue sarcomas, including angiosarcoma, primary cutaneous leiomyosarcoma, dermatofibrosarcoma protruberans, Leukemias, Myeloid sarcoma, leukemia cutis, and chloroma, Hodgkins Lymphoma or B cell lymphoma?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 36</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed, gastric carcinoma, including GEJ adenocarcinoma?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 33</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known DPD deficiency?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 34</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is enrolled in Phase II:  Does patient have histologically or cytologically confirmed small cell lung cancer whose disease has relapsed or progressed after greater than or equal to 1 prior therapy, one of which must have been a platinum doublet?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 39</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically documented solid tumors whose disease has progressed on standard therapy or for which there is no available standard therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 41</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed solid tumor malignancy that is metastatic or treatment refractory cancers which are not curable or do not have known palliative measures or treatments that are associated with a survival advantage (as defined by the subject or the physician Investigator)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 38</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient&apos;s disease recurrent or refractory to standard therapy or remaining treatment options are unlikely to be effective or patient refuses such therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 37</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have any of the following tumor types: melanoma, bone sarcomas, Soft tissue sarcomas, including angiosarcoma, primary cutaneous leiomyosarcoma, dermatofibrosarcoma protruberans, Leukemias, Myeloid sarcoma, leukemia cutis, and chloroma, Hodgkins Lymphoma or B cell lymphoma?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 40</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 42</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have histologically confirmed solid tumor malignancy that is metastatic or treatment refractory cancers which are not curable or do not have known measures or treatments that are associated with a survival advantage (as defined by the subject or the physician Investigator)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4449891&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5590789</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>1</displayOrder>
      <dateCreated>2016-12-06T13:11:33</dateCreated>
      <dateModified>2016-12-06T13:11:33</dateModified>
      <questionText>Has patient received prior ACT infusion within 6 months of study enrollment (cohorts include ACT with TIL, HLA-class I TCR-engineered lymphocytes, HLA-class II TCR-engineered lymphocytes, and CAR-engineered T cells)?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Receive Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>PT_RCVD_TX_IND</shortName>
       <publicID>4890174</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded response indicating whether a patient meets the criteria to participate in a clinical trial with regards to administration of therapy.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior therapy with mTOR inhibitors except for rapalog treatment as part of GVH prophylaxis or treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Has patient received more tha</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received more than 2 lines of therapy beyond corticosteroids with or without calcineurin inhibitors or sirolimus?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received Trastuzumab, Bevacizumab, or nitrosoureas/mitomycin C less than 6 weeks prior to registration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient not received prior therapy with mTOR inhibitors except for rapalog treatment as part of GVH prophylaxis or treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received no more than 1 prior regimen in the platinum resistant setting?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving adjuvant chemoradiation after surgical resection of the primary site of disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received ibrutinib within 2 weeks prior to beginning therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has ovarian cancer and a BRCA mutation, has patient received prior treatment with olaparib per guidelines for standard care treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received at least two prior chemotherapeutic or biologic (e.g., Rituximab alone) regimens and is not currently eligible for standard curative options?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received neoadjuvant or adjuvant therapy within 6 months prior to diagnosis of metastatic disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had less than or equal to 3 lines of prior therapy in the metastatic disease setting?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Patient has not received prior P13K, AKT or mTor inhibitors?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received at least two prior lines of therapy for mCRPC?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior P13K, AKT,or mTOR inhibitors?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Was last dose of prior cytotoxic chemotherapy received at least 28 days prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received one prior systemic chemotherapeutic regimen for management of recurrent, persistent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior ACT infusion within 6 months of study enrollment (cohorts include ACT with TIL, HLA-class I TCR-engineered lymphocytes, HLA-class II TCR-engineered lymphocytes, and CAR-engineered T cells)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received greater than 2 prior chemotherapy regimens for the current malignancy (full dose chemotherapy in conjunction with concurrent radiation therapy will be included in prior therapy)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received one prior systemic chemotherapeutic regimen for management of recurrent, persistent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/Bevacizumab) at least one of which must have contained bevacizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient currently receiving medications or herbal supplements noted below which cannot be discontinued at least 1 week prior to receiving any protocol treatment or as specified in protocol section 5.3?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received at least one prior line of therapy for mCRPC?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received at least one line of standard systemic treatment for locally advanced or metastatic disease setting of the respective tumor type?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior platinum based chemotherapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4890174&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5590794</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>2</displayOrder>
      <dateCreated>2016-12-06T13:13:46</dateCreated>
      <dateModified>2016-12-06T13:13:46</dateModified>
      <questionText>Has prior ACT therapy been completed and residual disease has been documented by either radiographic progression or active disease observed on biopsy (i.e. hematologic or solid tumor malignancy must be deemed active by the treating investigator)?</questionText>
      <instruction>
       <text>The investigator may deem that the disease is active on the basis of a pre-treatment biopsy demonstrating viable tumor cells or clinical progression of disease (ie RECIST progression is not required). </text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Agent Intervention Disease or Disorder Status Code Indicator</longName>
       <shortName>AGNT_INT_DZ_STS_IND</shortName>
       <publicID>5026557</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A coded response for questions related to the use of agents that produce an effect, or that are intended to alter the course of a disease in a patient, and the status of the patient&apos;s disease.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>If patient is in the dose exp</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is in the dose expansion portion ONLY, does patient have: 1) progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) tumors must be EGFR T790M negative confirmed by central testing prior to treatment (If EGFR-T790M status is unknown, patient may consent for trial for biopsy and testing for EGFR T790M will be performed as part of the initial biopsy for the trial: patients who test positive for EGFR T790M by central testing will be ineligible for the dose expansion), 3) be treatment naïve for 3rd generation EGFR-TKI (CO-1686 and AZD9291) and mTOR inhibitors?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is on the dose expansion portion, does patient have: 1) have a tumor which is EGFR-T790M positive using central genotyping (if EGFR-T790M status is unknown, patients may consent for central EGFR T790M testing as part of screening for the trial; patients who test negative for EGFR T790M by central genotyping will be ineligible), and 2) be treatment naïve to T790M-directed EGFR TKI (e.g. AZD9291, rociletinib, etc.)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>For the dose expansion portion ONLY, does patient have: 1) have progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) tumors must be EGFR-T790M negative confirmed by central testing prior to treatment (If EGFR-T790M status is unknown patients may consent for trial for biopsy and testing for EGFR T790M will be performed as part of initial biopsy for trial; patients who test positive for EGFR T790M by central testing will be ineligible for the dose expansion), 3) be treatment naïve to 3rd generation EGFR-TKI (CO-1686 and AZD9291) and EGFR monoclonal antibodies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is in the dose expansion portion ONLY, does patient have: 1) progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) tumors must be EGFR T790M negative confirmed by central testing prior to treatment (If EGFR-T790M status is unknown, patient may consent for trial for biopsy and testing for EGFR T790M will be performed as part of the initial biopsy for the trial: patients who test positive for EGFR T790M by central testing will be ineligible for the dose expansion), 3) be treatment naïve for 3rd generation EGFR-TKI (CO-1686 and osimertinib (AZD9291)) and mTOR inhibitors?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has prior ACT therapy been completed and residual disease has been documented by either radiographic progression or active disease observed on biopsy (i.e. hematologic or solid tumor malignancy must be deemed active by the treating investigator)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has NSCLC (Cohort 1) was there evidence of radiologic or clinical disease progression during previous treatment with systemic PD-1 directed therapy and/or patient was deemed not to have derived clinical benefit from PD-1 directed treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>For patient registered to  Dose Expansion Cohort A, does patient have: 1) progression of disease on erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib must be EGFR-T790M negative confirmed by central testing prior to treatment If EGFR-T790M status is unknown patients may consent for trial and for biopsy, and testing for EGFR T790M will be performed as part of initial biopsy for trial., 3) be treatment naïve to 3rd generation EGFR-TKI (rociletinib, HM61713 and AZD9291) and EGFR monoclonal antibodies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>For Dose Expansion Cohort D: patient must have: 1) tumor that harbors an  EGFR Exon 20 insertion by a CLIA certified test, and 2) have progressive disease on or aftter platinum based chemotherapy, and 3) be treatment naïve to both EGFR-TKI and EGFR monoclonal antibody?  Does For patient registered to  Dose Expansion Cohort A, does patient have: 1) progression of disease on erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib must be EGFR-T790M negative confirmed by central testing prior to treatment (if EGFR-T790M status is unknown patients may consent for trial and for biopsy, and testing for EGFR T790M will be performed as part of initial biopsy for trial), and 3) be treatment naïve to 3rd generation EGFR-TKI (rociletinib, HM61713 and AZD9291) and EGFR monoclonal antibodies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>For patient registered to  Dose Expansion Cohort A, does patient have: 1) progression of disease on erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib must be EGFR-T790M negative confirmed by central testing prior to treatment (if EGFR-T790M status is unknown patients may consent for trial and for biopsy, and testing for EGFR T790M will be performed as part of initial biopsy for trial), and 3) be treatment naïve to 3rd generation EGFR-TKI (rociletinib, HM61713 and AZD9291) and EGFR monoclonal antibodies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5026557&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5590817</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>3</displayOrder>
      <dateCreated>2016-12-06T13:20:16</dateCreated>
      <dateModified>2016-12-06T13:20:16</dateModified>
      <questionText>Does patient have measurable disease?</questionText>
      <instruction>
       <text>Leukemia and Non-Hodgkin&apos;s lymphoma patients must have measurable disease according to the revised response criteria for malignant lymphorma.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Measurable Disease Response Evaluation Criteria in Solid Tumors Eligibility Determination  Code Indicator</longName>
       <shortName>MEA_DS_RECIST_CD_IND</shortName>
       <publicID>4617852</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded indicator response regarding whether a patient has measurable disease as defined by RECIST v1.1.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have measurable</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease by RECIST 1.1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease according to RECIST criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural or peritoneal mesothelioma?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable or evaluative disease, as defined by RECIST 1.1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable or evaluable/non-measurable disease per RECIST 1.1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease according to RECIST criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural or mesothelioma?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 1</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Does patient have measurable disease according to RECIST 1.1 and have relapsed or become refractory to conventional therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease by RECIST v1.1 with at least one measurable target lesion?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have disease measurable by RECIST v1.1 or other tumor-specific criteria or disease assessable by physical exam or other methods if not measurable by RECIST?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have radiographically measurable disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex  - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable GIST as defined by RECIST 1.1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease outside of biopsy site present per RECIST criteria?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is enrolled in Phase II: Does patient have measurable disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease by RECIST 1.1 or evaluable disease with bone metastases demonstrated by Tc99 Bone Scan?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease per RECIST version 1.1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease per RECIST guidelines?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have evaluable or measurable disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have measurable disease by RECIST 1.1 by CT Scan or MRI 28 days prior to start of protocol therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is randomized to the Phase 2 portion, does patient have measurable disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4617852&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5590824</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>4</displayOrder>
      <dateCreated>2016-12-06T13:22:49</dateCreated>
      <dateModified>2016-12-06T13:22:49</dateModified>
      <questionText>Is disease suitable for assessment by pre- and post-biopsies?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Biopsy Assessment Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>BX_ASMT_IND</shortName>
       <publicID>5583175</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded response to determine patient eligibility for clinical trial participation for questions related to assessments of the removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosisas outlined in the protocol.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have tumor lesio</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have tumor lesion readily accessible for biopsy per the investigator&apos;s discretion?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is disease suitable for assessment by pre- and post-biopsies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had core biopsy within 7 days prior to day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have tumor lesion safely accessible for biopsy per the investigator&apos;s discretion?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have tumors deemed easily accessible for biopsies with low likelihood of complication?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have tumors determined to be easily accessible for biopsy (e.g. pleural-based lesions, peripheral lymph nodes, soft tissue metastases, large liver metastases, etc.)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Did patient have biopsy in permissible site including extremities: upper (including shoulder) and lower (including hip) and/or Trunk: Body wall?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5583175&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5590862</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>5</displayOrder>
      <dateCreated>2016-12-06T13:28:11</dateCreated>
      <dateModified>2016-12-06T13:28:11</dateModified>
      <questionText>Patient has not received prior anti-PD-1 or ant-PD-L1 therapy after ACT and before study atezolizumab (MPDL3280A) administration?</questionText>
      <instruction>
       <text>There is no limit to the number of lines of prior therapy.  Prior anti-PD-1 or anti-PD-L1 therapy and other immunotherapies are allowed.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Antibody Therapy Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>XBOD_TX_CTEC_CD_IND</shortName>
       <publicID>4619915</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded indicator response regarding whether a patient meets the antibody therapy criteria in order to participate in a clinical trial.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Has received prior therapy wi</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, ziv-aflibercept or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with any therapy on the PD-1/PD-L1 axis or anti-CTLA-4 inhibitors?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Patient has not received prior treatment with anti-PD-1 or anti-PD-L1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 antibody?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have disease that is documented to be refractory to at least one PD1/PD-L1 inhibitor, defined as disease progression following at least 2 infusions of the same drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior treatment with any PARP inhibitor or any anti-PD-1/anti-PD-L1 antibody?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has bisphosphonate, or RANKL antibody therapy been initiated or the dose/regimen adjusted within 30 days prior to Cycle 1 Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or pathway-targeting agents?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of prior treatment with anti-CTLA-4 antibody, anti-PD 1 antibody or anti-PDL1 antibody?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has had prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents are following requirements  met: minimum of 12 weeks from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Patient has not received prior anti-PD-1 or ant-PD-L1 therapy after ACT and before study atezolizumab (MPDL3280A) administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with any therapy on the PD-1/PD-L1 axis or anti-CTLA-4 inhibitors, unless enrolling the urothelial carcinoma with previous checkpoint inhibition therapy expansion cohort?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior treatment with any anti-PD-1 blocking therapies or HDACi, or anti-CTLA-4 antibody, CD137 agonist or other immune activating therapy such as anti-CD 40 antibody within the last 3 months of enrollment in the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or ziv-aflibercept?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior treatment with anti-PD1 or anti-CTLA4 therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has had prior treatment with anti-CTLA-4 are the following requirements met: minimum of 12 weeks from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior treatment with anti-PD-1 or anti-PD-L1 or pathway-targeting agents?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient has prior exposure to immune mediated therapy including anti-CTLA-4 agent, but excluding therapeutic anticancer vaccines and anti-PD-1 or anti-PD-L1 therapy in NSCLC patients?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had prior exposure to immune mediated therapy including anti-CTLA-4 agent, but excluding therapeutic anticancer vaccines and anti-PD-1 or anti-PD-L1 therapy in NSCLC patients?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 15 weeks since prior anti-CD137 or anti-CTLA-4 (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with any anti-PD-1 or anti-PD-L1 antibody?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has the patient received checkpoint inhibitors such as anti-CTLA-4 or anti-PD1/PD-L1 and for nitrosoureas or mitomycin C within 6 weeks prior to C1D1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received prior anti-CTLA-4 have a minimum of 12 weeks elapsed from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose, and there is no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with any anti-PD-1 or anti-PD-L1 antibody?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4619915&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593224</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>6</displayOrder>
      <dateCreated>2016-12-06T14:38:34</dateCreated>
      <dateModified>2016-12-06T14:38:34</dateModified>
      <questionText>Have all ACT related toxicities resolved to grade 1 with the exception of alopecia, vitiligo and endocrine abnormalities requiring replacement therapy which may be grade 2?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Therapy-Related Toxicity Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>TX_RL_TX_CTEC_CD_IND</shortName>
       <publicID>4449897</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response regarding whether a person has bodily harm due to the poisonous effects associated with the action or administration of therapeutic agents, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Are all treatment-related tox</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Are all treatment-related toxicities CTCAE v4 grade less than or equal to 1 (except alopecia) at the time of enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are all prior treatment-related toxicities CTCAE v4 less than or equal to grade 1 (except alopecia) at the time of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Have all acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, resolved to Grade less than or equal to 1 prior to study entry?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Have all toxicities of prior therapy (except alopecia or long-standing grade 2 neuropathy that has been discussed with study PI) resolved to grade less than or equal to 1 as per CTCAE v4.0?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has prior treatment-related toxicity resolved to less than or equal to Grade 1 or baseline with exception of alopecia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Have all ACT related toxicities resolved to grade 1 with the exception of alopecia, vitiligo and endocrine abnormalities requiring replacement therapy which may be grade 2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment with the exception of alopecia and grade 2 platinum-therapy related neuropathy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are all prior treatment-related toxicities CTCAE-v4 grade less than or equal to 1 (except alopecia) at the time of enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has prior treatment-related toxicity resolved to less than or equal to Grade 1 or baseline with exception of alopecia and permanent grade less than or equal to 2 toxicities related to prior immune checkpoint inhibitor treatment (e.g. PD-1/PD-L1, CTLA-4, CD40, LAG3) treatment with the review and approval by the Lead PI?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4449897&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593232</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>7</displayOrder>
      <dateCreated>2016-12-06T14:39:59</dateCreated>
      <dateModified>2016-12-06T14:39:59</dateModified>
      <questionText>Has patient been off other anit-cancer therapy, including ACT, for 28 days prior to study administration of atexolizumab?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Intervention or Procedure Discontinued Indicator</longName>
       <shortName>INT_PROC_DISCON_IND</shortName>
       <publicID>4572456</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response for questions addressing the discontinuation of interventions and/or procedures.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Were the interventions or pro</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Were the interventions or procedures discontinued accordingly?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received hydroxyurea or glucocorticoids for suppression of leukocytosis, have these agents been discontinued at least 24 hours prior to initiation of therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is enrolled on Phase I portion, has prior EGFR-TKIs (except erlotinib) been discontinued at least 7 days prior to initiation of erlotinib and Onalespib?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient been off other anit-cancer therapy, including ACT, for 28 days prior to study administration of atexolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient requires treatment with a RANKL inhibitor (e.g. denosumab) can it be discontinued before treatment with atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient requires treatment with a RANKL inhibitor (e.g. denosumab), is patient able to discontinue it before treatment with atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient require treatment with a RANKL inhibitor (e.g. denosumab) which cannot be discontinued before treatment with atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4572456&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593248</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>8</displayOrder>
      <dateCreated>2016-12-06T14:41:01</dateCreated>
      <dateModified>2016-12-06T14:41:01</dateModified>
      <questionText>Is patient greater than or equal to 18 years old?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Age Code Indicator</longName>
       <shortName>PT_AGE_CD_IND</shortName>
       <publicID>4379766</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator that asks about the patient/participant&apos;s age.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Is patient greater than or eq</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 18 years old?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 18 years old on the day of consent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 18 years old?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than 18 years old?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 18 and less than or equal to 70 years old?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal 6 years old if treated at the NIH Clinical Center (greater than or equal to 18 years old if treated at other participating sites)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 16 years old?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 3 years of age?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 15 years old?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 12 years old?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient greater than or equal to 18 years old on the day of signing informed consent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379766&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593253</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>9</displayOrder>
      <dateCreated>2016-12-06T14:42:02</dateCreated>
      <dateModified>2016-12-06T14:42:02</dateModified>
      <questionText>Is ECOG performance status 0, 1 or 2?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Eastern Cooperative Oncology Group Performance Status Assessment Code Indicator</longName>
       <shortName>ECOG_PERF_AS_CD_IND</shortName>
       <publicID>4379755</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator relating to the ECOG performance status of a patient.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is Zubrod performance status 0, 1 or 2 (Karnofsky greater than or equal to 60%)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Is ECOG performance status 0</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0 or 1 and has an estimated life expectancy of greater than 3 months?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex-1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0, 1, or 2 (Karnofsky greater than or equal to 60%)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0 or 1 (Karnofsky greater than or equal to 70%)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0, 1 or 2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0 or 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0 or 1 (Karnofsky greater than or equal to 80%)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0, 1, or 2 (Karnofsky greater than or equal to 50%)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0, or 1 (Karnofsky greater than or equal to 60%)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status less than or equal to 2 (Karnofsky or Lansky greater than or equal to 70%)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0, 1 or 2 (Patients greater than or equal to 16 years of age must have a Karnofsky performance level of greater than or equal to 70%) and children less than 16 years old must have a Lansky performance of greater than equal to 70%?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0, 1 or 2 or Karnofsky greater than 50% (if greater than or equal to 16 years of age); or children less than 16 years old must have a Lansky performance of greater than or equal to 50%?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0, 1 or 2 or Karnofsky greater than or equal to 60% if patient is  greater than 16 years of age; or Lansky greater than or equal to 60% if patient is less than or equal to 16 years old?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status less than or equal to 1 or Karnofsky greater than or equal to 70%?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is ECOG performance status 0, 1, or 2 (Karnofsky or Lansky greater than or equal to 70%)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379755&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593261</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>10</displayOrder>
      <dateCreated>2016-12-06T14:43:06</dateCreated>
      <dateModified>2016-12-06T14:43:06</dateModified>
      <questionText>Does patient have a life expectancy of greater than 3 months?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Life Expectancy Eligibility Determination Code Indicator</longName>
       <shortName>LF_EXP_ELI_DT_CD_IND</shortName>
       <publicID>4449894</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response regarding whether the patient has a life expectancy that meets the requirements for participation on a clinical trial.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than 6 months?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Does patient have a life expe</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than 3 months?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than 12 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than 9 months?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have life expectancy of greater than 12 months?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than 2 months?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than or equal to 4 months?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than or equal to 12 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of at least 3 months?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than 6 months, as assessed by study physician?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than 3 months with appropriate therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than or equal to 16 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a life expectancy of greater than or equal to 16 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4449894&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593282</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>11</displayOrder>
      <dateCreated>2016-12-06T14:44:40</dateCreated>
      <dateModified>2017-01-10T16:37:56</dateModified>
      <questionText>Is pre-study absolute neutrophil count greater than or equal to 1,000/mcL?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Laboratory Procedure Absolute Neutrophil Count Eligibility Determination Code Indicator</longName>
       <shortName>LAB_ANC_ELG_CD_IND</shortName>
       <publicID>4379767</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator whether a medical procedure has been performed that involves testing a sample of blood for the absolute neutrophil count, the real number of white blood cells (WBC) that are neutrophils and is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count, as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Is pre-study absolute neutrop</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1,500/mcl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count greater than or equal to 1.5 x 109/L?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex-1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1.2 X 10^9/L?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count greater than or equal to 1 x 10^9/L?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count greater than or equal to 1,000/mcL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count greater than or equal to 1.5 x 10^9/L?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1,200/mcL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count greater than 500/mcL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count greater than 1,000/mcL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count greater than or equal to 1.5 x 10^9/L? </doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than 1,500/mcl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex-10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1,000/mcl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, independent of growth factor support for at least 14 days prior to screening?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1,000/mcl, without growth factors within 2 weeks of initiation of treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1,500/mm3?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study absolute neutrophil count (ANC) greater than or equal to 1,500/mcl within 28 days prior to administration of therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379767&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593469</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>12</displayOrder>
      <dateCreated>2016-12-06T14:49:53</dateCreated>
      <dateModified>2016-12-06T14:49:53</dateModified>
      <questionText>Is pre-study platelet count greater than or equal to 75,000/mcL (greater than or equal to 50,000/mcL for patients with hematologic malignancies?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Laboratory Procedure Platelet Count Eligibility Determination Code Indicator</longName>
       <shortName>LAB_PLT_ELG_CD_IND</shortName>
       <publicID>4379783</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator whether a medical procedure has been performed that involves testing a sample of blood for the platelet count, the real number of irregularly shaped disk like cytoplasmic fragment of a megakaryocyte that is shed in the marrow sinus and subsequently found in the peripheral blood where it functions in clotting, as a method of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Is pre-study platelet count g</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 100,000/mcl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 100 x 10^9/L?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 75 X 10^9/L?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 75,000/mcL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 150,000/mcl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 50,000/mcL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than 50,000/mcL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 50,000/mcL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 75,000/mcL unless due to marrow involvement by lymphoma in which case a platelet count of greater than or equal to 30,000/mcL will be used?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than 100,000/mcl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 50,000/mcl, or recovery to baseline count?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 75,000/mcL (greater than or equal to 50,000/mcL for patients with hematologic malignancies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 100,000/mcl, independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screening?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 75,000/mcL, within 2 weeks of randomization?</doctext>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 50,000 cells/mm3 if marrow plasmacytosis is less than 50% OR platelet count is greater than or equal to 30,000 cells/mm3 if marrow plasmacytosis is greater than or equal to 50%?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 100,000/mm3?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study platelet count greater than or equal to 100,000/mcl within 28 days prior to administration of therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379783&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593473</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>13</displayOrder>
      <dateCreated>2016-12-06T14:50:55</dateCreated>
      <dateModified>2016-12-06T14:50:55</dateModified>
      <questionText>Is pre-study hemoglobin greater than or equal to 8 g/dl?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Hematology Hemoglobin Assessment Code Indicator</longName>
       <shortName>HMT_HGB_AS_CD_IND</shortName>
       <publicID>4379789</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator whether there was a hematology assessment for hemoglobin, the red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Is pre-study hemoglobin great</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 9 g/dl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 9 g/dl OR greater than or equal to 5.6 mmol/L?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 8 g/dl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 90 g/L (or 9 g/dl)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 10 g/dl?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than 9 g/dL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 8 g/dL? </doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 9 g/dL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 9.0 g/dL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 10 g/dl and patient has not had blood transfusions in the 28 days prior to entry/randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 10 g/dL with no blood transfusion in the past 28 days?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 8 g/dl, within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 9 g/dl, independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screening?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 10 g/dl within 4 weeks prior to administration of study treatment  and patient has not had blood transfusions (packed red blood cells and platetet transfusions) in the past 28 days?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 9 g/dl without transfusion for at least 7 days prior to screening?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 8 g/dL within 2 weeks of the initiation of treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 9 g/dl (patients may be transfused to this level)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than 10 g/dl within 4 weeks prior to administration of study treatment  and patient has not had blood transfusions (packed red blood cells and platelet transfusions) in the past 28 days?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study hemoglobin greater than or equal to 10 g/dl within 28 days prior to administration of study treatment  and patient has not had blood transfusions (packed red blood cells and platelet transfusions) in the past 28 days?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379789&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593502</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>14</displayOrder>
      <dateCreated>2016-12-06T14:53:23</dateCreated>
      <dateModified>2016-12-06T14:53:23</dateModified>
      <questionText>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level less than or equal to 3 X ULN may be enrolled)?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Laboratory Procedure Within Clinical Study Protocol Upper Limit of Normal Total Bilirubin Measurement Code Indicator</longName>
       <shortName>LAB_TBM_CD_IND</shortName>
       <publicID>4379839</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator related to the top value of the range for total bilirubin falling within parameters set forth by the guidelines for a clinical trial.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than 1.5 x the upper limit of normal for the institution?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum total bilirubin less than or equal to 1.5 X upper limit of normal (ULN) OR direct bilirubin less than or equal to ULN for patients with total bilirubin levels greater than 1.5 ULN?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Is pre study serum bilirubin</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre study serum bilirubin less than 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin within normal institutional limits?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.25 x institutional upper limit of normal, with the exception of less than 2.9 mg/dL for patients with Gilbert&apos;s disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum total bilirubin less than 2 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x the upper limit of normal for the institution?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre study serum bilirubin less than or equal to 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than 1.5 X upper limit of normal (ULN); or less than 3 x institutional ULN for Gilbert&apos;s syndrome or HIV protease inhibitors; or less than 5 x ULN and direct bilirubin less than 0.7 mg/dL for patients on atazanvir containing HIV regimen?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x institutional upper limit of normal OR is direct bilirubin within normal range if pre-study total bilirubin greater than 1.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x the institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study bilirubin less than 1.5 x institutional upper limit of normal or less than 2.5 x upper limit of normal if liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x institutional upper limit of normal, less than or equal 3.0 x upper limit of normal if due to Gilbert&apos;s syndrome or hemolysis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre study total bilrubin less than or equal to 1.5 x upper limit of normal of patient has known Gilbert&apos;s disease or similar syndrome with slow conjugation of bilirubin is total bilirubin less than or equal to 3.0 mg/dL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin below institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre study total bilirubin less than or equal to 1.5 x upper limit of normal or if patient has known Gilbert&apos;s disease or similar syndrome with slow conjugation of bilirubin is total bilirubin less than or equal to 3.0 mg/dL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal, unless Gilbert&apos;s syndrome or disease infiltration of the liver is present?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level less than or equal to 3 X ULN may be enrolled)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin total bilirubin less than or equal to 2.0 mg/dL (except patients with Gilbert Syndrome, who can have total bilirubin less than 3.0 mg/dL)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x local institutional upper limit of normal (ULN) OR if total bilirubin is elevated due Gilbert&apos;s disease or disease-related hemolysis then is total bilirubin less than or equal to 3.0 x local institutional ULN?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre study serum bilirubin less than 1.5 x institutional upper limit of normal (with the exception of those with Gilbert syndrome)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal, except for patients with Gilbert syndrome ALT less than or equal to 3.0 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal (patients with Gilbert&apos;s syndrome may have serum bilirubin greater than 1.5 x upper limit of normal)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 × institutional upper limit of normal if no demonstrable liver metastases or less than or equal to 3 × institutional upper limit of normal in the presence of liver metastases or Gilbert’s Syndrome (unconjugated hyperbilirubinemia)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 44</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level less than or equal to 3 X ULN may be enrolled), within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Total bilirubin less than or equal to 2.0 mg/dL unless due to Gilbert&apos;s syndrome, hemolysis, or ineffective hematopoiesis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre study total bilirubin less than 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal, except for patients with Gilbert syndrome; ALT less than or equal to 3.0 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 30</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre study total bilirubin less than or equal to 1.5 x upper limit of normal or if patient has known Gilbert&apos;s disease or similar syndrome with slow conjugation of bilirubin is total bilirubin less than or equal to 3.0 mg/dL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 32</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to the institution&apos;s upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 31</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal (patients with Gilbert&apos;s syndrome may have direct bilirubin more than 1.5 x upper limit of normal)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 33</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than 1.5 × institutional upper limit of normal (ULN) (less than 2.0 × ULN for subjects with documented Gilberts syndrome or less than  3.0 × ULN for subjects for whom the indirect bilirubin level suggests an extra-hepatic source of elevation)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 35</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x institutional upper limit of normal if no demonstrable liver metastases or less than or equal to 3 x institutional upper limit of normal in the presence of liver metastases or Gilbert&apos;s Syndrome (unconjugated hyperbilirubinemia)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (except patients with Gilberts syndrome who can have total bilirubin less than 3 mg/dl)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 34</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x upper limit of normal, except for patients with Gilbert syndrome?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 29</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum total bilirubin less than or equal to upper limit of normal (ULN) OR direct bilirubin less than or equal to ULN for patients with total bilirubin levels greater than ULN; (except patients with Gilbert&apos;s Syndrome, who must have a total bilirubin less than 3.0 mg/dL)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 38</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum bilirubin within normal limits (WNL) or less than or equal to 1.5 x ULN in patients with liver metastases; or total bilirubin less than or equal to 3.0 x ULN with direct bilirubin WNL in patients with documented Gilberts Syndrome?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 39</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than 1.5 × institutional upper limit of normal (ULN) (less than 2.0 × ULN for patients with documented Gilberts syndrome or less than  3.0 × ULN for subjects for whom the indirect bilirubin level suggests an extra-hepatic source of elevation)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 37</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x institutional upper limit of normal (except patients with Gilberts syndrome who can have total bilirubin less than 3 mg/dl)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 40</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than 1.5 x institutional upper limit of normal or less than 2.5 x upper limit of normal if patient is know to have liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 41</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than 1.5 x institutional upper limit of normal (ULN) (less than 2.0 x ULN for subjects with documented Gilbert&apos;s syndrome or less than 3.0 x ULN for subjects for whom the indirect bilirubin levels suggests an extrahepatic source of elevation)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 43</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than 1.5 x institutional upper limit of normal OR greater than 1.5 x institutional upper limit of normal is allowed if direct bilirubin is within normal range?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 45</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level less than or equal to 3 X ULN may be enrolled), within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 36</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (except patients with Gilberts syndrome who can have total bilirubin less than 3 mg/dl)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 42</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than 1.5 x institutional upper limit of normal or less than 2.5 x upper limit of normal if patient is know to have liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 47</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin less than or equal to 1.5 x the institutional upper limit of normal within 28 days prior to administration of therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 46</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study total bilirubin within normal institutional limits OR if patient has confirmed Gilberts syndrome is total bilirubin less than or equal to 2.0 x ULN?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379839&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593506</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>15</displayOrder>
      <dateCreated>2016-12-06T14:54:56</dateCreated>
      <dateModified>2016-12-06T14:54:56</dateModified>
      <questionText>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver involvement?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination Code Indicator</longName>
       <shortName>LAB_AST_ALT_COD_IND</shortName>
       <publicID>4379840</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Are pre-study AST (SGOT), ALT</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal if liver involvement?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal  for patients with liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST and ALT less than or equal to 2.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with metastatic liver disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than 3 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study ALT (SGPT) less than 2.5 x upper limit of normal (ULN), OR less than 5 x ULN in the presence of liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study ALT (SGPT) or AST (if available at center) less than 2.5 x upper limit of normal (ULN), OR less than 5 x ULN in the presence of liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 3 x upper limit of normal or less than 5 x upper limit of normal in patients with Gilbert&apos;s disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver involvement?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal in patients with Gilbert&apos;s disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST and ALT less than 2.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal for patients with liver involvement?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal if liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than 3 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases? </doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal (AST and/or ALT less than or equal to 5 x upper limit of normal for patients with liver involvement)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver involvement?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST and ALT less than or equal to 3 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 1.5 x institutional upper limit of normal (AST and/or ALT less than or equal to 3 x ULN for patients with liver involvement)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 × institutional upper limit of normal if no demonstrable liver metastases or less than or equal to 5 × institutional upper limit of normal in the presence of liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study SGPT (ALT) or SGOT (AST) less than or equal to 2.5 x the upper limit of normal in the absence of hepatic metastases; SGPT (ALT) less than or equal to 3 x ULN or SGOT (AST) less than or equal to 5 x ULN in the presence of hepatic metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study ALT less than or equal to 3.0 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 43</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 3 x upper limit of normal within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 29</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with known hepatic metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 30</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal for patients known to have liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 41</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 42</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal or less than or equal to 5.0 x institutional upper limit of normal (only if elevated LFTs are due to disease)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 45</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext> Are pre-study AST (SGOT)/ALT (SGPT) less than 3 x upper limit of normal or less than to 5 x upper limit of normal for patients with liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 47</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 38</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal for patients known to have liver metastasest?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 37</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study aspartate transaminase (AST) less than or equal to 2.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 46</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance greater than or equal to 30 mL/min/1.73 m2 by Cockcroft-Gault or creatinine less than 1.5 x upper limit of normal, within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 44</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal if no demonstrable liver metastases or less than or equal to 5 x upper limit of normal for patients with liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 39</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal or less than or equal to 5 x institutional upper limit of normal for patients with liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 40</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 1.5 x upper limit of normal or less than or equal to 2.5 x upper limit of normal for patients with liver metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 48</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal, within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 49</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 1.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 50</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases within 28 days prior to administration of therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379840&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593735</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>16</displayOrder>
      <dateCreated>2016-12-06T15:02:29</dateCreated>
      <dateModified>2016-12-06T15:02:29</dateModified>
      <questionText>Is pre-study creatinine clearance greater than or equal to 30 mL/min/1.73m2 by Cockcroft-Gault?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Laboratory Procedure Creatinine Result Code Indicator</longName>
       <shortName>LAB_CREAT_CD_IND</shortName>
       <publicID>4379838</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator related to a creatinine laboratory procedure.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Is pre-study serum creatinine</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR calculated creatinine clearance (Cockroft-Gault formula) greater than or equal to 50 mL/min OR 24-hour urine creatinine clearance greater than or equal to 50 mL/min?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study calculated creatinine clearance (CrCl) greater than or equal to 30 mL/min and less than 60 mL/min (Cockroft-Gault)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 X ULN OR Measured or calculated creatinine clearance (CrCl) greater than or equal to 60 mL/min for subject with creatinine levels greater than 1.5 X institutional ULN?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to twice the upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL (less than or equal to 133 umol/L) OR calculated creatinine clearance (Cockroft-Gault formula) greater than or equal to 50 mL/min OR 24-hour urine creatinine clearance greater than or equal to 50 mL/min?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR creatinine clearance greater than or equal to 40 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR creatinine clearance greater than or equal to 50 mL/min (if using the Cockcroft-Gault formula)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than 1.5 X institutional upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min for patients with creatinine levels greater than or equal to 1.5 X institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR creatinine clearance greater than or equal to 50 mL/min/1.73 m^2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine within normal institutional limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to 1.5 x upper limit of normal or a calculated creatinine clearance greater than or equal to 60 mL/min (Cockcroft-Gault method) for patients receiving combination of cisplatin and pemetrexed and greater than or equal to 45 mL/min for patients receiving pemetrexed?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR creatinine clearance greater than or equal to 50 mL?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR creatinine clearance greater than or equal to 50 mL/min (if using the Cockcroft-Gault formula)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal institutional limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal institutional limits OR creatinine clearance greater than or equal to 60 mL using the modified Cockcroft-Gault formula?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal institutional limits OR creatinine clearance greater than or equal to 50 mL/min for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study calculated creatinine clearance (CrCl) greater than 50 mL/min using Cockroft-Gault equation?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to 1.5 x upper limit of normal or a calculated creatinine clearance greater than or equal to 60 ml/min/1.73 m2 (Cockcroft-Gault method) for patients receiving combination of cisplatin and pemetrexed and greater than or equal to 45 ml/min/1.73 m2 for patients receiving pemetrexed?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL (less than or equal to 120 umol/L) OR calculated creatinine clearance (Cockroft-Gault formula) greater than or equal to 50 mL/min OR 24-hour urine creatinine clearance greater than or equal to 50 mL/min?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal institutional limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal 1.5 x upper limit of normal OR creatinine clearance greater than or equal to 40 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than 1.5 X institutional upper limit of normal OR creatinine clearance greater than or equal to 50 mL/min for patients with creatinine levels greater than or equal to 1.5 X institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 (eGFR) for patients with creatinine levels above the upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal institutional limits OR creatinine clearance greater than or equal to 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 29</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 2.0 mg/dL OR creatinine clearance greater than or equal to 50 mL/min?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 (eGFR) appropriate to race for patients with creatinine levels above the upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance greater than or equal to 50 mL/min by either measured or calculated clearance?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than 2.5 x institutional upper limit of normal OR measured or calculated creatinine clearance greater than or equal to 30 mL/min for patients with creatinine levels above 2.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than 1.5 mg/dL (equal to 132 umol/L) OR creatinine clearance greater than or equal to 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 35</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance greater than or equal to 60 mL/min/1.73 m^2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 30</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR creatinine clearance greater than or equal to 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 32</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to 2.5 x institutional upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 34</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 x upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 31</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than 1.0 X institutional upper limit of normal OR creatinine clearance greater than or equal to 50 mL/min for patients with creatinine levels greater than or equal to 1.0 X institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 37</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal institutional limits for age OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 33</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal 1.5 x upper limit of normal OR creatinine clearance greater than or equal to 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 36</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than 1.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 38</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine below institutional upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 40</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study BSA-Normalized creatinine clearance greater than or equal to 60 mL/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 43</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal institutional limits OR creatinine clearance greater than or equal to 50 mL/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 42</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study calculated creatinine clearance greater than or equal to 45 mL/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 39</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance, estimated GFR, greater than or equal to 30 mL/min/1.73m2 (Cockcroft-Gault)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 41</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine within normal institutional limits for age OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 47</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 x upper limit of normal OR creatinine clearance greater than or equal to 40 mL/min based on either Cockroft-Gault estimate or based on urine collection (12 or 24 hours)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 44</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance greater than or equal to 30 mL/min/1.73m2 by Cockcroft-Gault?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 45</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 x the upper limit of normal OR creatinine clearance greater than or equal to 50 mL/min (if using the Cockcroft-Gault formula)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 46</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study calculated creatinine clearance greater than or equal to 45 mL/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 50</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance (using the Cockcroft-Gault formula) greater than or equal to 45 mL/min/1.73 m2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 52</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal 1.5 x institutional upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 me2 for patients with creatinine levels above 1.5 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 51</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to the institutional upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 54</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 2.0 x institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 53</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance or radioisotope GFR greater than 60 mL/min/1.73 m2 by either Cockcroft- Gault formula or analysis normal serum creatinine based on age?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 48</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 x upper limit of normal OR creatinine clearance greater than or equal to 50 mL/min for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 49</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance (CrCl) greater than or equal to 30 mL/min using Cockroft-Gault equation?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 55</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study calculated creatinine clearance by MDRD (CrCl) greater than 50 ml/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 58</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to the institutional upper limit of normal OR creatinine clearance greater than 60 mL/min/1.73 m2 by either Cockcroft-Gault formula or 24-hour urine collection analysis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 57</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 x institutional ULN  or creatinine clearance or radioisotope GFR greater than or equal to 70mL/min/1.73m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 56</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR calculated creatinine clearance (Cockroft-Gault formula) greater than or equal to 50 mL/min OR 24-hour urine creatinine clearance greater than or equal to 50 mL/min?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 60</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance greater than or equal to 50 mL/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 73</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance greater than or equal to 30 mL/min/1.73 m2 by Cockcroft-Gaul or creatinine less than 1.5 x upper limit of normal, within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 59</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to 1.5 x ULN and concurrent creatinine clearance (CrCl) greater than or equal to 50mL/min/1.73 m2 for patients with creatinine greater than 1.5 x ULN?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 63</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine serum creatinine less than or equal to 1.5 x ULN, or measured creatinine clearance (CrCl) greater than or equal to 45 mL/min as calculated by the Cockcroft-Gault method (confirmation of creatinine clearance is only required when creatinine is greater than 1.5 x institutional ULN)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 68</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 mg/dL OR creatinine clearance greater than or equal to 50 mL/min/1.73 m2 for patients with serum creatinine greater than 1.5 x higher than institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 62</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study BSA-Normalized creatinine clearance greater than or equal to 30 mL/min/1.73 m2 (using Cockcroft-Gault CrCl)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 65</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal 1.5 x upper limit of normal OR creatinine clearance greater than or equal to 40 mL/min/1.73 m^2 (calculated using the CKD-EPI equation or Cockgroft-Gault formula) for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 72</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal 1.5 x upper limit of normal OR creatinine clearance greater than or equal to 40 mL/min/1.73 m^2 (calculated using the CKD-EPI equation or Cockgroft-Gault formula) for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 64</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study calculated creatinine clearance greater than or equal to 60 mL/min/1.73 m2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 74</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine within normal institutional limits OR calculated creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 69</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to 1.5 x institutional upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above 1.5 x institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 70</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study calculated creatinine clearance greater than or equal to 50 mL/min (if using the Cockcroft-Gault formula)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 66</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to 1.5 x ULN OR calculated or measured creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 71</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to the institutional upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 67</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal 1.5 x institutional upper limit of normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above 1.5 x institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 61</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study serum creatinine less than or equal to the upper limit of institutional normal OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 78</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine less than or equal to 1.5 x upper limit of normal OR creatinine clearance greater than or equal to 50 mL/min?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 79</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is creatinine clearance greater than or equal to 50 mL/min within 28 days prior to administration of therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 75</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance greater than 50 mL/min?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 77</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study calculated creatinine clearance (CrCl) greater than 50 mL/min using Cockroft-Gault equation or 24-hour urine sampling?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 76</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study creatinine clearance greater than or equal to 30 mL/min/1.73 m2 by Cockcroft-Gault or creatinine less than 1.5 x upper limit of normal, within 2 weeks of randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379838&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593739</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>17</displayOrder>
      <dateCreated>2016-12-06T15:04:04</dateCreated>
      <dateModified>2016-12-06T15:04:04</dateModified>
      <questionText>If patient is not receiving therapeutic anticoagulation, are pre-study INR and aPTT less than or equal to 1.5 x upper limit of normal?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Blood Coagulation Assessment  Code Indicator</longName>
       <shortName>LAB_BLD_COAG_COD_IND</shortName>
       <publicID>4379842</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable indicator related to assessment of clot formation in blood.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.3 X institutional ULN?  Patients receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization.</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study Prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.2 x institutional ULN?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.5 X institutional upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study International Normalized Ratio (INR) or Prothrombin Time (PT) less than or equal to 1.5 X ULN unless subject is receiving anticoagulant therapy not requiring laboratory monitoring as long as PT or PTT is within therapeutic range of intended use of anticoagulants?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Is pre-study INR less than or</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study INR less than or equal to 1.5 x upper limit of normal or PT less than or equal to 1.5 x upper limit of normal seconds above control unless patient is currently receiving warfarin therapy for the treatment or prevention of venous thrombosis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study INR less than or equal to 1.4?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study prothrombin time (PT)/International Normalized Ratio (INR) or partial thromboplastin time (PTT) test greater than or equal to 1.3 x the laboratory upper limit of normal within 7 days prior to the first dose of study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study INR less than 2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study PTT less than or equal to 40 seconds unless due to lupus coagulant?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study PT/INR and PTT less than 1.3 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study prothrombin time or INR less than or equal to 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study INR less than or equal to 2?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study Activated Partial Thromboplastin Time (aPTT) and PT less than or equal to 1.2 X ULN?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study prothrombin time or INR and PTT less than or equal to 1.3 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study coagulation parameters (INR, aPTT) within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study PT/INR and PTT less than or equal to 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study coagulation parameters within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed or except patients on anticoagulation?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is not receiving therapeutic anticoagulation, are pre-study INR and aPTT less than or equal to 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study INR less than or equal to 1.4 unless the patient is receiving therapeutic doses of Coumadin?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study prothrombin time (PT)/International Normalized Ratio (INR) or partial thromboplastin time (PTT) test greater than or equal to 1.5 x the laboratory upper limit of normal within 7 days prior to the first dose of study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study International normalized ratio ((NR) and aPartial Thromboplastin Time (aPTT) less than or equal to 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study aPTT and PT less than to 1.2 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study prothrombin time (PT) or partial thromboplastin time (PTT) less than 1.5 × upper limit of normal (ULN), OR International normalized ratio (INR) less than 1.5?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study coagulation parameters (INR and aPTT) within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.5 X institutional ULN unless patient is on anticoagulant therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If receiving patient is receiving warfarin, is INR less than or equal to 3.0 without any evidence of active bleeding within 14 days prior to first dose of study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study International normalized ratio (INR) and aPartial Thromboplastin Time (aPTT) less than or equal to 1.5 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is pre-study prothrombin time (PT) or partial thromboplastin time (PTT) less than 1.5 × upper limit of normal (ULN), OR International normalized ratio (INR) less than 1.5?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is receiving warfarin, is INR less than or equal to 3.0 without any evidence of active bleeding within 14 days prior to first dose of study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 29</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study aPTT and PT greater than or equal to 1.2 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 30</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study aPTT and PT less than or equal to 1.2 x upper limit of normal?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 31</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study coagulation parameters (INR and aPTT) within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed or except pateints on anticoagulants?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 32</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Are pre-study international normalized ratio (INR) or prothrombin time (PT) and partial thromboplastin time (PTT) or activated PTT (aPTT) less than or equal to 1.5 x ULN?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379842&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5593873</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>18</displayOrder>
      <dateCreated>2016-12-06T15:06:40</dateCreated>
      <dateModified>2016-12-06T15:06:40</dateModified>
      <questionText>If patient is receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, are they on a stable dose?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Anticoagulant Agent Administration Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>XCOA_AGT_ADM_COD_IND</shortName>
       <publicID>4474276</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable response regarding whether a patient receives anticoagulant medication.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Will anticoagulant medication</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Will anticoagulant medication be administered?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If required, will warfarin use be within the parameters described in section 5.5.1 of protocol?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving full anti-coagulant therapy with Coumadin?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient require concurrent use of anticoagulation?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving anticoagulation or anti-platelet therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, are they on a stable dose?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving anticoagulation or anti-platelet therapy including, heparin or low molecular weight heparin, warfarin, clopidogrel, ibuprofen and other NSAIDS, tirofiban, and other anticoagulants, drugs, or herbal supplements that affect platelet function?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is on full dose anticoaugulation, has patient been on a stable dose for at least 14 days?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving anticoagulation or anti-platelet therapy including, include heparin or low molecular weight heparin, warfarin, clopidogrel, ibuprofen and other NSAIDS, tirofiban, and other anticoagulants, drug or herbal supplements that affect platelet function?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is on full dose anticoaugulation, has patient been on a stable dose for at least 14 days?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4474276&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5594048</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>19</displayOrder>
      <dateCreated>2016-12-06T15:14:55</dateCreated>
      <dateModified>2017-06-28T16:27:12</dateModified>
      <questionText>Does patient, women of childbearing potential and men, agree to use adequate contraception, prior to study entry, for duration of study participation and for 5 months (150 days) after completion of study drug administration (completion of atezolizumab administration)?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Contraception Eligibility Determination Code Indicator</longName>
       <shortName>CONT_EL_DT_CD_IND</shortName>
       <publicID>4449913</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response related to patient&apos;s criteria to determine eligibility based on the use of prevention of conception or impregnation by the use of devices or drugs or surgery.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient, women of childb</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after the last dose of drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex -3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry and for duration of study participation?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and up to 90 days following completion of therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is male and sexually active, patient agrees to use adequate contraception prior to study entry, for the duration of study participation and for 31 weeks after the last dose of investigational product?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation and for 31 weeks after the last dose of investigational product?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after completion of MLN8237 administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is male and is sexually active with a women of child bearing potential, patient agree to use adequate contraception prior to study entry, for the duration of study participation and for 31 weeks after the last dose of investigational product?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does female patient of childbearing potential, agree to use an adequate method of contraception throughout the study and for up to 12 weeks after the last dose of study drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, woman of childbearing potential and men, agree to use two forms of contraception, prior to study entry, for duration of study participation and for 31 weeks after the last dose nivolumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use two highly effective forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 3 months after the last dose of drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use highly effective contraception (as per section 3.3.11) prior to study entry, for the duration of study participation, and for 3 months after completion of study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after the last CDX-011 (glembatumumab vedotin) dose?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after the last dose of MLN0128 and AZD9291?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men with female partner of childbearing potential, agree to use adequate contraception prior to study entry, during study participation and for 4 months after the last dose of drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men with partners of childbearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 2 months after completion of study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after the last dose AZD1775 and belinostat administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception, as listed in protocol, prior to study entry, for the duration of study participation, and for 3 months for women and 6 months for men following the date of the last dose of AZD9291 and/or necitumumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months for women and 6 months for men following the date of the last dose of AZD9291 and/or navitoclax?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after study completion?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for duration of study participation and for 4 months after completion of study drugs?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal contraception not allowed) prior to study entry, for duration of study participation and for 4 months after completion of study drug administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 23 weeks for women and 31 weeks for men after stopping nivolumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after completion of AT13387 (onalespib) administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception during treatment with MM-938 for 90 days following the final dose of Veliparib and MM-398?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 30</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for duration of study participation and for 4 months after completion of IPdR administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 31</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [eg. USPI, SmPC, etc]) after the last dose of study drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and up to 90 days following completion of ibrutinib administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 29</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception during treatment with MM-398 and for 90 days following the final dose of Veliparib and MM-398?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 33</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of child-bearing potential and men, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling [eg, USPI, SmPC, etc;]) after the last dose of study drug, or agree to completely abstain from heterosexual intercourse?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 32</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 5 months (150 days) after the last dose of study agent (men must also agree to use adequate contraception for at least 5 months (150 days) after completion of atezolizumab and/or ABT-888 administration)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 37</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use two highly effective forms of contraception for the duration of study participation and for 6 weeks after completion of olaparib and cediranib administration (12 weeks for men)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 36</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception, prior to study entry, for duration of study participation and for 5 months after completion of study drug administration (completion of atezolizumab administration)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 39</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 23 weeks for women and 31 weeks for men after last dose of investigational drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 34</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for duration of study participation and for 3 months after completion of study drugs (4 months for men)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 38</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 weeks after dosing with selumetinib ceases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 35</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 5 months (150 days) after the last dose of study agent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 42</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception during study participation, and for 6 months after completion of bevacizumab therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 41</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months after the last dose of study agent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 45</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 weeks after dosing with AZD6244 ceases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 44</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 6 months following participation?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 43</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential agree to use adequate contraception prior to study entry, during study participation, and for 150 days after the last dose of study agent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 40</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 150 days after the last dose of study agent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 48</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does female patient childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 5 months after the last dose of drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 51</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does female patient childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 7 months after the last dose of drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 52</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 5 months(150 days) after the last dose of study agent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 46</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential agree to use adequate contraception prior to study entry, during study participation, and for 4 weeks after dosing with AZD6244 ceases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 47</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception, prior to study entry, for duration of study participation and for 5 months (150 days) after completion of study drug administration (completion of atezolizumab administration)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 50</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 120 days after last dose of study therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 49</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 4 months after completion of olaparib and ramucirumab administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 60</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 53</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 180 days after the last dose of paclitaxel?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 61</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 months for women and 7 months for men after last dose of study drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 64</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men with partners of childbearing potential, agree to use adequate contraception (barrier method of birth control, or abstinence; hormonal contraception is not allowed due to drug-drug interactions which can render hormonal contraceptives ineffective) prior to study entry, for duration of study participation and for 4 months after completion of study drug administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 65</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, during study participation, and for 3 months after completion of Olaparib and Ramucirumab administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 55</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men who are sexual partner of a female of childbearing portenial, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 23 weeks for women and 31 weeks for men after last dose of study drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 54</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does female patient of childbearing potential, agree to use adequate contraception prior to study entry, during study participation, and for 7 months after the last dose of drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 62</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men who are sexual partner of a female of childbearing potential, agree to use adequate contraception prior to study entry, for the duration of study participation, and for 23 weeks for women and 31 weeks for men after last dose of study drug?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 57</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for duration of study participation and for 4 months after completion of IPdR administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 63</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry, for duration of study participation and up to 3 months after end of treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 56</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men with partners of childbearing potential, agree to use adequate contraception (hormonal contraception not allowed) prior to study entry, for duration of study participation and for 4 months after completion of study drug administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 58</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of child bearing potential and men, agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence; sterilization) prior to the study, for the duration of study participation, and for 3 months after completion of administration of Aza-TdC?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 69</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of child-bearing potential and men, agree to use adequate contraception prior to study entry, for the duration of the study and 6 months after completion of anetumab ravtansine or MK-3475 (pembrolizumab) administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 66</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is female of childbearing potential uses hormonal contraceptive, does patient agree to use an additional barrier method of contraception while on study treatment and for 30 days after discontinuation of study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 70</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men and their partners who are sexually active, agree to use two highly effective forms of contraception in combination (see olaparib 1B page 161-162 for acceptable methods) for the duration of study participation and for 3 months after completion of olaparib and cediranib administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 68</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, women of childbearing potential and men, agree to use adequate contraception prior to study entry and for the duration of study participation?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 67</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient, men and women of childbearing potential agree to use adequate contraception prior to study entry, for the duration of study participation, and for 4 months after completion of administration of either agent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4449913&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5594990</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>20</displayOrder>
      <dateCreated>2016-12-06T15:47:41</dateCreated>
      <dateModified>2016-12-06T15:47:41</dateModified>
      <questionText>Is patient able to understand and is willing to sign a written informed consent document?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Consent Ability Yes No Not Applicable Code Indicator</longName>
       <shortName>PT_CONS_ABIL_IND_3</shortName>
       <publicID>4382991</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>a yes/no/not applicable question related to a person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary being able to give permission.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Is patient able to understand</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient able to understand and is willing to sign a written informed consent document?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient able to understand and is willing to sign a written informed consent document or a parent/guardian able to do the same?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient able to provide informed consent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient able to understand and is willing to sign an IRB-approved written informed consent document?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4382991&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5595003</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>21</displayOrder>
      <dateCreated>2016-12-06T15:52:33</dateCreated>
      <dateModified>2016-12-06T15:52:33</dateModified>
      <questionText>If patient has received prior treatment with anti-CTLA-4 antibody, was last dose greater than 6 weeks previously and there is no history of severe immune-related adverse effects from anti-CTLA-4 antibody (NCI CTCAE Grade 3 and 4)?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Monoclonal Antibody Personal Medical History Code Indicator</longName>
       <shortName>MON_AB_PMH_CD_IND</shortName>
       <publicID>4617974</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded indicator response regarding whether a patient meets the eligibility criteria for enrollment in a clinical trial based on prior treatment with monoclonal antibodies.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Has patient had a prior monoc</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., less than or equal to Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Have at least 4 weeks elapsed from end of monoclonal antibody therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Have at least 4 weeks elapsed from end of monoclonal therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received prior treatment with anti-CTLA-4, has it been a minimum of 12 weeks from the first dose of anti-CTLA-4 and  more than 6 weeks from the last dose, and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received prior monoclonal antibody therapy, was it completed at least 3 half-lives of the antibody or 6 weeks ago?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Was last dose of a monoclonal antibody at least 3 half-lives prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Was last dose of a monoclonal antibody at least 30 days prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received prior treatment with anti-CTLA-4 antibody, was last dose greater than 6 weeks previously and there is no history of severe immune-related adverse effects from anti-CTLA-4 antibody (NCI CTCAE Grade 3 and 4)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received prior treatment with anti-CTLA-4  are the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and greater than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received prior treatment with anti-CTLA-4  are the following requirements met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and greater than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received prior monoclonal antibody therapy, was it completed  more than 6 weeks ago (or  3 half-lives of the antibody whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any monoclonal antibody therapy within 4 weeks prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4617974&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5595159</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>22</displayOrder>
      <dateCreated>2016-12-06T15:54:07</dateCreated>
      <dateModified>2016-12-06T15:54:07</dateModified>
      <questionText>If patient has received prior herbal therapy was last dose more than 1 week prior to cycle 1, day 1?</questionText>
      <instruction>
       <text>Herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to Cycle 1, Day 1.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Therapy Complementary and Alternative Medicine Administered Code Indicator</longName>
       <shortName>TX_ALT_MD_ADM_CD_IN</shortName>
       <publicID>4449956</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response regarding whether nontraditional therapeutic agents/procedures were administered for treatment to alter a disease process (e.g., herbal preparation, vitamin, massage, magnets).</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received herbal therapy intended as anticancer therapy within 1 week prior to randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Is patient taking concurrent</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient taking concurrent herbal supplements (including, but not limited to, St. John&apos;s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng) while on study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient used natural herbal products or other complementary alternative medications (CAM) or &quot;folk remedies&quot; within one week of starting study and will continue using them concurrently while participating on this study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient taking concurrent herbal supplements (including, but not limited to, cannabis,  St. John&apos;s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng) while on study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient currently using natural herbal products or other complementary alternative medications (CAM) or folk remedies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving vitamin E supplementation?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received herbal therapy, intended as anticancer therapy, within 1 week prior to cycle 1, day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient using (currently) natural herbal products or other folk remedies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received prior herbal therapy was last dose more than 1 week prior to cycle 1, day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 1</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Has patient received herbal preparations during the indicated time period</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient currently taking natural herb products or other complementary alternative medications or if used previously, patients must have at least 1-week washout and must stop using them while participating in this study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>ABTC - 1602 Question</name>
         <type>Alternate Question Text</type>
         <context>ABTC</context>
         <doctext>Has the patient received herbal or non-traditional medications while receiving AMG 232 therapy within 30 days prior to start of treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving, or is intended to receive ongoing treatment with: herbal remedies (e.g., St. Johns wort), or strong inhibitors or inducers of P-glycoprotein (Pgp) or breast cancer resistance protein 1 (Bcrp1)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patients medication list such as herbal medicines (e.g., St. Johns wort), vitamins, and supplements, been reviewed before starting first dose of AMG 232?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has taken any herbal medicines (e.g., St. Johns wort), vitamins, and supplements within the 30 days prior to receiving the first dose of AMG 232 has continued use, if applicable, been reviewed by the Principal Investigator?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4449956&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5595188</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>23</displayOrder>
      <dateCreated>2016-12-06T16:07:23</dateCreated>
      <dateModified>2016-12-06T16:07:23</dateModified>
      <questionText>If patient has received palliative therapy for bone metastases was it discontinued more than 2 weeks prior to cycle 1, day 1?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>No</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Prior Local Palliative External Beam Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>LCL_PAL_EXBMRX_CD_IND</shortName>
       <publicID>5566296</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded response indicating whether a patient that has received local palliative external beam radiation therapy meets the criteria for participation in a clinical trial.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received palliative therapy for bone metastases was it discontinued more than 2 weeks prior to cycle 1, day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>If patient has received exter</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received external beam radiation therapy that is local and palliative, was it completed at least 2 weeks prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Was last dose of palliative radiation or cyberknife therapy completed greater than or equal to 2 weeks prior to entering study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5566296&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5595202</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>24</displayOrder>
      <dateCreated>2016-12-06T16:10:43</dateCreated>
      <dateModified>2016-12-06T16:10:43</dateModified>
      <questionText>If patient has asymptomatic untreated CNS disease have all of the following criteria been met: no more than 3 lesions, less than or equal to 1 cm in size each, evaluable or measurable disease outside the CNS, no metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm), no history of intracranial hemorrhage or spinal cord hemorrhage, no ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted, and no neurosurgical resection or brain biopsy within 28 days prior to Cycle 1, Day 1?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Asymptomatic Untreated Central Nervous System Disorder Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>ASYM_UNTX_CNSDZ_IND</shortName>
       <publicID>5479293</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to asymptomatic central nervous system disease that has not been treated.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>If patient has asymptomatic u</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic untreated CNS disease are all of the following criteria met: Evaluable or measurable disease outside the CNS:; No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm); No history of intracranial hemorrhage or spinal cord hemorrhage; No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted; No neurosurgical resection or brain biopsy within 28 days prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic untreated CNS disease are all of the following criteria are met: Evaluable or measurable disease outside the CNS,; No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm); No history of intracranial hemorrhage or spinal cord hemorrhage;  No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted; No neurosurgical resection or brain biopsy within 28 days prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic untreated CNS disease have all of the following criteria been met: no more than 3 lesions, less than or equal to 1 cm in size each, evaluable or measurable disease outside the CNS, no metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm), no history of intracranial hemorrhage or spinal cord hemorrhage, no ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted, and no neurosurgical resection or brain biopsy within 28 days prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have at least one measurable CNS lesion that is asymptomatic, untreated, and does not require local therapy at the time of enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has untreated brain metastases, is patient clinically asymptomatic and stable?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5479293&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5595239</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>25</displayOrder>
      <dateCreated>2016-12-06T17:01:44</dateCreated>
      <dateModified>2016-12-06T17:01:44</dateModified>
      <questionText>If patient has asymptomatic treated CNS metastases are all of the criteria listed above met as well as the following:  Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study; No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1;  Screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids.</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Asymptomatic Central Nervous System Disease Prior Treatment Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>ASYM_TX_CNSDZ_IND</shortName>
       <publicID>5577914</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to asymptomatic central nervous system disease and previous therapies.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic treated CNS metastases, have all of the criteria listed above been met as well as the  following: radiographic demonstration of improvement upon the completion of CNS‑directed therapy and no evidence of interim progression between the completion of CNS‑directed therapy and the screening radiographic study, no stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1; and screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic treated CNS metastases, have all of the criteria listed above been met as well as the  following: radiographic demonstration of improvement upon the completion of CNS? directed therapy and no evidence of interim progression between the completion of CNS? directed therapy and the screening radiographic study, no stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1; and screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>If patient has asymptomatic t</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic treated CNS metastases are all of the criteria listed above met as well as the following:  Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study; No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1;  Screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids.</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has central nervous system (CNS) metastases is it inactive, defined as: no signs of cerebral edema after successful definitive treatment of brain metastases (surgical resection, whole brain irradiation, stereotactic radiation therapy, or a combination of these) with stable or improved radiographic appearance on magnetic resonance imaging (MRI) scan at least 1 month after completion of treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic treated CNS metastases are all of the criteria listed above met as well as the following:  Radiographic demonstration of clinical stability upon the completion of CNS directed therapy and no evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study; no stereotactic radiation or whole-brain radiation within 28 days prior to randomization; and screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic treated CNS metastases are all of the criteria listed above met as well as the following:  Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and radiographic screening for the current study; No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1;  Screening CNS radiographic study greater than or equal to 4 weeks from completion of radiotherapy and greater than or equal to 2 weeks from discontinuation of corticosteroids</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has central nervous system (CNS) metastases is it inactive, defined as: symptoms of brain metastases after successful definitive treatment of brain metastases (surgical resection, whole brain irradiation, stereotactic radiation therapy, or a combination of these) with stable or improved radiographic appearance on magnetic resonance imaging (MRI) scan at least 1 month after completion of treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5577914&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5595231</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>26</displayOrder>
      <dateCreated>2016-12-06T16:53:46</dateCreated>
      <dateModified>2016-12-06T17:01:44</dateModified>
      <questionText>If patient has eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) does patient meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations Rash must cover less than 10% of body surface area (BSA). Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%). No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Dermatologic Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>DRM_DZDR_IND</shortName>
       <publicID>5479475</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to any abnormal condition having to do with the skin or the practice of dermatology.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>If patient has eczema, psoria</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) does patient meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations Rash must cover less than 10% of body surface area (BSA). Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%). No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has  eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g. patients with psoriatic arthritis would be excluded), does patient meet the following: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; Rash must cover less than 10% of body surface area (BSA); Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%) ; No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only are the following conditions met: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; Rash must cover less than 10% of body surface area (BSA); Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%); No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids? 
</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are the following conditions met: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; Rash must cover less than 10% of body surface area (BSA); Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%. aclometasone dipropionate 0.05%); No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are the following conditions met: Rash must cover less than 10% of body surface area (BSA). Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%). And there are no acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded), are the following conditions met: Rash must cover less than 10% of body surface area (BSA). Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%). And there are no acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5479475&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5595235</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>27</displayOrder>
      <dateCreated>2016-12-06T16:57:30</dateCreated>
      <dateModified>2016-12-06T17:01:44</dateModified>
      <questionText>If patient is HIV-positive are the following criteria met: patient is on a stable regimen of highly active anti-retroviral therapy (HAART), there is no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections, CD4 count above 250 cells/mcL and has an undetectable HIV viral load on standard PCR-based tests?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person HIV Infection Clinical Trial Eligibility Criteria Indicator</longName>
       <shortName>PRSN_HIV_INFEC_IND</shortName>
       <publicID>5036420</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response that asks if the patient has any state accompanied by evidence of HIV in the body.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have a history o</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of HIV infection?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have poorly controlled HIV?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is positive for human immunodeficiency virus (HIV) does patient have the following: a stable regimen of highly active anti-retroviral therapy (HAART), no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections, a CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) are the following criteria met:  patient is generally healthy from an HIV perspective and on a stable antiretroviral regimen for greater than 6 months, no AIDS-defining conditions in the past 12 months other than historically low CD4+ cell counts, and has an undetectable viral load on standard assays?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is HIV-positive are the following criteria met: patient is on a stable regimen of highly active anti-retroviral therapy (HAART), there is no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections, CD4 count above 250 cells/mcL and has an undetectable HIV viral load on standard PCR-based tests?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient known to have human immunodeficiency virus (HIV) infection?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is HIV-positive are the following criteria met: patient is on a stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong or moderate CYP3A4 inducers or inhibitors, there is no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections, CD4 count above 250 cells/mcL and has an undetectable HIV viral load on standard PCR-based tests?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If positive for human immunodeficiency virus (HIV), does the patient have the following? a. A stable regimen of highly active anti-retroviral therapy (HAART) b. No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections c. A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests.</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CITN-1</name>
         <type>Alternate Question Text</type>
         <context>CITN</context>
         <doctext>HIV viral load is &lt; 200 copies/mm3 by standard clinical assays.</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5036420&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
       </module>
   <module>
    <displayOrder>3</displayOrder>
    <maximumModuleRepeat>0</maximumModuleRepeat>
    <longName>Exclusion Criteria</longName>
        <preferredDefinition>Exclusion criteria</preferredDefinition>
    <publicID>5590595</publicID>
    <version>1</version>
    <usageCategory>
     <usageType>None</usageType>
    </usageCategory>
         <question>
      <publicID>5596550</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>0</displayOrder>
      <dateCreated>2016-12-07T15:30:31</dateCreated>
      <dateModified>2016-12-07T15:30:31</dateModified>
      <questionText>Has patient received prior chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</questionText>
      <instruction>
       <text>Hormone-replacement therapy or oral contraceptives are allowed.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Chemotherapy Nitrosourea Compound Mitomycin C Radiation Therapy Exclusion Criteria Yes No Not Applicable Code Indicator</longName>
       <shortName>PT_CHEMO_NITRO_MITO_C_RD_IND_3</shortName>
       <publicID>4382992</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>the yes/no/not applicable indicator related to the administration of chemotherapy and radiation therapy as medical characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Has patient received prior ch</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy, targeted small molecular therapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or targeted therapies within 2 weeks prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior targeted therapy, chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or radiotherapy less than or equal to 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or radiotherapy within 4 weeks prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior nitrosoureas or mitomycin C within 6 weeks prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had systemic cytotoxic chemotherapy or other targeted agents or any other investigational agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had systemic cytotoxic chemotherapy or other targeted agents or any other investigational agents within half-lives (6 weeks for nitrosoureas or mitomycin C) prior to starting the study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had systemic cytotoxic chemotherapy or other targeted agents or any other investigational agents within 4 half-lives (6 weeks for nitrosoureas or mitomycin C) prior to starting the study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy, biologic therapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>NRG_CRF Text</name>
         <type>Alternate Question Text</type>
         <context>NRG</context>
         <doctext>Will the prior chemotherapy or radiotherapy be discontinued at least 4 weeks prior to starting treatment on this study ( 6 weeks for nitrosoureas or mitomycin C)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy, radiotherapy or biologic therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or targeted small molecular therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or at least 5 half-lives, whichever is longer, prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received oral targeted agents or any other investigational agents, have at least 4 half-lives of the agent (6 weeks for nitrosoureas or mitomycin C) elapsed prior to starting study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any radiotherapy or chemotherapy for their current gynecological cancer?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior chemotherapy, radiotherapy immunotherapy or anticancer agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4382992&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5596556</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>1</displayOrder>
      <dateCreated>2016-12-07T15:32:02</dateCreated>
      <dateModified>2016-12-07T15:32:02</dateModified>
      <questionText>Has patient failed to recover from adverse events (except alopecia) due to agents administered more than 4 weeks earlier?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Prior Therapy Adverse Event Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>PRTX_AE_CTE_COD_IND</shortName>
       <publicID>4379856</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable response related to whether a person has fully recovered from adverse events as a result of prior agent administration.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Has patient failed to recover</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to agents administered more than 4 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover to baseline or CTCAE less than or equal to grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant AEs defined as lab elevation with no associated symptoms or  sequelae?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to agents administered?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to agents administered more than 3 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover (less than or equal to grade 1) from adverse events due to agents administered (except for alopecia)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events (to grade less than or equal to in severity) due to agents administered more than 4 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>TEST</context>
         <doctext>Has patient failed to recover from acute adverse events to grade less than 2 or baseline due to agents administered, with exception of alopecia, unless approved by the Protocol Chair?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from clinically significant adverse events due to prior agents administered to less than or equal to grade 1 or baseline with the exception of alopecia and peripheral neurophathy, unless approved by Protocol Chair?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover (less than or equal to grade 1 or baseline) from adverse events due to agents administered more than 4 weeks earlier (except for alopecia)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events (except alopecia) due to agents administered more than 4 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than CTCAE Grade 1 or baseline, with the exception of alopecia)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to agents administered more than 2 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from serious adverse events due to agents administered more than 4 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to prior administered agents as noted above?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than CTCAE Grade 1)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1, except alopecia, peripheral sensory neuropathy, and stable endocrine insufficiencies such as thyroid and adrenal insufficiency)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1), except alopecia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover to less than grade 1 from adverse events due to agents administered more than 3 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from serious (CTCAE grade 3 or more) adverse events form the previously received agents?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover to eligibility levels from prior toxicity?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover to less than or equal to grade 1 from adverse events due to agents administered more than 3 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events (other than alopecia) due to agents administered more than 3 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from serious (CTCAE grade 3 or more) adverse events from the previously received agents?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., has residual toxicities greater than Grade 1)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1), with the exception of patients with less than or equal to grade 2 neuropathy or less than or equal to grade 2 alopecia who may qualify for the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient failed to recover to grade 1 or less (except alopecia) from adverse events due to agents administered more than 4 weeks earlier?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379856&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5622545</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>2</displayOrder>
      <dateCreated>2017-01-10T16:50:25</dateCreated>
      <dateModified>2017-06-29T17:07:20</dateModified>
      <questionText>Has patient received any other investigational agents within 4 weeks prior to cycle 1, day 1?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Prior Investigational Therapeutic Procedure Administered Code Indicator</longName>
       <shortName>PR_INV_TX_PRO_CD_IND</shortName>
       <publicID>4449951</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response regarding whether prior investigational therapies were administered.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received prior biologics or immunotherapy within 28 days (or during) of romidepsin administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Has the patient received any</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has the patient received any other investigational drugs?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib and during the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has the patient received any other investigational agents or participated in an investigational trial within the past 4 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any other investigational agents within 4 weeks or 5 half-lives (whichever is later) prior to first dose of the study regimen?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has the patient received any other investigational agent within 3 weeks prior to initiation of study therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 1</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Has patient received other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>COG CRF Text 2</name>
         <type>Alternate Question Text</type>
         <context>COG</context>
         <doctext>Has patient had use of an investigation drug or beta adrenergic blockers, including metoprolol, sotalol, within 30 days of enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has the patient received any other investigational agents within the past 4 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any investigational agents (except ibrutinib) within 4 weeks prior to beginning treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received oral targeted agents, have at least 4 half-lives of the agent have elapsed prior to initiation of study therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received oral targeted agents, have at least 4 half-lives of the agent elapsed prior to initiation of study therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received investigational drug or immunotherapy (e.g. rituximab) less than or equal to 4 weeks prior to entering the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Was last dose of any investigational agent at least 4 weeks prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Was last dose of any investigational agent at least 30 days prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any other investigational agents within 4 weeks prior to cycle 1, day 1 (or within 5 half-lives if the investigational product, whichever is longer)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received investigational therapy or any ancillary therapy considered investigational (utilized for a non-FDA approved indication and in the context of a research investigation) less than or equal to 4 weeks prior to registration (patients with prostate cancer are permitted to continue hormone therapy)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib and during the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any other experimental drug or therapy within 21 days of baseline?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any other investigational agents within 4 weeks prior to cycle 1, day 1 (or within 5 half-lives of the investigational product, whichever is longer)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received any other investigational agents within 4 weeks prior to cycle 1, day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient taken an investigational drug within 28 days or 5 half-lives (minimum 14 days), whichever is shorter, prior to randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with any investigational agent within 4 weeks prior to Cycle 1, Day 1, or five drug half-lives (whichever is longer)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4449951&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5596699</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>3</displayOrder>
      <dateCreated>2016-12-07T15:39:54</dateCreated>
      <dateModified>2017-06-27T15:23:08</dateModified>
      <questionText>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-a or interleukin [IL]-2) within 6 weeks prior to Cycle 1, Day 1?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Systemic Immunostimulant Therapeutic Procedure Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>IMSTIMTX_IND</shortName>
       <publicID>5577294</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A coded response to questions which are necessary to allow a patient to participate in a clinical study that address the systemic treatment of substances that stimulate the immune system as outlined in the clinical trial protocol.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon-alpha or interleukin-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to Cycle 1, Day 1? 
</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon-a or interleukin-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-a or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Has patient received treatmen</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon-? or interleukin-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon-α or interleukin-2) within 6 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-a or interleukin [IL]-2) within 6 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon-a or interleukin-2) within 6 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunostimulatory agents (including, but not limited to, interferon-a or interleukin-2 [aldesleukin]) within 6 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5577294&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5596704</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>4</displayOrder>
      <dateCreated>2016-12-07T15:43:00</dateCreated>
      <dateModified>2017-01-10T16:50:25</dateModified>
      <questionText>Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1?</questionText>
      <instruction>
       <text>Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea, premedication for a radiologic contrast allergy) may be enrolled. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. Patients who receive low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>IMMUNO_TX_CTEC_C_IND</shortName>
       <publicID>4750626</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded indicator response regarding whether a patient has meets the eligibility criteria for immunosuppressive therapy.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Patient does not require immunosuppressive doses of systemic corticosteroids (greater than 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Does patient have a condition</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a condition requiring systemic treatment with either corticosteroids (greater than 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient require active systemic immunosuppressive therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have any condition requiring greater than 10 mg/d prednisone equivalents?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient require daily corticosteroids at high doses (prednisone greater than or equal 20 mg daily, or an equivalent) from 28 days prior to first dose and during treatment with ibrutinib?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient with autoimmune disease requiring systemic corticosteroid treatment (and previously ineligible to receive systemic immunotherapies for melanoma) not require more than 20mg of daily dose methylprednisone or its equivalent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) was last dose a minimum of 2 weeks prior to Cycle 1, Day 1? </doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient on systemic corticosteroids (IV or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasis, or strong CYP3A4/CYP2C19 inducers/inhibitors?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient been off systemic immunosuppressive medications greater than 2 weeks prior to treatment start?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1? 
</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient on systemic corticosteroids (IV or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient require the use of corticosteroids to control cerebral edema or treat neurologic symptoms?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving or has received systemic immunosuppressive therapy (greater than  2 weeks) including oral steroid doses greater than 10 mg/day of prednisone or equivalent within 2 months prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient been diagnosed with immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Was last dose of systemic corticosteroid greater than 10mg/day of Prednisone or equivalent greater than or equal to 4 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has prior treatment with systemic immunostimulatory agents, (including but not limited to interferon [IFN]-a or interleukin [IL]-2 was last dosed a minimum of 6 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient require daily corticosteroids at high doses (prednisone greater than or equal to 20 mg daily, or an equivalent) from 28 days prior to first dose and during treatment with ibrutinib?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 6 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient with autoimmune disease requiring systemic corticosteroid treatment (and previously ineligible to receive systemic immunotherapies for melanoma) not require more than 20mg of daily dose methylprednisone, prednisone, or its equivalent?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving systemic glucocorticoids for any purpose other than to modulate symptoms from an event of suspected immunologic etiology?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4750626&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5598003</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>5</displayOrder>
      <dateCreated>2016-12-08T10:21:37</dateCreated>
      <dateModified>2017-01-10T16:50:25</dateModified>
      <questionText>Is patient taking bisphosphonate therapy for symptomatic hypercalcemia?</questionText>
      <instruction>
       <text>Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.  </text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Current Therapeutic Procedure Biphosphonate Administered Code Indicator</longName>
       <shortName>TX_PROC_BIP_AD_CD_IND</shortName>
       <publicID>4449933</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response regarding whether current biphosphonate therapy is being administered.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is receiving concurrent bisphosphonate treatment, was it initiated after the first dose of study therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Is patient receiving bisphosp</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient receiving bisphosphate treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is receiving concurrent bisphosphonate treatment was it initiated prior to the first dose of study therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient taking bisphosphonate therapy for symptomatic hypercalcemia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient does not have osteoporosis, is patient receiving prophylactic treatment with bisphosphonates?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient is receiving prophylactic bisphosphonate therapy, does patient have bone disease except for osteoporosis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4449933&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5596758</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>6</displayOrder>
      <dateCreated>2016-12-07T15:48:37</dateCreated>
      <dateModified>2017-01-10T16:50:25</dateModified>
      <questionText>Does patient have known primary central nervous system (CNS) malignancy or symptomatic CNS metastases?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Central Nervous System Disease or Disorder Eligibility Determination Code Indicator</longName>
       <shortName>CNS_DX_EL_DT_CD_IND</shortName>
       <publicID>4449952</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response related to eligibility criteria for a person who receives medical treatment having disease related to the brain and spinal cord.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known brain metastases or carcinomatous meningitis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have brain metastases that are symptomatic or untreated or not stable for greater than or equal to 3 months (must be documented by imaging) or requiring corticosteroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has brain metastases and requires corticosteroids or non-enzyme inducing anticonvulsants, has dose of corticosteroids been stable and has been seizure free for 1 month prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Does patient have symptomatic</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known brain metastases (even if treated)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active brain metastases or carcinomatous meningitis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has a history of CNS metastases, has patient received treatment and has either not had seizures or has been on stable doses of anti-seizure medicine and has had no seizures for 2 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have clinical evidence of leptomeningeal or brain metastases causing spinal cord compression that are symptomatic or untreated or not stable for greater than or equal to 3 months (must be documented by imaging) or requiring corticosteroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a primary brain tumor, active brain metastases or epidural disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has central nervous system (CNS) metastases, are they stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 3 months and is off steroid treatment for 2 weeks prior to study enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active brain metastases or leptomenigeal disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active brain metastases or epidural disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has known CNS involvement, is CNS disease cleared before treatment with Nivolumab, and there is no permanent CNS damage?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known brain metastases or leptomenigeal disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active or untreated brain metastases or leptomeningeal metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has a history of CNS metastases, has patient received treatment and has either not had seizures or has been on stable doses of anti-seizure medicine and has had no seizures for 4 weeks?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active CNS leukemia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have symptomatic, uncontrolled brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active brain disease including symptomatic brain metastases or the presence of leptomeningeal disease, or infraterntoiral tumors?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has a prior history of brain metastases, have they been treated, patient is asymptomatic from the brain metastases and corticosteroids prescribed for management of the brain metastases have been discontinued at least 7 days prior to registration?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have symptomatic brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have presence of leptomeningeal carcinomatosis, greater than 1 cm mid-line shift, uncial herniation, significant hemorrhage/hydrocephalous or history of seizure?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known or symptomatic, uncontrolled brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have leptomeningeal metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known, symptomatic/untreated brain/CNS metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known brain metastases, known primary central nervous system (CNS) malignancy or symptomatic CNS metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 32</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have symptomatic central nervous system (CNS) metastases or leptomeningeal carcinomatosis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 29</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known primary central nervous system (CNS) malignancy or symptomatic CNS metastases, except as noted in the protocol?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 30</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have unstable brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 31</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known primary central nervous system (CNS) malignancy or symptomatic CNS metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has asymptomatic untreated CNS disease are all of the following criteria are met: Evaluable or measurable disease outside the CNS,; No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm); No history of intracranial hemorrhage or spinal cord hemorrhage;  No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted; No neurosurgical resection or brain biopsy within 28 days prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 33</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known CNS metastases or seizure disorder (unless treated and stable for greater than or equal to 6 months without requirement for corticosteroids and without seizure activity)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 34</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have symptomatic brain metastases or leptomeningeal disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 35</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have untreated brain metastases, spinal cord compression, or leptomeningeal carcinomatosis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 37</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known brain metastases or carcinomatous meningitis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 39</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have untreated brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 38</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have untreated central nervous system (CNS) involvement?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 40</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known central nervous system involvement of myeloma?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 36</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known active central nervous system (CNS) metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 42</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known active and untreated brain metastases or carcinomatous meningitis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 45</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have presence of diffuse leptomeningeal carcinomatosis, (focal /localized involvement is acceptable), greater than 1 cm mid-line shift, uncal herniation, or significant hemorrhage/hydrocephalous (small intra-lesional hemorrhage is acceptable)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 50</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known active or history of brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 52</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have clinical evidence of leptomeningeal or brain metastasis causing spinal cord compression that are symptomatic or untreated or not stable for greater than or equal to 3 months (must be documented by imaging) or requiring corticosteroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex 51</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has central nervous system (CNS) metastases, are they stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 4 weeks and is off steroid treatment for 2 weeks prior to study enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 49</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have primary brain cancers or active CNS metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 53</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 47</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known active or history of brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 46</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have clinical evidence of leptomeningeal or brain metastases causing spinal cord compression that are symptomatic or untreated or not stable for greater than or equal to 4 weeks (must be documented by imaging) or requiring corticosteroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 41</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known central nervous system involvement at the time of study entry?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 48</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active brain metastases?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 43</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have evidence of active disease in the central nervous system (CNS) defined as either the presence of active lesions on MRI obtained within 4 weeks of registration or progressive neurological decline?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 44</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have diffuse leptomeningeal carcinomatosis (focal/localized involvement is acceptable), greater than 1 cm mid-line shift, uncal herniation, or significant hemorrhage/hydrocephalous?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 54</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known brain metastases with progressive neurologic dysfunction, requirement of steroids and lack of improvement on head imaging obtained prior to consent to this clinical trial or carcinomatosis meningitis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4449952&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5596762</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>7</displayOrder>
      <dateCreated>2016-12-07T15:49:57</dateCreated>
      <dateModified>2017-01-10T16:50:25</dateModified>
      <questionText>Does patient have known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient CHO Cells Other Recombinant Human Anti-TGF-beta Monoclonal Antibody Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>CHO_RHMA_HYSTV_IND</shortName>
       <publicID>5479618</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to an immune response that occurs following exposure to CHO Cells or other recombinant human IgG4 monoclonal antibodies directed against transforming growth factor-beta (TGFb).</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have known hyper</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5479618&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597164</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>8</displayOrder>
      <dateCreated>2016-12-07T16:10:19</dateCreated>
      <dateModified>2018-03-16T04:41:39</dateModified>
      <questionText>Does patient have a history of severe allergic reactions, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Personal Medical History Severe Allergic Reaction Or Hypersensitivity Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>HX_ALCRN_HPSY_IND</shortName>
       <publicID>5479731</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to the patients medical background regarding severe allergic reactions and hypersensitivities following exposure to an innocuous substance.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have a history o</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of severe allergic reactions, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of severe allergic reactions, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies (i.e., antibodies with generic names ending in &quot;ximab&quot; or &quot;zumab&quot;, respectively) or fusion proteins?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5479731&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597168</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>9</displayOrder>
      <dateCreated>2016-12-07T16:13:44</dateCreated>
      <dateModified>2017-01-10T16:50:25</dateModified>
      <questionText>Does patient have known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease?</questionText>
      <instruction>
       <text>Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Personal Medical History Liver Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>PT_HX_LIVER_DX_IND</shortName>
       <publicID>4889731</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/not applicable response regarding whether the patient meets the criteria to participate in a specific clinical trial based on the person&apos;s medical history of liver disease.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have clinically</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have clinically important history of liver disease, including viral or other hepatitis or cirrhosis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known, clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease?  
</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has a known history of hepatitis C (HCV), do they have an undetectable viral load and any treatment received for HCV has been completed at least three weeks prior to enrollment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active hepatic or biliary disease (with exception of patients with Gilbert&apos;s syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4889731&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5598020</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>10</displayOrder>
      <dateCreated>2016-12-08T10:39:44</dateCreated>
      <dateModified>2017-01-10T16:50:25</dateModified>
      <questionText>Does patient have a history or risk of autoimmune disease that threatens vital organ function, including, but not limited to, systemic lupus erythematosus, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener&apos;s granulomatosis, Guillain-Barre syndrome, multiple sclerosis, or glomerulonephritis?  </questionText>
      <instruction>
       <text>Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Autoimmune Or Immunodeficiency Disease or Disorder Personal Medical History Code Indicator</longName>
       <shortName>AUT_IMMUN_DZ_PMH_IND</shortName>
       <publicID>4750651</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded indicator response regarding whether a patient has a personal medical history of autoimmune disease or immunodeficiency disease/disorder.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have autoimmune</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history or primary immunodeficiency?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, lichen sclerosis, or glomerulonephritis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener&apos;s Granulomatosis]); CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and Myasthenia Gravis, multiple sclerosis)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjögrens syndrome, Bells palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have autoimmune diseases, including but not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as SLE, connective tissue diseases, scleroderma, autoimmune vasculitis, inflammatory bowel disease (IBD), Crohn&apos;s, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active autoimmune disease, a history of known or suspected autoimmune disease or a history of a syndrome requiring systemic corticosteroids (greater than10 mg daily of prednisone equivalent) except for the treatment of malignancy with the exception of: Isolated vitiligo; resolved childhood atopy; history of a positive ANA titer without associated symptoms or history of symptoms of an autoimmune disorder; Controlled thyroid disorders; Type I diabetes mellitus; Psoriasis, Sjögren&apos;s syndrome, and arthropathies not requiring systemic treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history or risk of autoimmune disease that threatens vital organ function, including, but not limited to, systemic lupus erythematosus, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener&apos;s granulomatosis, Guillain-Barre syndrome, multiple sclerosis, or glomerulonephritis?  </doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of active or severe autoimmune disease: Inflammatory bowel disease, including ulcerative colitis and Crohn&apos;s Disease, rheumatoid arthritis, systemic progressive scleroderma, systemic lupus erythematosis, autoimmune vasculitis (e.g., Wegeners Granulomatosis), CNS or motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome, myasthenia gravis, multiple sclerosis)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of active primary immunodeficiency?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history or risk of autoimmune disease, including but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease vascular thrombosis associated with antiphospholipid syndrome, Wegener&apos;s granulmatosis, Sjogren&apos;s syndrome, Bells palsy, Guillain-Barre&apos; syndrome&apos;, multiple slerosis, autoimmune thyroid disease, vasculitis or glomerulonephritis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of a well-characterized and defined immune deficiency prior to the diagnosis of MF/SS or is receiving systemic steroid therapy greater than 10mg/day of Prednisone or equivalent within 4 weeks or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjögren&apos;s syndrome, Bells palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, lichen sclerosis, or glomerulonephritis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4750651&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597177</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>11</displayOrder>
      <dateCreated>2016-12-07T16:20:11</dateCreated>
      <dateModified>2018-03-16T04:41:39</dateModified>
      <questionText>Does patient have a history of grade 3 and 4 pulmonary, CNS and renal events attributed to anti-CTLA-4 agents?</questionText>
      <instruction>
       <text>Patients with a prior history of immune related events to anti-CTLA-4 may be eligible after discussion with the Sponsor.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Adverse Event Assessment Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>AE_ASMT_IND</shortName>
       <publicID>5480128</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine eligibility for clinical trial participation as outlined in the study protocol for questions related to assessments of the patients unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have any prior G</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have any prior Grade greater than or equal to 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE greater than Grade 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of grade 3 and 4 pulmonary, CNS and renal events attributed to anti-CTLA-4 agents?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Did patient experienced greater than or equal to grade 3 irAE during previous treatment with one of the checkpoint inhibitors?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to CTCAE v 4.0 grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia (Grade 2 or 3 toxicities from prior antitumor therapy that are considered irreversible [defined as having been present and stable for greater than 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5480128&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597202</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>12</displayOrder>
      <dateCreated>2016-12-07T16:36:12</dateCreated>
      <dateModified>2017-01-10T16:50:25</dateModified>
      <questionText>Does patient have a history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan?</questionText>
      <instruction>
       <text>History of radiation pneumonitis in the radiation field (fibrosis) is permitted.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Pulmonary Inflammation Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>LNG_IFMN_DZ_IND</shortName>
       <publicID>5480029</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to lung inflammation and disease.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have a history o</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e. bonchiolitis obliterans, cryptogenic organizing pneumonia, etc.) or evidence of active pneumonitis on screening chest computed tomography (CT) scan?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of severe asthma or absolute requirement for chronic inhaled corticosteroid medications?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5480029&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597182</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>13</displayOrder>
      <dateCreated>2016-12-07T16:21:43</dateCreated>
      <dateModified>2017-01-10T16:50:25</dateModified>
      <questionText>Does patient have active tuberculosis (TB)?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Tuberculosis Personal Medical History Clinical Trial Eligibility Criteria Indicator</longName>
       <shortName>PRSN_TB_HX_IND</shortName>
       <publicID>5036431</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The yes/no/not applicable coded response that asks if the patient has a background of a chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis (TB).</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active tuberculosis (TB) including patients who are undergoing first month of therapy (RIPE or equivalent) for active TB and patients with TB immune reconstitution syndrome (IRIS) requiring steroids?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Does patient have a history o</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of TB (even if treated), evidence of active or latent TB or positive TB skin test (e.g. PPT)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a history of TB (even if treated), evidence of active or latent TB?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active tuberculosis (TB)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have a known history of previous clinical diagnosis of tuberculosis?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active tuberculosis (TB)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5036431&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5892842</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>14</displayOrder>
      <dateCreated>2017-06-28T16:35:46</dateCreated>
      <dateModified>2017-06-28T16:35:46</dateModified>
      <questionText>Does patient require treatment with a RANKL inhibitor (e.g. denosumab) which cannot be discontinued before treatment with atezolizumab?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Intervention Required Negation Discontinue Prior To Therapeutic Procedure Occurrence Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>INTVN_REQ_NEG_DXD_PRR_TX_IND</shortName>
       <publicID>5889491</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A coded response to questions which are necessary to allow clinical study participation that are related to patient required interventions considered essential and mandatory in order to prevent permanent impairment or damage that cannot be stopped prior to the administration of a therapeutic procedure as outlined in the study protocol.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient requires treatment with a RANKL inhibitor (e.g. denosumab), it cannot be discontinued before starting treatment with atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient require treatment with a RANKL inhibitor (e.g. denosumab) which cannot be discontinued before treatment with atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>If patient requires treatment</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>If patient requires treatment with a RANKL inhibitor (e.g. denosumab), it cannot be discontinued before starting treatment with atexolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5889491&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597186</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>15</displayOrder>
      <dateCreated>2016-12-07T16:23:04</dateCreated>
      <dateModified>2017-06-28T16:35:46</dateModified>
      <questionText>Has patient had severe infections within 4 weeks prior to Cycle 1, Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Infectious Disorder Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>INFDR_IND</shortName>
       <publicID>5577815</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A coded response to questions which are necessary to allow a patient to participate in a clinical study related to disorders resulting from the presence and activities of microbial, viral, fungal, or parasitic agents as outlined in the study protocol.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had a severe infection within 4 weeks prior to Cycle 1, Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Has patient had severe infect</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had severe infections within 4 weeks prior to Cycle 1, Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had severe infections within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5577815&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597190</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>16</displayOrder>
      <dateCreated>2016-12-07T16:24:20</dateCreated>
      <dateModified>2017-06-28T16:35:46</dateModified>
      <questionText>Has patient had signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Infectious Disorder Sign or Symptom Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>INF_SYPM_IND</shortName>
       <publicID>5577840</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A coded response to questions which are necessary to allow a patient to participate in a clinical study related to the evidence of disorders resulting from the presence and activities of microbial, viral, fungal, or parasitic agents as outlined in the study protocol.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had severe infections within 4 weeks prior to Cycle 1, Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Has patient had signs or symp</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had signs or symptoms of infection within 2 weeks prior to randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5577840&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5622558</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>17</displayOrder>
      <dateCreated>2017-01-10T17:02:03</dateCreated>
      <dateModified>2017-06-28T16:35:46</dateModified>
      <questionText>Has patient received oral or intravenous (IV) antibiotics within 2 weeks prior to Cycle 1, Day 1?</questionText>
      <instruction>
       <text>Patients receiving prophylactic antibiotics (e.g. for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Antibiotic Administration Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>ABX_ADMN_IND</shortName>
       <publicID>5577858</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A coded response to questions which are necessary to allow a patient to participate in a clinical study related to the administration of substances used in the treatment of bacterial and other microbial infections.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Has patient received oral or</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received oral or intravenous (IV) antibiotics within 2 weeks prior to Cycle 1, Day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received oral or intravenous (IV) antibiotics within 2 weeks prior to randomization?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5577858&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5622554</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>18</displayOrder>
      <dateCreated>2017-01-10T17:00:20</dateCreated>
      <dateModified>2017-06-28T16:35:46</dateModified>
      <questionText>Has patient had major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Major Surgical Procedure Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>MAJ_SUR_IND</shortName>
       <publicID>5480033</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to major surgical interventions.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Has patient had major surgica</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had major surgical procedure within 28 days prior to Cycle 1 Day 1 or anticipation of need for a major surgical procedure during the course of the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had any major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study with the exception of the planned breast cancer surgery that is part of the trial design?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>If patient has had major surgery, have they recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is elective or planned major surgery to be performed during the course of the clinical trial?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had major surgery within 28 days of study day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had major surgery 28 days prior to day 1?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had any major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had any major surgical procedures within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5480033&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5622549</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>19</displayOrder>
      <dateCreated>2017-01-10T16:57:50</dateCreated>
      <dateModified>2017-06-28T16:35:46</dateModified>
      <questionText>Has patient received a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or it is anticipated that a live, attenuated vaccine will be required during the study and up to 5 months after last dose of atezolizumab?</questionText>
      <instruction>
       <text>Influenza vaccination should be given during influenza season only (approximately October to March).  Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.</text>
      </instruction>
      <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Attenuated Live Virus Vaccine Clinical Trial Eligibility Criteria Code Indicator</longName>
       <shortName>LIV_VIR_VAC_IND</shortName>
       <publicID>5480037</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>A response to determine patient eligibility for clinical trial participation as outlined in the study protocol for questions related to the administration of live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strain.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Has patient received administ</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or it is anticipated that a live, attenuated vaccine will be required during the study?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient recieived a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient had administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or has had anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after last dose of atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or it is anticipated that a live, attenuated vaccine will be required during the study and up to 5 months after last dose of atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Has patient received administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=5480037&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597194</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>20</displayOrder>
      <dateCreated>2016-12-07T16:28:50</dateCreated>
      <dateModified>2017-06-28T16:35:46</dateModified>
      <questionText>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Person Uncontrolled Concurrent Disease or Disorder Exclusion Criteria Code Indicator</longName>
       <shortName>UNCTL_DZ_CRT_COD_IND</shortName>
       <publicID>4379958</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>The coded yes/no/unknown indicator whether a person has an uncontrolled, concurrent disease, any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person, that would restrict entrance or bar from participation in a clinical trial.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Does patient have uncontrolle</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris (Canadian Cardiovascular Society grade II-IV despite medical therapy), cardiac arrhythmia, active bleeding diatheses, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 4</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, diabetes mellitus, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 3</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 6</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to conditions noted in the protocol that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 5</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 7</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 8</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 9</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to conditions noted in protocol section 3.2.3 noted below, that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 10</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to conditions noted in protocol in Section 3.4.4 as noted below, that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 11</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to: ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation symptomatic congestive heart failure (requiring hospital stay within the last 6 months),  myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 12</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have active and/or uncontrolled infections or is still recovering from an infection or actively febrile patients with uncertain etiology of febrile episode?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 13</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 17</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness that would increase the risk of toxicity or limit compliance with study requirements, including but not limited to, uncontrolled serious infection requiring i.v. antibiotics at the time of registration, symptomatic congestive heart failure, unstable angina pectoris, symptomatic/uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 14</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have any serious intercurrent or psychiatric illness that could, in the investigator&apos;s opinion, potentially interfere with the completion of treatment according to this protocol?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 16</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 18</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina, previous cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 15</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, the following:  ongoing or active infection; history of significant bleeding disorder, including congenital (von Willebrand&apos;s disease) or acquired (anti-factor VIII antibodies) disorders; large pleural effusions; or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 20</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (including sinus bradycardia), or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 19</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have any serious medical condition, uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, cardiac arrhythmias, laboratory abnormalities, or psychiatric illness and/or biopsychosocial conditions that may limit compliance)?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 22</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, symptomatic pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 21</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, pneumonitis, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 24</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, congestive heart failure NYHA grade greater than or equal to 3, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 25</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 23</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorder in the opinion of the investigator?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 29</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness that would increase the risk of toxicity or limit compliance with study requirements, including but not limited to, ongoing uncontrolled serious infection requiring i.v. antibiotics at the time of registration, symptomatic congestive heart failure, unstable angina pectoris, symptomatic/uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 27</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, myocardial infarction within 6 months, congestive heart failure, symptomatic congestive heart failure, unstable angina pectoris, active cardiomyopathy, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, active liver disease or cerebrovascular disease with previous stroke, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 28</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness that would increase the risk of toxicity or limit compliance with study requirements, including but not limited to, ongoing uncontrolled serious infection requiring IV antibiotics,  symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 36</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 26</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including but not limited to, active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 32</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, cognitive impairment, active substance abuse, or psychiatric illness/social situations that, in the view of the Investigator, would preclude safe treatment or the ability to give informed consent and limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 31</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have any clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, known HIV infection requiring protease inhibitor therapy, known Hepatitis B, known Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 35</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, uncontrolled seizures, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 34</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled inter-current illness including, but not limited to, ongoing or active infection, active tuberculosis (TB), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 30</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have any clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, known HIV infection requiring protease inhibitor therapy, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 37</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Does patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4379958&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
     <question>
      <publicID>5597198</publicID>
      <version>1</version>
      <isDerived>false</isDerived>
      <displayOrder>21</displayOrder>
      <dateCreated>2016-12-07T16:30:12</dateCreated>
      <dateModified>2017-06-28T16:35:46</dateModified>
      <questionText>Is patient pregnant or breastfeeding?</questionText>
            <isEditable>Yes</isEditable>
      <isMandatory>Yes</isMandatory>
      <multiValue>No</multiValue>
      <dataElement>
       <longName>Patient Pregnancy Yes No Not Applicable Code Indicator</longName>
       <shortName>PT_PREG_IND3</shortName>
       <publicID>4382994</publicID>
       <version>1</version>
       <context>Theradex</context>
       <workflowStatusName>RELEASED</workflowStatusName>
       <preferredDefinition>an assessment response or indicator that can have a value of yes, no, or not applicable regarding a patient&apos;s pregnancy.</preferredDefinition>
              <valueDomain>
        <longName>Yes No Not Applicable Code Indicator</longName>
        <shortName>YES_NO_NA_CD_IND</shortName>
        <publicID>3298541</publicID>
        <version>1</version>
        <type>Enumerated</type>
        <context>CCR</context>
        <workflowStatusName>RELEASED</workflowStatusName>
        <datatypeName>CHARACTER</datatypeName>
        <maximumLengthNumber>1</maximumLengthNumber>
        <minimumLengthNumber>1</minimumLengthNumber>
                         <permissibleValue>
          <value>Y</value>
          <valueMeaning>
           <publicID>2560453</publicID>
           <version>1</version>
           <longName>Yes</longName>
                       <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA33-6</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Yes</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2010-11-18T15:39:31</dateCreated>
             <dateModified>2011-11-11T16:13:29</dateModified>
             <modifiedBy>MAESKEB</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>YES</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>KUMMEROA</createdBy>
             <dateCreated>2011-03-14T09:47:25</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>The affirmative response to a question.</text>
             <type>NCI</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NHLBI</context>
            </definition>
                      <preferredDefinition>The affirmative response to a question or activity.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>N</value>
          <valueMeaning>
           <publicID>2559515</publicID>
           <version>1</version>
           <longName>No</longName>
                       <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2012-03-05T17:58:01</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>CTEP</context>
                           <classification>
               <name>Children&apos;s Oncology Group (COG)</name>
               <publicID>2961451</publicID>
               <version>1</version>
               <preferredDefinition>Children&apos;s Oncology </preferredDefinition>
               <classificationSchemeItem>
                <name>Statistics and Data Center</name>
                <publicID>2961452</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
                <preferredDefinition>Children&apos;s Oncology Group SDC</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2012-04-26T14:16:12</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not a Serious Adverse Event</name>
             <type>C3D Name</type>
             <context>CCR</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>LA32-8</name>
             <type>LOINC_CODE</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2016-05-12T14:24:31</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>LOINC_NAME</type>
             <context>ONC SDC Project</context>
                         </designation>
            <designation>
             <createdBy>HARTLEYG</createdBy>
             <dateCreated>2016-01-05T17:25:28</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Exception</name>
             <type>VM Alt Name</type>
             <context>Theradex</context>
                         </designation>
            <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2017-04-13T08:07:52</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>No</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                         </designation>
            <designation>
             <createdBy>GARRIDOJ</createdBy>
             <dateCreated>2017-08-16T09:59:34</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>1 - No</name>
             <type>VM Alt Name</type>
             <context>ECOG-ACRIN</context>
                         </designation>
                                  <definition>
             <createdBy>REEVESD</createdBy>
             <dateCreated>2009-06-08T04:17:58</dateCreated>
             <dateModified>2012-04-25T15:48:58</dateModified>
             <modifiedBy>REEVESD</modifiedBy>
             <languageName>ENGLISH</languageName>
             <text>No occurrence of a Serious Adverse Event (SAE)</text>
             <type>Manually-curated</type>
                           <classification>
               <name>NMDP: CDEs to review</name>
               <publicID>2695319</publicID>
               <version>1</version>
               <preferredDefinition>NMDP CDEs to be reviewed</preferredDefinition>
               <classificationSchemeItem>
                <name>2029r1: Fanconi Anemia / Constitutional Anemia Pre-HSCT Data</name>
                <publicID>2964895</publicID>
                <version>1</version>
                <type>Case Report Form</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
                      <preferredDefinition>The non-affirmative response to a question.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-07-09T00:00:00</beginDate>
         </permissibleValue>
         <permissibleValue>
          <value>X</value>
          <valueMeaning>
           <publicID>2581003</publicID>
           <version>1</version>
           <longName>Not applicable</longName>
                       <designation>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>Not applicable sequence feature</name>
             <type>UML Value Name</type>
             <context>NCIP</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.Measurement</name>
                <publicID>2812473</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>gov.nih.nci.mageom.domain.Measurement</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-06-07T15:54:35</dateCreated>
             <languageName>ENGLISH</languageName>
             <name>NA</name>
             <type>NAACCR Alt Name</type>
             <context>PS-CC</context>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>No Value Exists.</preferredDefinition>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
                <preferredDefinition>edu.wustl.catissuecore.domain.ValueDomain</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
            <designation>
             <createdBy>DWARZEL</createdBy>
             <dateCreated>2014-12-18T01:56:53</dateCreated>
             <dateModified>2014-12-18T01:59:53</dateModified>
             <modifiedBy>DWARZEL</modifiedBy>
             <languageName>ENGLISH</languageName>
             <name>Doesn&apos;t Apply</name>
             <type>VM Alt Name</type>
             <context>NCIP</context>
                           <classification>
               <name>FDA MedWatch Form 3500</name>
               <publicID>4382692</publicID>
               <version>1</version>
               <preferredDefinition>CDEs in MedWatch Form FDA 3500</preferredDefinition>
               <classificationSchemeItem>
                <name>Suspect Product(s)</name>
                <publicID>4394093</publicID>
                <version>1</version>
                <type>Case Report Form</type>
                <preferredDefinition>Suspect Product(s) Case Report Form CDEs</preferredDefinition>
               </classificationSchemeItem>
              </classification>
                         </designation>
                                  <definition>
             <createdBy>COOPERM</createdBy>
             <dateCreated>2007-08-02T15:44:56</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>How a sequence feature was determined is not applicable.</text>
             <type>UML Value Definition</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caArray_1.1</name>
               <publicID>2534950</publicID>
               <version>1.1</version>
               <preferredDefinition>This model makes up a the portion of caArray that reflects MGED&apos;s MAGE model.</preferredDefinition>
               <classificationSchemeItem>
                <name>gov.nih.nci.mageom.domain.BioSequence</name>
                <publicID>2812479</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>NCIP</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:22:44</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable 9e.g., census tracting not attempted); Census Tract Certainty information for 1970/80/90 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
            <definition>
             <createdBy>CURTIST</createdBy>
             <dateCreated>2007-04-30T12:32:10</dateCreated>
             <languageName>ENGLISH</languageName>
             <text>Not applicable (e.g., census tracting not attempted); Census Tract Certainty information for 2000 not coded.</text>
             <type>NAACCR</type>
                           <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>MMQL</name>
                <publicID>3111285</publicID>
                <version>1</version>
                <type>UML_PACKAGE_ALIAS</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Clinical Trial Mgmt Systems</name>
               <publicID>2183535</publicID>
               <version>1</version>
               <preferredDefinition>This Workspace will address the Cancer Center community need for consistent, open and comprehensive tools for clinical trials management.</preferredDefinition>
               <classificationSchemeItem>
                <name>LocalValueDomains</name>
                <publicID>3024955</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>Division of Cancer Control and Population Sciences</name>
               <publicID>2193114</publicID>
               <version>1</version>
               <preferredDefinition>Classification of the Division of Cancer Control and Population Sciences</preferredDefinition>
               <classificationSchemeItem>
                <name>Demographic11.1</name>
                <publicID>3242099</publicID>
                <version>1</version>
                <type>GROUP_TYPE</type>
               </classificationSchemeItem>
              </classification>
              <classification>
               <name>caTissue_Suite</name>
               <publicID>2782636</publicID>
               <version>1</version>
               <preferredDefinition>caTissue Suite version 1.0</preferredDefinition>
               <classificationSchemeItem>
                <name>edu.wustl.catissuecore.domain.ValueDomain</name>
                <publicID>2813063</publicID>
                <version>1</version>
                <type>UML_PACKAGE_NAME</type>
               </classificationSchemeItem>
              </classification>
                          <context>PS-CC</context>
            </definition>
                      <preferredDefinition>Determination of a value is not relevant in the current context.</preferredDefinition>
          </valueMeaning>
          <beginDate>2002-02-11T00:00:00</beginDate>
         </permissibleValue>
                       </valueDomain>
                      <referenceDocument>
         <name>Is patient pregnant or breast</name>
         <type>Preferred Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient pregnant or breastfeeding?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>CRF Text1</name>
         <type>Alternate Question Text</type>
         <context>NRG</context>
         <doctext>At the time of study entry, is the patient pregnant or lactating?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 1</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient pregnant, breastfeeding or plans to become pregnant?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
        <referenceDocument>
         <name>Theradex - 2</name>
         <type>Alternate Question Text</type>
         <context>Theradex</context>
         <doctext>Is patient pregnant?</doctext>
         <languageName>ENGLISH</languageName>
                 </referenceDocument>
              <cdeBrowserLink>https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&amp;FirstTimer=0&amp;PageId=ElementDetailsGroup&amp;publicId=4382994&amp;version=1</cdeBrowserLink>
      </dataElement>
             <validValue>
        <displayOrder>0</displayOrder>
        <value>Y</value>
        <meaningText>Yes</meaningText>
        <description>The affirmative response to a question or activity.</description>
                <valueMeaning>
         <publicID>2560453</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>1</displayOrder>
        <value>N</value>
        <meaningText>No</meaningText>
        <description>The non-affirmative response to a question.</description>
                <valueMeaning>
         <publicID>2559515</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
       <validValue>
        <displayOrder>2</displayOrder>
        <value>X</value>
        <meaningText>Not applicable</meaningText>
        <description>Determination of a value is not relevant in the current context.</description>
                <valueMeaning>
         <publicID>2581003</publicID>
         <version>1</version>
        </valueMeaning>
       </validValue>
           </question>
       </module>
       <protocol>
    <protocolID>5589458</protocolID>
    <longName>10014</longName>
    <context>Theradex</context>
    <shortName>10014</shortName>
    <preferredDefinition>Data collection CDEs for Protocol 10014.</preferredDefinition>
   </protocol>
         <classification>
    <name>RESERVED FOR SENTINEL MONITOR</name>
    <publicID>2465726</publicID>
    <version>1</version>
    <preferredDefinition>RESERVED FOR SENTINEL MONITOR</preferredDefinition>
    <classificationSchemeItem>
     <name>Monitor for DEETJENM</name>
     <publicID>5288647</publicID>
     <version>1</version>
     <type>CATEGORY_TYPE</type>
     <preferredDefinition>Created by system process</preferredDefinition>
    </classificationSchemeItem>
   </classification>
   </form>

   </forms>
